Download Book in PDF format

ALLERGIC DISEASES
IN R. MACEDONIA
Editor
Prof. Vladimir Cvetanov, M.D. Ph.D.
Skopje, 2006
Editorial Board:
Prof. Vladimir Cvetanov, M.D., Ph.D. (President)
Prof. Elisaveta Stikova, M.D., Ph.D.
Prof. Jovanka Karadzinska-Bislimovska, M.D., Ph.D.
Jordan Minov, M.D., Ph.D.
Authors:
Prof. Vladimir Cvetanov, M.D., Ph.D. , Emeritus
Prof. Jovanka Karadzinska-Bislimovska, M.D., Ph.D.
Prof. Elisaveta Stikova, M.D., Ph.D.
Jordan Minov, M.D., Ph.D.
Primarius Neda Ezova, M.D.
Snezana Milkovksa, biologist, Ph.D.
Ass. Snezana Risteska-Kuc, M.D., M.Sc.
Olivera Spasovska, M.D.
Mimoza Marsenic, M.D.
Publishers:
Institute of Occupational Health,
WHO Collaborating Center and GA2LEN Collaborating Center
Macedonian Society of Basic and Clinical Immunology and Allergology
For the publishers:
Prof. Jovanka Karadzinska-Bislimovska, M.D., Ph.D. (IOH)
Prof. Mirko Spiroski, M.D., Ph.D. (MSBCIA)
Translation in English:
Jordan Minov, M.D., Ph.D.
Ass. Saso Stoleski, M.D.
Ass. Dragan Mijakoski, M.D.
Lecture:
Lence Danevska
ii
Cover illustration and music background
Konstantin-Kocko Cvetanov and Ladislav Cvetkovski
Field researchers:
Valentina Petreska, M.D., Ljubica Andonovska, M.D. (Ohrid)
Roza Naumoska, M.D., Zaneta Bocevska, M.D. (Prilep)
Fanica Kapusevska, M.D. (Pehchevo)
Afrim Makelara, M.D. (Debar)
Nikola Ajcev, M.D. (Dojran)
Marija Isjanovska, registered nurse (Skopje)
Collaborators in the statistical, electronical, and pharmaceutical preparation:
Prof. Rozalinda Isjanovska, M.D., Ph.D.; Prof. Kristin Vasilevska, M.D., Ph.D.;
Jordan Minov, M.D. Ph.D.; Ass. Saso Stoleski, M.D.; Ass. Dragan Mijakoski, M.D.;
Kostadina Jugreva, pharmacist; Ass. Vladimir Kendrovski, M.D.,Ph.D. (Skopje); Vlado
Stefanoski, M.D. (Ohrid)
The content of the electronic version of this book is almost identical with the printed version of the same
book published in Macedonian language in 2006.
Electronic version is available at:
http://www.msbcia.org.mk/allergyMKD
iii
iv
PREFACE
The interest of the author of these lines and his collaborators for the frequency of the
allergic disorders in our country is dating back twenty years ago. The causes were
professional, pragmatic and also due to the fact that we didn’t want to accept the usually
delivered sentence “Unfortunately there is no relevant data for Macedonia concerning the
prevalence of ….”. Such explanation for certain entities was most frequently illustrated
with exact figures for the elaborated occurrence in some countries as for example in the
U.S.A., Australia, European countries as well as countries of our neighborhood.
In 1993 analyzing the group of almost 700 randomly selected patients we received the
first piece of information for allergic rhinitis. In 1994 our research was enriched with
many distinctions of this occurrence, but in both cases the data were only for the city of
Skopje.
The team at the Institute for Occupational Health in collaboration with the Occupational
Health Services, during 1995 and 1996 accomplished a polycentric study for the extension
of bronchial asthma in 11 towns of the Republic of Macedonia. These reasons and taking
into consideration the previous experiences and already established collaboration with
the medical doctors from other towns in Macedonia, urged us to realize the Project No.
400998 approved by the Ministry for Education and Science. The research duration was
5 years (from 1998 to 2003) and was conducted in six towns. The Project’s results are
elaborated in this publication.
Since the editors were not announcing their strong intention to distribute this particular
publication to all Collaborating Centers of Occupational Health with WHO and National
Association for allergy and clinic immunology, the attitude pointed out by the author of this
lines would be completely diminished as of 1998 he critically reviewed and emphasized
the discontent of the nomenclature of allergic entities with the one of the ICD-10 of
WHO of 1992. This condition became more complex when the European Academy for
Allergology and Clinic Immunology in 2001 proclaimed a new revised nomenclature
and classification of allergic disorders. In relation to this update, Mr. Van Cauwenberge
as a title of one of his disputes set the question: “New nomenclature, is it a fashion or a
need?” Our answer would be: “It is certainly not a fashion, but at this moment it is not a
need, too”.
We have been trying to present the results of this research various aspects, emphasizing
the public health features. Have we succeeded?
Editor and Principal Investigator of the Project
Prof. Vladimir Cvetanov, M.D., Ph.D.
vi
Contents
Part I Introduction
Redefinition of the facts and concepts concerning allergic diseases 3
Actual knowledge about pathogenesis of allergic diseases
4
Revised classification and nomenclature of allergic diseases
6
Hypersensitivity 6
Atopy 7
Allergy 7
Allergens 7
Allergic rhinitis 8
Allergic conjunctivitis 8
Asthma 8
Atopic eczema/dermatitis syndrome (AEDS) 9
Urticaria 9
Contact eczema/dermatitis 9
Hypersensitivity to drugs, food, and venoms 9
Anaphylaxis
10
References
10
Relevancy of the national statistics system for evaluation of allergic diseases 11
Actual condition in the Republic of Macedonia 11
Structure of the health care system and possibilities for collecting and
analyzing of the health-statistics data 12
Application of international classification of diseases and diseases with allergic etiology13
Allergic rhinitis 13
Allergic conjunctivitis 14
Asthma15
Atopic dermatitis17
Drug hypersensitivity 18
Food hypersensitivity
19
Insect allergy
20
The need of epidemiological research 21
References:
22
Aeropallinological and epidemiological studies in R. Macedonia 22
Characteristics of the centers where the study was conducted
23
Skopje (Sk)
23
Dojran (Do)
23
Ohrid (Oh)
24
Prilep (Pr)
24
Debar (De)
24
Pehchevo (Pe) 25
Part II Aeropallinological monitoring 1.0.
1.1.
1.2.
1.3.
1.4.
1.5. 1.6. 1.7. 1.8. 2.0. 2.1. 2.2. 2.3. 2.5. Outdoor aeroallergens 29
Definition
29
Aeropallinological methods 29
Methodology of aeropallinological research
31
Influence of aeropollution on pollen grains concentration and dissemination
Results 36
Pollen calendar(s) 48
Conclusions
61
References:
62
Indoor aeroallergens
63
Moulds 63
House dust mites 68
Pets
71
References:
79
vii
1
27
32
Part III Epidemiological survey
1.1.
2.0.
2.1.
2.2.
2.3.
2.4.
2.5.
2.6.
2.7.
3.0.
3.1.
3.2.
3.3.
3.4.
3.5.
3.6.
3.7.
3.8.
4.0.
4.1.
4.2.
4.4.
4.5.
4.6.
4.7.
4.8.
4.9.
4.10.
5.0.
5.1.
5.2.
5.3.
5.4.
5.5.
5.6.
5.7.
5.8.
6.0.
6.1.
6.2.
6.3.
6.4.
6.5.
6.6.
6.7.
6.8.
6.9.
7.0.
7.1.
7.2.
7.4.
7.5.
7.6.
7.7.
7.8.
7.9.
8.0.
8.1.
81
Characteristics of the examined subjects
84
References: 96
Allergic rhinitis - ICD - 10; J 30.4
97
Defintion 97
Classification
97
Pathogenesis
97
Clinical manifestations
99
Diagnosis 99
Management of Allergic Rhinitis
103
Contraindications 107
Frequency of allergic rhinitis 108
Allergic conjunctivitis - ICD - 10; H 10.8123
Classification and definition 123
Pathogenesis
123
Clinical manifestations
124
Diagnosis 124
Treatment 125
Environmental control
125
Frequency of allergic conjunctivitis
125
Results of our epidemiological study of AC in R. Macedonia 126
Asthma - ICD - 10; J. 45
133
Definition 133
Risk factors
133
Clinical manifestations
136
Diagnosis and assessment
137
Management
138
Prevention of asthma 139
Multinational, national, and regional epidemiological studies of asthma139
Epidemiological studies of asthma in R. Macedonia140
Results from our epidemiological survey of asthma in R. Macedonia 141
Atopic dermatitis - ICD 10; L 20.8-L20.9
159
Definition 159
Pathogenesis
159
Clinical manifestations
160
Diagnosis 161
Management
162
Epidemiological studies of atopic dermatitis
163
Conclusions
168
References:168
Drug hypersensitivity - ICD - 10; T 88.7 170
Definition 170
Pathogenesis
170
Clinical manifestations
171
Diagnosis 171
Prevention 173
Epidemiological studies of drug hypersensitivity 173
Results of the actual study of drug hypersensitivity in R. Macedonia 175
Conclusions
182
References: 183
Food hypersensitivity - ICD 10; L 23.6; L 25.4; L 27.2; T 78.0
185
Definition 185
Pathogenesis
185
Diagnosis 186
Prevention 187
Epidemiological studies of food hypersensitivity 188
Results of our study of food hypersensitivity in R. Macedonia188
Conclusions
195
References:
195
Insect sting allergy - ICD 10 (T 63.4 X 23)
197
Definition and classification 197
viii
8.2. Insects from Hymenoptera order and allergens from Hymenoptera venoms. 8.3. Clinical manifestations
199
8.4. Diagnosis
200
8.5. Prevention
200
8.6. Treatment
201
8.7. Specific immunotherapy
201
8.8. Epidemiological studies of insect sting allergy 202
8.9.
Results of our study of insect sting allergy in R. Macedonia 202
8.10. Conclusions
207
8.11. References: 207
197
Part IV Economic burden of certain allergic diseases in R. Macedonia 209
1.0.
1.1.
1.2.
1.3.
1.4.
Economic burden of allergic rhinitis and asthma 211
Allergic rhinitis (AR)
211
Asthma 213
Conclusions
216
References: 216
Part V Appendices Appendix 1: Appendix 2. Appendix 3. Appendix 10.
Appendix 11.
219
221
231
235
250
252
List of abbreviations 253
Index 256
Contacts: 260
ix
Professor Vladimir Cvetanov, M.D., Ph.D. was born in Skopje in 1935.
He graduated in 1961 at the Medical Faculty in Skopje. From 1962 until
1965 he worked as a general practitioner at the Health Station of the Radusha
pit. During 1965 to 1966 he attended post-graduate studies at “Andrija
Stampar” Medical School in Zagreb, while in 1967 he passed his specialist
exams of occupational health. In 1970 he completed his master studies
becoming the first Master of Science at the Medical Faculty in Skopje. In
1979 he completed his Ph.D. thesis particularly focusing on hypersensitive
pneumonitis. Results obtained and presented in this study are named as
“Macedonian Study” by some Scandinavian authors. In 1984 was conferred
the degree sub-specialist of allergology and clinical immunology and 1993
he added allergology and pulmology to the list of his specialties.
Since 1993 he is a regular Full-time Professor at the Chair of Hygiene and
Occupational Health at the Medical Faculty in Skopje. Simultaneously he
was actively participating in the teaching process of subspecialty in allergology and pulmology. During one
period of time, he was also lecturing at the post-graduate studies in Ljubljana and Sarajevo.
Professor Cvetanov is considered as a promoter of the Institute of Occupational Health back in 1972 and in
1986 of the Allergy Center within the same Institute. He was a Director of the Institute until his retirement
in 2000.
He is the author of 207 scientific publications focused on the occupational pathology and allergology.
When in the newly constructed building of the Institute of Occupational Health in 1977, all optimum
conditions were provided; the Institute turned into a teaching basis of the Medical Faculty. Professor
Cvetanov introduced the modern functional diagnostics of the respiratory system in 1967, while the
experiences gained by the ”small spirometry” were summarized and published in 1969. In 1970, in the
publication “Allergies and Asthma”, he published the application of skin tests with workplace allergens in
detection of bronchial asthma in workers exposed to flour dust.
In 1976 he set the test for determination of precipitins with dual immune diffusion on gel-agar, indirect test
on basophil deregulation, in 1978 the actual test for diagnosis of penicillin and drug hypersensitivity, while
in 1980 he introduced LIF test in the diagnosis of occupational contact dermatitis. In 1991, at the Institute
of Occupational Health an aeropalinological research survey started resulting in 1993 with its final results
publication and knowledge of the first official facts about the city of Skopje. In 1994 at this Institute the use
of rhinomanometry was induced as an additional and important test in diagnostics of allergic rhinitis.
He received the first award for his poster presented at the Balkan Congress for Allergology held in Sofia
(Bulgaria) on 28-30 May, 1998, entitled “The link between allergic manifestations of airways and actual
microflora in Macedonia”.
He is the editor and the first author of the published books: “Health Condition and Work Ability” in 1989;
“Social Medicine-Health Promotion” in 1995; “Allergic Diseases-Management” in 1998; “Macedonian
National Consensus for Allergic Rhinitis” in 1999, and the monographic publication “Specific
immunotherapy” in 2001. He is one of the authors of the “Macedonian National Consensus for Diagnosis
and Treatment of Asthma and Chronic Obstructive Pulmonary Disease” in 1999 and of the book “Clinical
Allregology” published in Sofia in 2001.
Professor Cvetanov is the principal investigator and participant of two projects related to epidemiological
allergic rhinitis (1993/1994), polycentric study for bronchial asthma (1995/96) and the Project No.400998
(1998-2003).
He was the President of the First Macedonian Immunology Congress in 1996 and of the Macedonian
Society of Basic and Clinical Immunology and Allergology in the period between 1996 and 2000.
For his work he was awarded the highest certificate of gratitude by the Macedonian Medical Association
in 1996.
xi
Professor Jovanka Karadzinska-Bislimovska, M.D., Ph.D. was born in
Belgrade in 1955. She graduated at the Medical Faculty in Skopje in 1979.
She completed the specialization in occupational health in 1988, and the
subspecialty in pulmology and allergology in 2003. She completed postgraduate studies in 1986 and acquired the degree Master of Science. In
1990, by presenting her Ph.D. thesis entitled “Defining the level of allergic
sensitivity and occurrence of pulmonary disorder with allergic etiology in
workers involved in rice processing industry” she acquired the degree Ph.D.
in Medical Science.
She has realized several study visits in Stockholm (Sweden) in 2000, Oxford
(Great Britain) in 2001, and Jerusalem (Israel) in 2005.
Starting 1980 she has been employed at the Institute of Occupational Health at the Department for
Cardiorespiratory Functional Diagnostics, and since 2003 she is the Director of the Institute. In 1986 she
was appointed junior assistant at the Chair of Hygiene with Social Medicine and Occupational Health,
Medical Faculty, while in 2002 she became full time regular professor at the same Chair. She is the Head of
the Chair of Occupational Health and Coordinator of the Project for Development of the School for Public
Health, assigned with the Medical Faculty in Skopje.
She is one of the authors of the handbook “Health Condition and Work Ability” (Skopje, 1989), the
monographic publication “Allergic Diseases – Management (Skopje, 1998), the handbook for teachers,
researchers and health professionals “Health Determinants in the Scope of New Public Health” (Sofia,
2005) and “Public Health: A Tool for Regional Development” (Bucharest, 2006).
She is the author of the chapter “Immunoallergic aspects of occupational allergic disorders” in the
monograph “Clinical Immunology” (Belgrade, 2002). She is also the author and co-author of more than
130 professional and scientific articles.
Professor Karadzinska-Bislimovska is a member of the European Respiratory Society and of the European
Academy of Allergology and Clinical Immunology. She is an actual deputy president of the Macedonian
Society for Basic and Clinical Immunology and Allergology.
For her work she was awarded with the Declaration of “Dr. Trifun Panovski” by the Macedonian Medical
Association in 2005.
xii
Professor Elisaveta Stikova, M.D., Ph.D. was born in Skopje in 1956.
She graduated at the Medical Faculty in 1980. In 1987 she completed her
specialization in occupational health. During 1988 she completed the postgraduate studies and became Master of Science. In 1990 after presenting
her doctorial thesis she has got her Ph.D. degree. In 1986 she was elected
as a junior assistant at the Chair of Hygiene with Social Medicine and
Occupational Health at the Medical Faculty in Skopje. Since 2002 she is a
regular full time professor at the same Chair. She is also a responsible teacher
for subjects related to medical ecology at the Faculty of Stomatology, as well
as for school and pre-school hygiene at the Pedagogy Faculty in Skopje.
She has realized several study visits to France and Spain (2002), U.S.A
(2003) and Israel (2005).
In 1980 she started to work at the Institute of Occupational Health. During the period between 1994 and
2004 she was appointed a Director of the Republic Institute for Health Protection. Currently she is still
working in the same Institute.
She is one of the authors of the handbook “Health Condition and Working Ability” (Skopje, 1989), the
handbook for teachers, researchers and health professionals “Health Determinants in the Scope of New
Public Health” (Sofia, 2005); she is also the author of the student’s handbook “Hygiene” (Skopje, 2003) and
handbooks for regular nutrition (Skopje, 2001), Health for All database indicators (Skopje, 2001), Codex
Alimentarius (Skopje, 2003), as well as her latest handbook “Medical Ecology” (Skopje, 2006) which is the
first book of this scope written in Macedonia.
Professor Stikova was engaged as a WHO national collaborator for topics related to nutrition and food
safety. She was also the first President of the National Committee for Food and of the Codex Alimentarius
Committee in the Republic of Macedonia. As a temporary collaborator of WHO she was closely involved
in issues related to health statistics and evaluation of sensitivity and adaptation on climatic changes.
Professor Stikova is an author and co-author of more than 130 scientific and professional articles,
principal researcher and participant in 7 international scientific-research projects. She is a regional cocoordinator of SCOPES Project “Development of Core Curriculum Health” and co-director of NATO
Project “Strengthening National Public Health Preparedness and Response for Chemical, Biological and
Radiological Agents Threats”.
She is a member of the International Committee for Occupational Medicine, and a member of the National
Board Committee.
xiii
Jordan Minov, M.D., Ph.D. was born in Skopje in 1960. He graduated in 1984
at the Medical Faculty in Skopje. In 2002 he completed the specialization in
internal medicine and in 2006 he completed the specialization in occupational
health. During 2001 he completed his master studies and acquired the degree
Master of Science, while in 2006 after public presentation of the doctorial
thesis “Influence of Specific Occupational Exposure on the Bronchial Asthma
Development in Pharmaceutical Industry Workers”, he acquired the degree
Ph.D. in Medical Science.
Currently he is employed at the Department for Cardiorespiratory Functional
Diagnostics within the Institute of Occupational Health – WHO Collaborating
Center.
He participates in the teaching process of the post-graduate studies (Occupational Health Course) at the
School of Public Health within the Medical Faculty in Skopje. Functional diagnostics of respiratory system
and occupational and non-occupational chronic obstructive pulmonary disorders are scope of special
professional and scientific interest in his devoted work.
He is one of the authors of the chapter “Occupational Lung Disorders as a Public Health Problem” of the
Handbook for teachers, researchers and health professionals “Health Determinants in the Scope of New
Public Health” (Sofia, 2005), as well as other 110 professional and scientific articles published in domestic
and foreign publications and presented on congresses in our country and abroad. He is involved in many
national and international projects, programs and workshops.
He is a member of the European Respiratory Society, European Academy of Allergology and Clinical
Immunology, World Allergy Organization, Macedonian Respiratory Society and Macedonian Society for
Basic and Clinical Immunology and Allergology.
Primarius Neda Ezova, M.D. was born in Rakle – Prilep in 1944. She graduated
at the Medical Faculty in 1971. In 1981 she passed the specialization exam in
occupational health, while in 2002 she completed her sub-specialist exam in
pulmology and allergology.
In 1987 Teaching-Scientific Council of the Medical Faculty promoted her to
assistant at the Chair for Hygiene with Social Medicine and Occupational
Health. The title Primarius was awarded to her in 1994.
Currently she is employed at the Allergy Center within the Institute of
Occupational Health – WHO Collaborating Center.
Her long-term professional activity is related to the scope of diagnostics, introduction and practical
conduction of several methods and tests in allergology and pulmology. Management of allergic disorders,
occupational and non-occupational chronic obstructive pulmonary disorders, as well as work-related
diseases are targets of special scientific interest in her professional involvement.
She is the author and co-author of 130 professional and scientific articles published in national and
international journals and presented in our country and abroad. She is one of the authors of the book
“Allergic Diseases – Management” and “Macedonian National Consensus for Allergic Rhinitis”.
She is a member of the European Respiratory Society, Macedonian Respiratory Society and Macedonian
Society for Basic and Clinical Immunology and Allergology.
xiv
Snezana Milkovska, Ph.D. was born in Skopje in 1962. She graduated in
1987 at the Faculty of Natural and Mathematical Sciences, Department of
Biology in Skopje. In 1998 she completed her post-graduate studies, while
in 2002 she acquired her Ph.D. in Biology at the same faculty. Her study
visits were conducted at the Institute for Epidemic and Parasitic Diseases
(Department for Allergy and Aeropalionology) in Sofia, Bulgaria and in
2005 in Lion, France during her stay she acquired European Certificate for
Aerobiology and Aeropalinology.
Currently she is employed at the Allergy Center of the Institute of Occupational
Health – WHO Collaborating Center where she actively participates in the
scientific and research tasks. Her scope of special interest is focused to
aeropalinology, epidemiology of allergic diseases, ecology and sustainable development. Being the only
specialist in aeropalinology in the country, she is also devoted to its development in Macedonia. In 1993
she completed Pollen calendar for the city of Skopje. During the same year she also prepared calendars for
the towns of Ohrid, Prilep, Pehchevo, Debar and Dojran and successfully defined allergic pallet of actual
allergens for skin tests in Macedonia.
As an author and co-author she has published about 70 professional and scientific articles. She is a member
of the Board of the Macedonian National Consensus for Allergic Rhinitis, a member of the Society of
Occupational Health, Society of Basic and Clinical Immunology and Allergology, Society of Environment
and Ecology in Macedonia and of the European Academy for Allergology and Clinical Immunology. She
actively participates in the project LEAP of the city of Skopje, as well as in the project “Epidemiological
characteristics of the allergic rhinitis in the Republic of Macedonia in correlation with the pollen micro
flora”.
She was a member of the Scientific and Organizational Board of the First Macedonian Immunology
Congress in 2000 and a secretary general of the First Macedonian Congress of Occupational Health with
International Participantion in 2004.
Assistant professor Snezana Risteska-Kuc, M.D., M.Sc. was born in Skopje
in 1960. She graduated in 1988 at the Medical Faculty in Skopje. In the year
2000 she completed the specialization in occupational health and in 2003 she
acquired her degree MSc in Medicine focusing on the occupational health.
She is employed at the Department for Industrial Toxicology within the Institute
of Occupational Health – WHO Collaborating Center. As an assistant, starting
from 1998, she has been participating in teaching process conducting practical
courses for students at the Chair of the Occupational Health.
Her professional and research interests are focused mainly on two targets of the
occupational health: occupational immunoallergology and industrial toxicology,
while her special attention is focused on the occupational rhinitis and functional nasal diagnostics with the
rhinomanometric method.
She is one of the authors of the “Macedonian National Consensus of Allergic Rhinitis” (1999) and the
handbook for teachers, researchers and health professionals “Health Determinants in the Scope of New
Public Health” (2005). Dr Kus is actively is involved in numerous scientific and applicative projects,
programs and workshops of national and international significance.
She has published more than 70 professional and scientific articles, some of them presented on congresses
in the country and abroad.
Ass. M.D. Snezana M.Risteska-Kuc is a member of the Macedonian Medical Association, Macedonian
Society of Occupational Medicine, Macedonian Society of Basic and Clinical Immunology and Allergology,
European Respiratory Society and Macedonian Respiratory Society.
xv
Olivera Spasovska, M.D. was born in Struga in 1957. She graduated at
the Medical Faculty in 1985. In 2001 she completed her specialization in
ophthalmology.
She is employed at the Department of Ophthalmology within the Institute of
Occupational Health – WHO Collaborating Center.
Her special scope of professional and scientific interest is prevention and early
detection and treatment of eye disorders, particularly those of allergic etiology.
As an author and coauthor she has published 20 professional and scientific
articles. Within the frames of the health-education process at the Institute of
Occupational Health, she participates in the education process of students of medicine and medical doctors
on their specialization interim. She is a member of the Macedonian Ophthalmology Society.
Mimoza Marsenic, M.D. was born in Kumanovo in 1951. She graduated at
the Medical Faculty in Skopje in 1978 and specialized clinical immunology
with allergology in 1984 at the Military Medical Academy in Belgrade.
At the Clinic for Pulmonary Disorder and Tuberculosis in Nis she spent
17 years, being in charge for the Department of Immunoallergology and
Management of Asthma.
Over the last eight years she has been employed at the Allergy Center within
the Institute of Occupational Health – WHO Collaborating Center.
Allergic and immunologic tests with special attention to drug hypersensitivity
as well as conducting specific and nonspecific immunotherapy are the major
targets of interests in her work.
She is the author and co-author of more than 60 professional and scientific articles presented on congresses
and other specialized gatherings in the country and abroad.
She is a member of the Macedonian Society for Basic and Clinic Immunology and Allergology and an
active participant of several scientific projects.
Valentina Petreska, M.D. was born in Ohrid in 1952. She graduated at
the Medical Faculty in Skopje in 1977, and in 1986 she completed her
specialization in occupational health.
She is currently the director of the Occupational Health Service within the
Health Institute in Ohrid. Health promotion at the workplace is her special
professional target.
She is an author and co-author of about 15 professional articles presented
on congresses in the country and abroad. She is a member of the Managing
Board of the Society of Occupational Health within the Macedonian
Medical Association.
xvi
Ljubica Andonovska, M.D. was born in Ohrid in 1950. She graduated in 1975
at the Medical Faculty in Skopje. She got her specialization in primary health
care in 1981 and during 1983 completed her professional improvement of
pulmology and allergology.
Since 1983 she has been employed at the Department of Pulmology and
Allergology within the Department of Internal Medicine of the General Hospital
in Ohrid. Respiratory and allergic disorders are major target of her professional
interest.
She is a member of the Macedonian Respiratory Society and Macedonian
Society for Basic and Clinical Immunology and Allergology.
Roza Naumoska, M.D. was born in Prilep in 1954. She graduated at the
Medical Faculty in Skopje in 1980 and in 1992 she completed her specialization
in occupational health.
Since 1981 she has been employed at the Occupational Health Service within
the Medical Center in Prilep and her working tasks are related to the issues
of the occupational medicine, especially targeted on the first aid factory’s
units. Since 1995 she has been appointed as head of the Service. Her special
professional interest is aimed at pulmonary disorders and allergology.
It has to be particularly emphasized her contribution and involvement in the
preparation of documents for the National Strategy of Occupational Health
and in organization and functioning of the occupational health services. Her
involvement in the Project for preparation of the manual for verification, application and registration of
occupational diseases and other related activities, is also worth to be stressed.
She is the author and co-author of more than 30 articles presented on congresses and seminars in the
country and abroad. She participated in a two-week seminar for health and safety at work in Sweden. She
actively participates by lecturing and conducting workshops of the projects “Healthy nutrition”, “Mental
hygiene” and LEAP.
During the period between 1998 and 2002 she was the President of the Society of Occupational Health
within the Macedonian Medical Association. Since 2002 she has been the Vice President and the member
of the Managing Board of the Society and a member of the editorial board of the Bulletin where she also
participates with her publications, comments and translations of professional literature.
She is a member of the Macedonian Respiratory Society, Macedonian Society for Basic and Clinical
Immunology and Allergology and IHAP.
Zaneta Bocevska, M.D. was born in Prilep in 1962. She graduated at the Medical
Faculty in 1987. She completed her specialization of pathological anatomy in
2005 and her post-graduate studies are still in progress.
She is employed at the Department of Pathological Anatomy within the General
Hospital in Prilep.
As an author or co-author she has published 24 papers presented on congresses
in the country and abroad.
She is a member of the European Society of Pathological Anatomy and a
member of the Presidency of the Macedonian Society of Pathologists within the
Macedonian Medical Association.
xvii
Fanica Kapusevska, M.D. was born in Krushevo in 1957. She graduated at the
Medical Faculty in 1983 and in 1992 completed her specialization in occupational
health.
Currently she is employed at the Occupational Health Service within the
Health Center in Pehchevo. Her special interest is focused on the occupational
malfunctions caused by vibrations, as well as occupational allergic disorders.
As an author or co-author she has published about ten professional works
presented on congresses within the country. She is the member of the Macedonian
Respiratory Society and Macedonian Society for Basic and Clinical Immunology
and Allergology.
Afrim Makerala, M.D. was born in Debar in 1959. He graduated at the
Medical Faculty in Pristine in 1985, while he completed his specialization in
occupational health at the Medical Faculty in Skopje.
Since 1988 he has been employed at the Medical Center in Debar. President
or a member is of several committees, related to the health issues as well as
of several NGOs. For his devoted work he has achieved few recognitions and
acknowledgement. Presenting professional articles he participated on few
congresses and seminars.
The Macedonian Chamber of Medicine has appointed him to conduct the exam required for licencing of
graduated medical workers.
He is a member of the Macedonian Chamber of Medicine, a member of the Albanian American Academy
of Science in U.S.A., of the Society of the Occupational Health and of the Association of Medical Doctors
of Albanian Nationality in Macedonia.
Nikola Ajcev, M.D. was born in Dojran in 1960. He graduated in 1987 at the
Medical Faculty in Skopje and during 2006 he completed his specialization in
internal medicine. Currently he is employed at the Health Unit Dojran within the
Health Center Gevgelija.
The influence of the living environment on human health with particular focus on
the microclimate of Dojran is a specific target of his professional involvement.
He participated in the preparation of the LEAP Project (Local Ecological Action
Plan for the Municipality of Dojran), especially working on and evaluating the
influence of the living environment on human health.
He is a member of the Macedonian Respiratory Society.
Marija Isjanovska was born in Skopje in 1949. She completed her education
at the Vocational Medical School in Skopje in 1968. She was employed as a
registered nurse at the Allergy Center within the Institute of Occupational Health
– WHO Collaborating Center in 1972 and remained there until her retirement in
2003.
xviii
Prof Rozalinda Isjanovska, M.D. Ph.D.
Institute of Epidemiology
and Biostatistics
Medical Faculty Skopje
Ass Saso Stoleski, M.D.
IOH - WHO CC Skopje
Prof Kristin Vasilevska, M.D. Ph.D.
Institute of Epidemiology
and Biostatistics
Medical Faculty Skopje
Ass Dragan Mijakoski, M.D.
IOH - WHO CC Skopje
Kostadina Jugreva, pharmacist
Skopje
Ass Vladimir Kendrovski,
M.D. Ph.D.
Republic Institute for
Health Protection, Skopje
Vlado Stefanoski, M.D.
Occupational Health Service
Ohrid
xix
Part I
Introduction
Redefinition of the facts and concepts concerning allergic diseases
Allergic diseases represent one of the most common chronic pathological conditions
throughout the world, as well as a serious challenge both to health care systems and
to society as a whole. In 1997, the European Allergy White Book (EAWP) reported
that almost one-third of the population of the planet suffers from one or more allergic
diseases.
The rising prevalence of the allergic diseases in the last decades caused intensive
investigations and significant improvement of the knowledge about their pathogenesis,
diagnostics and treatment options. Despite increasing knowledge, the gap between
achieved improvement and satisfactory management still exists. From the patients’ point
of view, there are also unmet needs.
In the late 1990s has started the polycentric project Global Approach to the Patient (GAP)
started and it was focused on the systemic nature of the allergic diseases and the need of
uniformed and standardized approach in their diagnostics and treatment. Having in mind
the increased knowledge about the allergological mechanisms, and sometimes confusing
terminology used by allergologists and organ specialists, a revision of the classification
and nomenclature was necessary. The report prepared by the European Academy of
Allergology and Clinical Immunology (EAACI) nomenclature task force representing the
five EAACI sections and the EAACI Executive Committee was published in 2001. The
aim of the report was to propose a revised nomenclature for allergic and related reactions
that can be used independently of target organ or patient age group. The nomenclature
was based on the actual knowledge of the mechanisms which initiate and mediate allergic
reactions.
Despite the fact that allergic diseases were identified in the antique period, the terms
“allergy” and “atopy” were introduced at the beginning of the last century. The term
“allergy” was promoted by von Pirquet in 1905 for altered (unexpected) reactions in some
people following the exposure to environmental agents which were absolutely harmless
for others. Atopy, derived from a Greek word meaning “out of place”, was introduced
by Coca & Cooke in the 1920s to describe a familial predisposition to develop several
diseases including asthma, eczema and rhinitis. In the 1930s, atopic dermatitis, considered
one manifestation of hypersensitivity, was subsequently defined by Wise and Sulzberger.
At the same time, immediate skin reaction in normal subjects following administration
of serum from atopic subjects was reported by Prausnitz & Küstner. Cooke and Grove
indicated presence of heat-labile substances, referred to as “reagins”, in the serum of
atopic patients. The cytophylity of the reagins, i.e. their activation after interaction with
other cells, was suggested by Otto. In 1948, corticosteroids were introduced as a treatment
option for asthma and other allergic diseases. The role of histamine in the immediate type
of allergic reaction was determined in 1953.
The field of allergy has developed rapidly during the last 50 years. In the 1960s,
Ishizaka & Ishizaka and Bennich & Johansson suggested that reagins should be a
new class of immunoglobulins. In 1968, the WHO International Reference Center for
Immunoglobulins decided that enough critical data were available to announce the
presensce of the fifth immunoglobulin isotype, immunoglobulin E (IgE). At the same
time, Coombs & Gell produced their classification of allergic reactions, i.e. familiar types
I – IV hypersensitivities. Although too much emphasis has been given to the supposedly
distinct and mutually exclusive roles of antibodies and immunocompetent cells, the
Coombs & Gell classification is still useful. In the mid-1980s, the role of leukotrienes in
the allergic reaction was determined.
Actual knowledge about pathogenesis of allergic diseases
Actual knowledge about pathogenesis of allergic diseases is focused on the hypothesis of
dynamic immune response, as orchestrated by dendritic cells and T helper lymphocytes
(Th), and mediated by effector cells of several types, antibodies, chemokines, and
cytokines. According to the currently favored hypothesis of how the immune system is
controlled, there is a balance between two subpopulations of Th, Th1 and Th2 cells. Th1
promote immune protection against bacterial and viral infections, and Th2 protect the
body from helminth infestations and perhaps also maintain pregnancy.
In atopic individuals the balance between Th1 and Th2 is altered with predomination of
Th2 type of immune response. In these individuals, exposure to certain environmental
allergens leads to Th2 activation and production of specific cytokines, such as interleukin
3 (IL-3), IL-4, IL-5, and IL-13, i.e. to activation of the allergic cascade. IL-4 is critical
in switching B-lymphocytes to produce specific IgE antibodies directed against certain
allergen. The specific IgE antibodies coat the surface of the mast cell present in the nasal
and bronchial mucosa or in the skin. When the specific allergen (e.g. a specific pollen grain)
is inhaled into nose, it can bind to the IgE on the mast cell, leading to its degranulation
and release of the mediators (histamine, leukotrienes, prostaglandin D2) responsible for
the early allergic reaction that occurs within 1-2 hours following the exposure to allergen
(Figure 1). IL-5 is of critical importance in the differentiation, survival, as well as in
the recruitment of eosinophils in the target tissue (nasal and bronchial mucosa, skin).
The eosinophil mediators, such as eosinophil cationic protein (ECP), major basic protein
(MBP), and eosinophil peroxydase, are of great importance in late allergic reaction and
chronic allergic inflammation. The most important cells of the allergic cascade include
Th2 cells, B-lymphocytes, mast cells, eosinophils, and structural cells (epithelial and
endothelial cells, fibroblasts), as well as dendritic cells which act as antigen-presenting
cells (APC).
Figure 1. Allergic cascade – early allergic reaction
Adapted from Brusic V, Petrovsky N, Gendel SM, et al. Computational tools for
the study of allergens. Allergy 2003; 58: 1083-1092.
Various agents can act as adjuvants in the activation of allergic cascade, such as
enterotoxins of Staphylococcus aureus (it seems to stimulate eosinophilic inflammation
and a polyclonal IgE response in atopic dermatitis), tobbaco smoke, indoor and outdoor
air pollutants, etc. In some cases the cascade should be activated by unknown agent (e.g.
infective agent, unknown allergen) causing inflammation that does not differ from the
allergen-induced inflammation in the classic allergic diseases (e.g. nonallergic asthma,
nonallergic rhinitis, nonallergic urticaria).
Typical allergic symptoms include asthma, rhinoconjunctivitis, gastrointestinal symptoms,
and characteristic skin lesions, which are usually refer to as “atopic diseases”. An atopic
individual may develop a spectrum of atopic diseases with age, sometimes refer to as “the
atopic march”. During the first years gastrointestinal and eczematous skin symptoms,
usually caused by food allergens, predominate. Allergic diseases caused by inhalant
allergens (e.g. asthma and rhinitis) develop later.
Atopy is defined as a personal or familial predisposition for production of specific IgE
antibodies following the exposure to environmental allergens that may lead to clinical
manifestations of allergic symptoms. The tendency to develop allergic, or IgE-mediated,
reactions to extrinsic allergens has a genetic component. The risk of a child to develop
an IgE-mediated allergy is estimated to 40-60% if both parents are atopic and to 5-10%
if both parents are nonatopic. Up to now, association between several gene loci and high
IgE levels, asthma and bronchial hyperresponsiveness has been reported, but no specific
genetic marker for atopy has been identified. There are suggestions that besides increased
IgE production, atopy may include some kind of higher sensitivity of the target organs,
such as bronchial hyperresponsiveness in subjects with allergic asthma, and disturbed
barrier function of the skin in subjects with allergic skin diseases, etc.
The atopic individual can not be identified before developing allergen-specific sensitization.
The atopy is a condition, not a disease. The presensce of IgE antibodies does not necessarily
mean clinically active disease. On the other hand, IgE-mediated allergic reactions may
occur also in nonatopic subjects (e.g. reactions to drugs and insect venoms).
Revised classification and nomenclature of allergic diseases
Revised classification and nomenclature of the allergic diseases according to the European
Academy of Allergy and Clinical Immunology (EAACI) Position Paper is given on Figure
2.
Hypersensitivity
Hypersensitivity is defined as a presence of objectively reproducible symptoms or signs,
initiated by exposure to a defined stimulus at a dose tolerated by normal subjects. This
definition does not accommodate classical responses to infection, autoimmunity, or toxic
reactions, but emphasizes the link between the symptoms and the environmental factors
to which the subjects attribute their symptoms. The old terms, such as “idiosyncrasy”,
“intolerance”, or “hyperreactivity”, are no longer needed.
Hypersensitivity
Figure 2. Classification of the hypersensitivity reactions
Adapted from Johansson SOG, Hourihane JO’B, Bousquet J et al. A
revised nomenclature for allergy. An EEACI position statement from the
EAACI nomenclature task force. Allergy 2001; 56 (9): 813-824.
Atopy
Atopy is defined as a personal or familial tendency to produce IgE antibodies in response
to low doses of allergens, usually proteins, and to develop typical symptoms such as
asthma, rhinoconjunctivitis, or eczema/dermatitis. The terms positive prick-tests subjects
or IgE-sensitized subjects should be used for asymptomatic subjects with positive prick
tests and/or increased IgE serum levels.
According to the results of our polycentric study,
the prevalence of atopy in adults in R. Macedonia was 34.8%.
Allergy
Allergy is defined as a hypersensitivity reaction initiated by immunologic mechanisms.
Allergy can be antibody- or cell- mediated. In most cases, the allergic reaction is mediated
by IgE antibodies (e.g. the antibody responsible for the allergic reaction belongs to IgE
isotype) and these subjects may be said to suffer from IgE-mediated allergy. IgEmediated reactions may also occur in nonatopic subjects (i.e. insect sting allergy, drug
allergy, etc). Non-IgE-mediated allergy may be caused by antibodies IgE classes other
than IgE, usually IgG (e.g. serum sickness, allergic alveolitis) or may be mediated by
sensitized lymphocytes (e.g. allergic contact dermatitis, celiac disease).
Hipersensitivity reactions caused by nonimmunological mechanisms (e.g. hypersensitivity
reaction to aspirin) should be called nonallergic hypersensitivity.
According to the current study,
the prevalence of allergic diseases in R. Macedonia was 35.6%,
41.4% in adults and 25.1% in children.
Allergens
Allergens are defined as antigens stimulating hypersensitivity mediated by an immunologic
mechanism. Most allergens reacting with IgE and IgG antibodies are proteins (molecular
weight from 10,000 to 40,000 daltons), usually with carbohydrate side chains, but they
also may be pure carbohydrates. In rare instances, allergens that cause IgE-mediated
reaction may be a low-molecular-weight chemical, such as isocyanates and anhydrides,
acting as haptens. In the cases of cell-mediated allergic reactions (e.g. allergic contact
dermatitis), allergens are also low-molecular-weight chemicals such as nickel, chromium,
formaldehyde, etc.
Allergic rhinitis
Allergic rhinitis is defined as rhinitis caused by immunological mechanisms. If we wish
to highlight the role of IgE, we should use the term IgE-mediated allergic rhinitis. The
World Health Organization (WHO) document “Allergic Rhinitis and its Impact on Asthma”
(ARIA) recommends that the terms “seasonal” and “perennial” should be replaced by
the terms intermittent allergic rhinitis and persistent allergic rhinitis, respectively. All
other forms of chronic rhinitis caused by nonimmunological mechanisms (e.g. vasomotor
rhinitis, hyperreflectory rhinopathy, etc) should be called nonallergic rhinitis.
According to the present study,
the prevalence of allergic rhinitis in R. Macedonia was 20.8%,
23.1% in adults and 16.5% in children.
Allergic conjunctivitis
Allergic conjunctivitis is defined as conjunctival inflammation caused by immunological
mechanisms. IgE-mediated allergic conjunctivitis may be divided into intermittent and
persistent allergic conjunctivitis, as in the subdivision of allergic rhinitis. In the cases of
allergic conjunctivitis combined with allergic rhinitis, the term allergic rhinoconjunctivitis
should be used.
According to the current study,
the prevalence of allergic conjunctivitis in adults in R. Macedonia was 12.9%.
Asthma
The term allergic asthma should be used for asthma caused by allergic mechanisms.
Other nonallergic types of asthma should be called nonallergic asthma. The old terms,
“extrinsic”, “intrinsic”, “exogenous”, and “endogenous” should no longer be used.
According to the results of our polycentric study,
the prevalence of asthma in the age group 20-44 in R. Macedonia was 5.4%.
There are a variety of allergic diseases of the skin with distinctly different pathogenic
mechanisms. The most common allergic skin diseases include atopic eczema/dermatitis,
urticaria, angioedema, allergic contact eczema/dermatitis, and exanthematous drug
eruptions.
Atopic eczema/dermatitis syndrome (AEDS)
Allergic AEDS is eczematous hypersensitivity reaction in the skin. IgE-associated AEDS
is a subgroup of allergic AEDS in which the clinical selection is based on Hanifin & Rajka
criterion, “family history or simultaneous occurrence of symptoms of atopy”. The word
“associated” should be used instead of the word “mediated” due to the lack of knowledge
about the precise role of IgE antibodies initiating the disease. T-cell-associated AEDS is
another subgroup of allergic AEDS, characterized by positive atopy patch tests to aeroand food allergens or allergen-specific T cells in the peripherial blood or in skin biopsies,
but in absence of IgE sensitization. AEDS caused by nonimmunological mechanisms
should be called nonallergic AEDS. The old term “intrinsic/cryptogenic AEDS” is no
longer needed.
According to the present study,
the prevalence of atopic eczema/dermatitis syndrome
in children in R. Macedonia was 3.8%.
Urticaria
Allergic urticaria is defined as urticaria caused by immunological mechanisms. If we
wish to highlight the role of IgE, the term IgE-mediated allergic urticaria should be
used. Urticaria caused by nonimmunological mechanisms should be called nonallergic
urticaria.
Contact eczema/dermatitis
Allergic contact eczema/dermatitis is a subgroup of contact eczema/dermatitis caused
by immunological mechanisms, predominantly cellular (Th1) related. The term irritant/
toxic contact eczema/dermatitis should be used when there are no immune mechanisms
involved.
Hypersensitivity to drugs, food, and venoms
In the situation of hypersensitivity to drugs, food, and insect venoms, the organ-based
classification is not adequate. The main reason is a different multisystem response pattern
when an individual is exposed to high allergen/antigen dosage (milligram to gram) via
mucosal membranes, as by food and drugs, or by injection, as by Hymenoptera venoms
and drugs.
Food allergy or allergic food hypersensitivity is a subdivision of food hypersensitivity
caused by immunological mechanisms. If the role of IgE is demonstrated, the term is
IgE-mediated food allergy. All other reactions should be referred to as nonallergic food
hypersensitivity. Similar terms should be used in the cases of hypersensitivity to drugs
and insect venoms.
According to the results of our polycentric study,
the prevalence of drug hypersensitivity in R. Macedonia was 10.5%,
11.2% in adults and 9.8% in children.
According to the results of our polycentric study,
the prevalence of food hypersensitivity in R. Macedonia was 4.2%,
3.3% in adults and 5.0% in children.
According to the results of our polycentric study,
the prevalence of insect venom allergy in R. Macedonia was 3.1%,
2.5% in adults and 3.8% in children.
Anaphylaxis
Anaphylaxis is a severe, life-threatening, generalized or systemic hypersensitivity reaction.
The reaction usually develops gradually, starting with itching of the throat, the palms, or
the soles, and local urticaria, developing to a multiple organ reaction often dominated by
severe asthma, culminating in hypotension and shock. Hypotension and bronchospasm
do not have to be present for a reaction to be classified as anaphylaxis.
Allergic anaphylaxis is a term which should be used for anaphylaxis caused by
immunological mechanisms. Allergic anaphylaxis usually is caused by IgE-mediated
mechanism (IgE-mediated anaphylaxis), but also may be caused by IgG- or cellmediated mechanisms. Another cases, which are much less common, should be called
nonallergic anaphylaxis. The term “anaphylactoid” should not be used.
References
1. Van Cauwenberge P. Changing the nomenclature: fashion or necessity? Allergy 2001;
56 (9): 809-812.
2. Johansson SOG, Hourihane JO’B, Bousquet J et al. A revised nomenclature for
allergy. An EEACI position statement from the EAACI nomenclature task force.
Allergy 2001; 56 (9): 813-824.
3. Kanceljak-Macan B. Suvremeni pogledi na alergijske bolesti [Current views on
allergic diseases, in Croatian]. Arh Hig Rada Toksikol 2004; 55: 123-134.
10
4. Bousquet J, Ansotegui R, van Ree R et al. European Union meets the challenge of
the grown importance of allergy and asthma in Europe. Allergy 2004; 59: 1-5.
5. Bousquet J. Allergy as a global problem: “Think globally, act globally”. Allergy
2002; 57: 661-662.
6. Brusic V, Petrovsky N, Gendel SM, et al. Computational tools for the study of
allergens. Allergy 2003; 58: 1083-1092.
7. Bonini S. ARIA and GAP extending still further. Summer School’02, Sofia.
Bulgaria.
8. Frew AJ. Allergic basis of asthma. Eur Resp Mon 2003; 8 (23), 74-84.
9. Mosmann TR, Sad S. The expanding universe of T-cells subsets: Th1, Th2 and more.
Immunology Today 1996; 17: 139-146.
10. von Hertzen LC, Haahtela T. Asthma and atopy – the price of affluence? Allergy
2004; 59: 124-138.
11. Punnonen J, Aversa G, Cocks BG et al. Role of IL-4 and IL-13 in synthesis of IgE
and expression of CD23 by human B-cells. Allergy 1994; 49: 576-586.
12. Frew AJ, Kay AB. Eosinophils and T-lymphocytes in late fase allergic reactions. J
Allergy Clin Immunol 1990; 85: 533-539.
13. Munitz A, Levi-Schaffer F. Eosinophils: ”new” roles for “old” cells. Allergy 2004;
59: 268-272.
14. Spiroski M, Kolevski P. Osnovni imunoloski metodi [Basic immunological methods,
in Macedonian]. Skopje: MEDIS – informatika, 1995: 93-104.
15. Spiroski M. Naucniot trud - da se napise i da se objavi. [The scientific article – to
write and to publish, in Macedonian]. Skopje: Institut za imunobiologija i humana
genetika, 2002: 162-167.
Relevancy of the national statistics system for evaluation of allergic diseases
Actual condition in the Republic of Macedonia
Determining of specific health indicators and its easy and fast collection is a basis for
establishing sustainable system for allergic diseases management.
There is a Law for health evidence in R. Macedonia (Official Gazette no. 37/79) that
defines the obligation to establish an appropriate health-statistics system dedicated to
monitoring of morbidity, mortality, capacity use, staff and data about conditions in health
care organizations and health care system in general.
At the same time, there is a tradition in collecting, analyzing and publication of the healthstatistics data.
Hence, there are expectations that official health-statistics system can offer usable data
for analyses, planning of the needs, and assessment of the direct and indirect expenses
11
for prevention, diagnosis and treatment for a special health-ecological problem, such
as allergic diseases of different organs and systems. Unfortunately, opposite of all well
based prerequisites (legal and sub legal basis, regular collecting and reporting the
data), it is a fact that the collected data practically cannot be used.
The reason for this may be located in two groups of problems:
1. Weaknesses and deficiencies in conducting of legally based obligations for
adequate reporting of registered diseases-conditions in different functional units
of the health care system, especially in the private segment,
2. Inadequate system, approach and instruments for collection, analysis and report
of the data
Structure of the health care system and possibilities for collecting and analyzing of
the health-statistics data
According to the basic principles for availability, efficiency and rationality, ambulatorypoliclinics and hospital health care in the Republic of Macedonia are provided on three
levels - primary, secondary and tertiary health care.
The provision of health care to different categories-population groups of inhabitants is
based on establishing several functional categories:
health care of children
health care of school children and youth
health care of adults
health care of workers
health care of women
Therefore, determining the conditions due to frequency and dynamics of disease incidence,
including diseases with allergic etiology, needs analysis of morbidity in each functional
category of health care system establishment. Additionally, routine statistics data are
collected separately for population living in urban and rural areas.
Although it seems that this kind of morbidity statistics is fractured, incoherent and
without possibility for global estimation, the fact that it gives opportunity for analysis
of some conditions in different population groups with some demographic and socioeconomical characteristics due to the registered morbidity is incomparable. However,
the question about functionality of established national health statistics about data for
diseases of interest for the policy makers and evidence based health policy, remains open.
Data presented in this book are a clear argument that diseases with allergic etiology
refer to negative response about this issue.
On the other hand, this complex system is completely open to a large number of subjective
weaknesses that often bring into question the relevance of collected data. The gaunt dots are
located in regular reporting and registering of detected conditions in health organizations,
collecting and delivering to authorized specialized public health organizations on regional
level, and then on national level, their analysis, and accessibility of the published data.
12
Finally, technological aspect of the setting makes this system highly sensitive to possibility
for errors and omissions. Unfortunately, health evidence is manually performed almost
in all health care segments. In spite of the presence of information technology in all
segments, the absence of unique software solution and networking of all healthstatistics subjects makes this system highly nonfunctional for the needs of its users.
Application of international classification of diseases and diseases with allergic
etiology
Speaking about advantages and weaknesses in providing information for allergic diseases
morbidity, it is necessary to make some comments on the possibilities of the official
system for recording of diseases and conditions and their implementation in the national
evidence system and morbidity registration. During the last 10 years, the International
Statistical Classification of Diseases (ICD 10) has been used in Macedonia.
This classification is based on alphanumeric scheme of coding which contains one letter
followed by 3 numbers with possibility of disease classification on three- or four signed
level.
The existing standard Tabular List for the morbidity, as an integral part of ICD-10 is of
special importance and is in favor of increased possibility to compare the collected data.
Therefore, in the national Tabular Lists for data tabling with a few exceptions as a result
of certain specificities in some functional categories of health care system, these standard
Tabular Lists are in use. The conditions due to some allergic entities that are discussed in
this study in the light of possibilities given by ICD-10 are presented below.
Allergic rhinitis
According to the ICD-10 this entity belongs to the group of other diseases of the respiratory
tract classified in the category J30-J39. Using the 3 signed classification, allergic rhinitis
belongs in the group J30- vasomotor and allergic rhinitis. Using the 4 signed classification
there is a possibility of additional classification of all important diagnostic aspects of this
entity:
J30.0 vasomotor rhinitis
J30.1 allergic rhinitis caused by pollen (the used synonyms are: pollen allergy, hay
fever and pollenosis)
J30.2 other seasonal allergic rhinitis
J30.3 other allergic rhinitis (long-term allergic rhinitis)
J30.4 allergic rhinitis, unsigned
The categories according to which morbidity is presented in the health care segment
for youth and children, school medicine and youth and services for general practice and
workers health care are in line with ICD-10 Tabular List of Morbidity. Therefore, allergic
rhinitis is shown together within a wide group of entities referring to nose and nasal
sinuses diseases and are signed as Ј30-Ј31, Ј33-Ј34.
13
Hence, allergic rhinitis as a specific entity can not be analyzed in correspondence to its
frequency having in mind that in official health statistics it appears as a sum placed in a
large group of diseases that are significant in the structure of respiratory illnesses in all
population groups.
Available data referring to respiratory morbidity in ambulatory-policlinic sector in R.
Macedonia comprising allergic rhinitis for the period 1998-2000 are presented in a
continuum.
Vasomotor and allergic rhinitis, chronic rhinitis, nasopharyngitis and
pharyngitis and other nasal and nasal sinuses diseases in
Republic of Macedonia in the period 1998 - 2000
J30-J31
J33-J34
Males
Females
Total
Males
School
Females
Total
Males
General
Females
Total
Males
Occupational
Females
Medicine
Total
0-6 years
1998
1999
2000
Number Rate/10000 Number Rate/10000 Number Rate/10000
535
401
936
556
502
1058
1504
1049
2553
4615
4233
8848
49,35
39,7
44,7
41,16
39,42
40,32
19,53
13,4
16,44
67,5
62,55
65,04
881
733
1614
895
791
1686
1346
1438
2784
3761
3190
6951
81,27
72,57
77,07
66,26
62,11
64,25
17,48
18,36
17,92
55,01
47,14
51,1
947
828
1775
746
695
1441
2024
1881
3905
3565
2920
6485
87,36
81,97
84,76
55,22
54,58
54,91
26,28
24,02
25,14
52,14
43,15
47,67
The data are in favor of the previous fact that official health-statistics data are practically
not useful when talking about monitoring the frequency and developing tendency of
allergic rhinitis. This disease is shown in the large group of other nasal and nasal sinuses
diseases. But hereby, we should mention the fact that each year there is an increased
frequency in some of the functional categories of the health system (children health care,
school children health care and adults).
Allergic conjunctivitis
According to ICD-10 this entity belongs to the groups of conjunctival diseases that are
classified into the category H10-H13, having in mind that H10 is divided into:
H10.0 mucous-purulent conjunctivitis
H10.1 acute atopic conjunctivitis
X10.2 other acute conjunctivitis
Н10.3 acute conjunctivitis, unsigned
Н10.4 chronic conjunctivitis
14
Х10.5 blepharoconjunctivitis
Х10.8 other conjunctivitis
Н10.9 conjunctivitis, unsigned
Having this in mind it is clear that although using the 4 signed classifications, ICD-10
gives no opportunity for allergic conjunctivitis classification but it is placed into category
of other conjunctivitis (H10.8).
The categories according to which the registered morbidity of children, school children
and youth and workers health care sectors is presented, emanate from ICD-10 Tabular
List of Morbidity.
Therefore, allergic conjunctivitis is shown as a large group of conjunctival diseases (H10H13) where besides allergic conjunctivitis, other diseases of conjunctiva are placed as
well.
Available data referring to the condition of allergic conjunctivitis in R. Macedonia for the
period 1998-2000 are presented in a continuum.
Registered conjunctivitis morbidity and other diseases of the conjunctiva in
Republic of Macedonia in the period 1998 - 2000
H10-H13
Males
Females
Total
Males
School
Females
Total
Males
General
Females
Total
Males
Occ. medicine Females
Total
0-6 years
1998
1999
2000
Number Rate/10000 Number Rate/10000 Number Rate/10000
7169
661,32
7016
647,21
8449
779,4
6329
616,96
6232
616,96
7483
740,8
13498
644,55
13248
632,62
15932
760,78
5426
401,7
4753
351,87
4489
332,32
5346
419,78
4909
385,47
4334
340,32
10772
410,47
9662
368,18
8823
336,2
10381
134,81
10362
134,56
10242
133,01
10117
129,19
10687
136,47
10549
134,7
20498
131,98
21049
135,52
20791
133,86
1507
22,04
1561
22,83
1849
27,04
1641
24,25
1226
18,12
1451
21,44
3148
23,14
2787
20,49
3300
24,26
Asthma
According to ICD-10 allergic asthma is presented with a 3 signed category J45 having
the following 4 signed categories:
Ј45.0
Ј45.1
Ј45.8
Ј45.9
predominant allergic asthma, comprising following categories - allergic
bronchitis, rhinitis with asthma, atopic asthma, extrinsic atopic asthma
and hay fever with asthma
non-allergic asthma
mixed asthma
asthma, unsigned
15
The category J46 according to ICD-10 is reserved for asthmatic status (acute severe
asthma).
According to ICD-10 Tabular List, categories J45 and J46 are presented together. This
approach is also used in the national lists for data collection in the children, school
children, youth and general practice health services.
Having in mind the specificity of worker population morbidity, besides J45-J46 categories
there is also a 4 signed category J45.0.
Asthma in Republic of Macedonia in the period 1998 - 2000
1998
J45.0
General
1999
Number Rate/10000
Number
2000
Rate/10000 Number Rate/10000
Males
3456
44,88
3412
44,31
3270
42,47
Females
3444
43,98
3569
45,57
3418
43,65
Total
6900
44,43
6981
44,95
6688
43,06
205
3
244
3,57
167
2,44
217
3,21
215
3,18
121
1,79
422
3,1
459
3,37
288
2,12
Males
Occupational
Females
medicine
Total
Asthma in Republic of Macedonia in the Occupational
Health Services in the period 1998 - 2000
J45-J46
(without
J45.0)
Males
Occupational
Females
medicine
Total
1998
1999
Number Rate/10000
Number
2000
Rate/10000 Number Rate/10000
325
4,75
298
4,36
274
4,01
304
4,49
219
3,24
209
3,09
629
4,62
517
3,8
483
3,55
Due to the fact that the Lists for tabling, collecting, analyzing and reporting the data for
asthma are designed to give access to the asthma (total) and allergic asthma condition,
such data can offer possibilities for current status evaluation. So, the conclusion is that
the morbidity rate of predominant allergic asthma in adults in the Republic of
Macedonia is 45/10000, without any significant difference due to gender and variations
in the three years period. Opposite to this the morbidity rate in occupationally exposed
workers is almost ten times lower than in the adults in the period between 1998 and 2000
showing decreasing tendency. Even if we manage to explain the ten times decreased
morbidity rate in workers health care services as a result of organizational changes,
the ten times decreased asthma incidence in occupationally exposed workers
is almost immposible to be logically explained. The reasons may be located in the
methodology for collecting and analyzing the data, significant decreasing in Occupational
Health Services and the number of active population.
16
Atopic dermatitis
According to ICD-10 a 3 signed category L20 is reserved for atopic dermatitis:
• L20.0
• L20.8
• L20.9
Besnier`s prurigo
Other atopic dermatitis (includes-eczema and neurodermatitis)
Atopic dermatitis, unsigned
Allergic contact dermatitis is coded with the 3 signed category L23. But, this category
excludes unsigned allergy (T78.4), unsigned dermatitis (L30.9), unsigned occupational
contact dermatitis and eczema (L25), napkin (L22), non-infectious allergic dermatitis
of the eyelid (Н01.1), irritant contact dermatitis (L24) and some other entities without
significance for this study.
In ICD-10 Tabular List these diseases are put into a large group of skin and subcutaneous
diseases (L-10 –L99).
Dermatitis and eczema (L20-L30) and urticaria (L50) are placed in the national tabling
lists of children, school children and youth health care services. In the general health
care service data for allergic contact dermatitis (L23), urticaria-total (L50) and especially
allergic urticaria are collected separately. Obviously this disease has a special attention
during determining of the national tabling lists of diseases in Occupational Health Services,
where data for allergic contact dermatitis (L23), irritant contact dermatitis (L24), urticariatotal (L50) and allergic urticaria are listed (tabling) separately.
Available data referring to the registered morbidity in ambulatory-policlinic sector in R.
Macedonia comprising atopic and other types of dermatitis for the period 1998-2000 are
presented in a continuum.
Atopic and other types of dermatitis morbidity (seborrheic, napkin dermatitis, allergic
contact dermatitis, irritant contact dermatitis, exfoliate dermatitis, dermatitis caused by
internal imported substances) registered in Republic of Macedonia in the period 1998 2000 in pre- and school children health care services
1998
L20-L30
0-6 years
School
Males
Females
Total
Males
Females
Total
Number
4008
3690
7698
3572
3969
7541
1999
Rate/10000
369,73
365,3
367,59
264,44
311,65
287,35
Number
4367
3939
8306
3445
4088
7533
Rate/10000
402,84
398,95
396,63
255,04
321,00
287,05
2000
Number Rate/10000
4927
454,5
4523
447,77
9450
451,25
3470
256,89
4188
328,85
7658
291,81
The data referring to the registered morbidity of allergic contact dermatitis in the adults
health care services and occupational health services (occupationally exposed workers) as
well as unsigned dermatitis in the occupational health services for the period 1998-2000
are presented in a continuum.
17
Allergic contact dermatitis in Republic of Macedonia in the occupational and general
health services in the period 1998 - 2000
1998
L23
Males
General
Females
Total
Males
Occupational
Females
medicine
Total
1999
2000
Number
Rate/10000
Number
Rate/10000
Number
Rate/10000
3336
3979
7315
737
612
1349
43,32
50,81
47,1
10,78
9,04
9,92
3664
3867
7531
651
557
1208
47,58
49,38
48,49
9,52
8,23
8,88
3695
3971
7666
520
450
978
47,98
50,71
49,36
7,61
6,77
7,19
Unsigned contact dermatitis registered in Republic of Macedonia in the occupational
health services in the period 1998 - 2000
1998
L25
Males
Occupational
Females
medicine
Total
1999
2000
Number
Rate/10000
Number
Rate/10000
Number
Rate/10000
88
96
184
1,29
1,42
1,35
98
99
197
1,43
1,46
1,45
93
99
192
1,36
1,46
1,41
Drug hypersensitivity
Drug allergy (hypersensitivity to an adequate medicament or medicament that is properly
applied) is signed with T88.7 in ICD-10. It is a 4 signed category by the group of
other surgical and medical care complications that are not classified elsewhere (Т88),
comprising:
• Т88.0
• Т88.1
• Т88.2
• Т88.3
• Т88.4
• Т88.5
• Т88.6
• Т88.7
• Т88.8
• Т88.9
Infection after immunization
Other immunization complications (excludes anaphylactic shock and other serum reactions)
Shock caused by anesthesia
Malignant hyperthermia caused by anesthesia
Unsuccessful or difficult intubations
Other complications due to anesthesia
Anaphylactic shock as an adverse effect caused by adequate medicament or medicament that is properly applied, excluding the anaphylactic shock caused by serum (Т80.5)
Unsigned adverse drug or medicament effect, including allergic reaction, hypersensitivity and idiosyncrasy
Other complications
Complications caused by surgical and medical care, unsigned
It should be mentioned that ICD-10 gives the opportunity for classification of photoallergic
(L56.1) as well as phototoxic response to drug (L56.0).
18
Drug hypersensitivity is classified in the tabling lists in a large group of conditions
as signed as certain trauma and surgical and medical care complications that are not
classified elsewhere, signed with 3 signed categories Т79-Т88. The national tabling and
data collecting lists contains a special category of complications caused by surgical and
medical care (Т80-Т88), which restrict the possibility of obtaining national data for
epidemiology and other characteristics connected to drug hypersensitivity.
Drug hypersensitivity data in the national morbidity statistics are presented as a large
group of diseases and conditions caused by surgical and medical care only with their 3
signed codes that completely disables the endeavors of collecting relevant national data
for epidemiology of drug hypersensitivity.
Food hypersensitivity
According to ICD-10, food hypersensitivity can be determined by food contact of the
human body. The following pathologic reactions can be manifested:
• L23 - allergic contact dermatitis
• L23.6 - allergic dermatitis caused by contact of food with skin, excluding
dermatitis by ingested food L27.2
• L25 - unsigned dermatitis
• L25.4 - unsigned contact dermatitis caused by contact of food with skin
• L27 - dermatitis caused by internally imported substances
(Excluding - reaction to food, except dermatitis Т88.7)
• L27.2 dermatitis caused by ingested food
• Т78 - Adverse effects, unclassified elsewhere • Т78.0 anaphylactic shock caused by adverse reaction to food
• Т78.1 other adverse reaction to food, unclassified elsewhere
• Т78.2 anaphylactic shock, unsigned
• Т78.3 angioneurotic edema
• Т78.4 allergy, unsigned
• Т78.8 other adverse effects, unsigned elsewhere
• Т78.9 adverse effect, unsigned
A large category (L10-L99), is reserved for all forms of dermatitis (atopic dermatitis,
unsigned dermatitis and dermatitis caused by internally imported substances) according to
the tabling lists in ICD-10, signed as other skin and subcutaneous diseases. Anaphylactic
shock caused by adverse reaction to food, unclassified elsewhere, should be put in the
category - certain early complications caused by trauma, surgical and medical care,
unclassified elsewhere with all 3 and 4 signed categories from Т79 to Т88.
19
There are several possibilities incorporated in the national lists for tabling and presenting
the data. The data for dermatitis and eczema (L20-L30) in children, school children and
youth health services are collected and presented separately. There is a special 3 signed
category for the data of complications due to surgical and medical care (Т80-Т88). In
the Occupational Health Services these groups of diagnoses are divided and presented
separately, such as allergic contact dermatitis (L23), and other diseases and conditions of
the skin caused by a contact or food intake that are listed in the group of other skin and
subcutaneous diseases (L10-L22, L24-L45, L51-L99).
It has to be pointed out once again that the data are listed only by their 3 signed codes
which disable the intentions of collecting relevant national data for epidemiology of
food hypersensitivity.
Insect allergy
Insect allergy can be classified in the group of toxic effects caused by contact with poison
of animals (T63), according to ICD-10:
•
•
•
•
•
•
Т63.0
Т63.1
Т63.2
Т63.3
Т63.4
Т63.5
snake poison
other reptile’s poison
scorpion poison
spider poison
other arthropods poison (insect bite, poison)
toxic effect caused by fish contact
ICD-10 also recommends 3 signed category X23 for coding insect allergy, being a part
of the large group of conditions assigned as contact with poison of animals and plants
(X20-X29).
Due to the special tabling lists by ICD-10 there is a possibility to put the insect allergy
into the large group of conditions known as toxic effects caused by mostly non-medical
substances considering the source (Т51-Т65), which is at the same time used in the national
lists for tabling, collecting and publishing the data. Contacts with poison of animals and
plants, according to the special ICD-10 morbidity and mortality tabling are not planned,
and in the national lists this category (X23) is placed in the large group of 3 signed coded
diseases and conditions known as other causes for accidental injury (W00 - X30 and X39X59).
Speaking about insect allergy, the same conclusion is imposed for the previous entities,
that national available data for disease epidemiology are completely inadequate for
the purpose of determining the basic epidemiological characteristics, frequency and
dynamics.
20
The need of epidemiological research
Having in mind these reasons, in order to determine the frequency of some allergic
entities, epidemiological-clinical research based on a previously made program that
offers optimal meticulous objectivity and comparison of data, is being done. These were
the basic ongoing goals in our research as well.
On the other hand, planning, conducting and evaluation of population epidemiological
studies is a long-term process, giving valuable, comprehensive and plausible data. They
are irreplaceable instrument for determining the prevalence of some conditions, but also
for analysis of specific characteristics of the examined event. But, due to their design
and mode of conduction, they require a perfectly organized network of institutions in the
research, experienced and adequately trained researchers as well as adequately designed
instruments pertinent for collecting relevant data. Therefore, this kind of epidemiological
study is performed incidentally and in line with the needs and research potential of the
research teams. The fact that they could be interrupted by financial barriers should always
be considered by the institutions, teams or individuals involved.
It is necessary to emphasize the fact that epidemiological cross-sectional studies, like
this one, according to its design enable collection of data about the prevalence of some
conditions, but however can not give an entire review of their developing tendency. The
data about decreasing or increasing of the disease frequency in a longer period of
time are basic indicators for health policy planning in the area.
Having in mind the allergic diseases the problem becomes bigger and more actual
considering the fact that the disease prevalence is increasing with an amazing speed in all
population groups - children, adults, occupationally exposed workers. On the other hand,
biomedical investigations and technological achievements are in a significant progress
which requires new technical performances of the necessary medical equipment aimed to
quick, correct and etiologic diagnosis and treatment of the diseases.
The intensive development of scientific and technological achievements opposite to the
increasing trend of the allergic diseases and conditions frequency, is an acceptable reason
to seek for easy and available sources of exact and relevant data as a basis for prevention
and adequate risk management of allergic diseases.
Contrary to the advantages of some kind of epidemiological studies, they mostly offer
data that are not completely comparable because of the chosen design and the basic aim
of the conducted research. They are focused on different target groups, diagnosis and
trigger factors that are determined by the purpose and research interest of the principal
investigator. The experience of a large number of meta-analyzes has confirmed this
observation.
21
References:
1. Ambulantno-poliklinicki morbiditet vo Republika Makedonija [Ambulatorypoliclinic morbidity in Republic of Macedonia, In Macedonian]. Republic Institute
for Health Protection, Skopje, 1998-2000.
Aeropallinological and epidemiological studies in R. Macedonia
The given contemplations and facts imposed the necessity of continuation in the
cross-sectional epidemiological study of allergic diseases in order to gain a relevant
aeropallinological information about the whole country. It resulted in the preparation
and realization of the study “Epidemiological Characteristics of the Allergic Rhinitis in
Republic of Macedonia in Correlation with the Pollen Microflora”, which was approved
and financed by the Ministry of Science and Education of the Republic of Macedonia. The
Project was performed under the code 400998 with the contract number 08-3564 from
08.07.1998 and contract annex 40079998 by 01.10.1999. Besides the epidemiological
research of allergic rhinitis and aeropallinological studies, with the previous experience
of the members from the Institute and other cities in Macedonia, the project enabled
research on other allergic diseases in the whole country as well.
The basic aims of the study were aeropallinological monitoring and design of pollen
calendars and maps, as well as forming of a palette of the most important allergens
in our country for the use of allergy centers and determining the basic epidemiologic
characteristics of pollenosis and other most common allergic diseases in the Republic of
Macedonia, and the factors in favor of their occurence.
The study incorporated two complementary segments, making one whole, aeropallinological
and epidemiological segment.
It had a polycentric character and was performed
in 6 centers in the Republic of Macedonia: Skopje, Dojran, Ohrid, Prilep, Debar and
Pehchevo, with different characteristics which resulted in getting a real impression of the
research area.
In addition to basic analysis for qualitative-quantitative relations in the pollen specter,
based on the 10-days average values of the dominant taxa in the pollen aero sediment,
pollen calendars were made for each of the cities, and values were shown in a standard
pillar diagram according to the EPI recommendations.
The dynamics of the total pollen grains count was analyzed and compared to the data
given by the Republic Hydro-metrological Institute (meteorological stations: Zajcev Rid,
Dojran, Ohrid, Prilep, Mavrovi Anovi and Berovo).
Statistical analysis of the data was made by analysis of variance (ANOVA), regression
correlative analysis, cluster analysis and t-test.
22
Characteristics of the centers where the study was conducted
The selection of the centers for aeropallinological monitoring was made based on the
criteria by their climate-vegetation-soil characteristics, horticultural treasure, economic
and tourist importance and their specific location in the Republic of Macedonia (Figure
3). The selection also gratifies the criteria for the clinical-epidemiological segment of the
study considering the fact that they are cities with different magnitude, depository and
economic potential as well as different kind of standard of living of their inhabitants.
Skopje (Sk)
The Skopje ravine is a relatively well differentiated, situated in the north part of the
Republic of Macedonia, taking the upper flow of the river Vardar. It comprises a surface
of 1924,215 km2, which is 7,6% of the total surface of the Republic of Macedonia.
The city of Skopje is an urban center with a wide gravitational radius and the most
important center in Macedonia, having concentrated one quarter of its total population.
According to the State Statistical Office, by the 2002 census Skopje has 506. 926 citizens.
It takes the middle part of the Skopje ravine and belongs to warm continental zone. The
average year temperature is 12 oC and the average rain quantity is about 501,7 mm per
year.
It is clear that the influence of the Continental-Mediterranean climate (as well as its
modifications with the effects of mountain climate) is one of the most dominant factors
on the vegetation of the given territory.
Based on the data analysis given by the Ministry of Agriculture, Forestry and Water
Supply, vertical profile of the Skopje ravine and the classification by some of our authors,
there are seven registered climate-vegetation-soil areas. They are a result of the regional
climate conditions of place-growth, different ecological conditions and finally influence
of anthropogenic factors.
Dojran (Do)
The Dojran ravine is a wide space placed in the southeast part of the Republic of
Macedonia. It is a borderline and ecological region, having the lowest part of the down
flow of river Vardar.
The city of Dojran is a tourist center with a wide gravitational radius. According to the
2002 census, Dojran has 3.426 inhabitants. The city is placed on the shore of the Lake
Dojran 180 meters above the sea level in the sub-Mediterranean area. The average year
temperature is 14,2 oC and the average rain quantity is about 645 mm per year. According
to the 1998 Spatial plan of the Republic of Macedonia this city has a low degree of
aeropollution.
23
There are 8 registered climate-vegetation-soil areas in the Dojran ravine, which are a result
of hydrologic, different ecologic conditions as well as influence of the anthropogenic
factors.
Ohrid (Oh)
The Ohrid-Struga ravine is a relatively good differentiated space placed in the southwest
part of the Republic of Macedonia comprising a part of the river Crn Drim flow.
The city of Ohrid is situated on the flat surface between the ravine and the Lake Ohrid
rising up to the next hill to the middle age Fortress. Today, Ohrid is the biggest and most
attractive urban tourist center in this area with a wide gravitation radius and about 760
meters above the sea level. According to the 2002 census Ohrid has 55.749 inhabitants.
The city belongs to the warm continental zone. The average year temperature is 11,2 oC
and the average rain quantity is about 689 mm per year.
There are 6 registered climate-vegetation-soil areas in the Ohrid-Struga ravine, which
are a result of regional climate place-growth, ecological conditions and influence of the
anthropogenic factors as well.
Prilep (Pr)
Prilep ravine is a wide space placed in the central part of the Republic of Macedonia,
surrounded by mountains (except towards south), occupying the field of Prilep (lowest
part). It comprises parts of the Crna and Old river flows, having two cities, Prilep and
Krushevo.
The city of Prilep is placed in the eastern part of the Prilep ravine. It is an urban center
with a wide gravitation radius, 673 meters above the sea level. According to the 2002
census Prilep has 76.768 inhabitants. The city belongs to the warm continental zone,
having average year temperature of 11,2 oC and the average rain quantity is about 557
mm per year.
There are 6 registered climate-vegetation-soil areas in the Prilep ravine, which are a result
of regional climate conditions and the influence of the anthropogenic factors as well.
Debar (De)
Debar ravine is a border area to the Republic of Albania, placed in the western part of
Macedonia, surrounded by mountains. It comprises parts of the Crn Drim and Radika
river flows.
24
The city of Debar is a functional center for the area with a small gravitation radius. It is
placed about 675 meters above the sea level, nearby Lake Debar. According to the 2002
census Debar has 19.542 inhabitants.
This city belongs to the warm continental zone. There is not a meteorological station in
the city of Debar, but according to the data taken from the station in Mavrovi Anovi, the
average year temperature is 11,8 oC and the average rain quantity is about 890 mm per
year.
There are 6 registered climate-vegetation-soil areas in the Debar ravine, which are a result
of regional climate place-growth, different ecological conditions and the influence of the
anthropogenic factors as well.
Pehchevo (Pe)
Pehcevo ravine is a border area to the Republic of Bulgaria, placed in the eastern part
of the Republic of Macedonia, surrounded by mountains (Picture 3). It comprises parts
of the river Bregalnica flow. There are two cities in the research territory, Pehchevo and
Berovo.
The city of Pehchevo is with a small gravitation radius, functional center for its immediate
ambience and less developed secondary activities.
According to the 2002 census Pehchevo has 5.517 inhabitants. This city belongs to the
cold continental zone.
There is no meteorological station in the city of Pehchevo, but according to the data taken
from the station in Berovo, the average year temperature is 8,8 oC and the average rain
quantity is about 632 mm per year.
There are 5 registered climate-vegetation-soil areas in the Pehchevo ravine (Picture 3).
They are a result of the regional climate place-growth, different ecological conditions and
the influence of the anthropogenic factors, which resulted in other species of forests and
cattle yards, but outnumbered in this ravine.
25
Part II
Aeropallinological
monitoring
28
1.0. Outdoor aeroallergens
Monitoring of pollen contents (aeropallinologic microflora) in the air, as a pollenosis
etiology factor, is directly connected to the pollenosis problem evaluation and conducting
the preventive actions. In most European countries pollen monitoring is a tradition of many
years. European monitoring system through EPI (European Pollen Information) enables
local, regional and international coordination of aeropallinology centers by follow-up of
the pollen grains distribution and provision of stipulation models. The need for creation
aeropallinologic calendar of some region results from the climate, vegetation, topography,
orography and hydrographic characteristics of that region. Since 1993, aeropallinologic
research has been performed at the Institute of Occupational Health - Skopje. First
observations comprised data about the city of Skopje without any representative statistics
about the entire territory of R. Macedonia.
Atmospheric air contains different industrial and biologic pollutants. It is necessary
to perform detailed monitoring of biologic pollutants in R. Macedonia together with
examinations of industrial components which have already given comparable and relevant
data. These data are of extensive importance in biologic, ecologic and allergologic
researches.
Pollen grains (PG) together with other aerosols are continuously present in the air,
especially in the pollen period and have specific effects on the health. They constitute
generative elements necessary in the process of reproduction. Pollen is released from
anemophilic taxa in large amounts in the period of pollination and is spread on the earth
ground as a “pollen rain”. Some of the PG are close to the earth ground and have short
period of sedimentation and deposition. But, pollen spread under the influence of dilution
and turbulence on the distance far from the source is very important in the process of
resolving questions on etiology of allergic diseases.
1.1. Definition
According to the British Aerobiologic Federation “aeropallinology is a scientific discipline
which studies PG transport through the atmosphere, especially the source of PG, their
release in the atmosphere, dispersion and deposition as well as their influence on
vegetable, animal and human systems”, so aeropallinology as a segment of aerobiology
studies pollen microflora in the free atmosphere.
1.2. Aeropallinological methods
One of the most important discussions in aeropallinology examinations is sampler
selection. According to the physical principles of their construction there are, generally,
two types of samplers. The first type (Gravimetric method) is simple; it is based on free
sedimentation of pollen rain and has historical importance. The second type (Volumetric
method) is based on forced pollen sedimentation mediated by vacuum pumps and shock
forces. These sampling methods collect PG directly from the air flow which is minimal
and adequate to the sedimentation velocity.
29
Today, both methods are used in aeropallinological practice. There are no great differences
in data obtained and both methods have some practical importance.
Efforts for construction of more effective PG sampler continue and today there is large
number of them.
The latest researches are focused on detecting and immunochemical quantification of
micron and submicron allergens using radioisotope-marked antibodies. They can be
detected by filters with cascade impactors which divide particles according to dimensions
or flow intensity, but although these methods give more precise results, they have no
wider use due to complex technique.
We have used gravimetric method (Durham) for aeropallinological monitoring, and for
the city of Skopje both volumetric and gravimetric methods.
The gravimetric method is older one, based on free sedimentation of “pollen rain”, and
performed by Durham apparatus (Figure 1). The advantages of this method are possibilities
of placing on different locations and conditions (for e.g. places without electricity).
The volumetric method is a new method used worldwide, based on forced pollen
sedimentation mediated by vacuum pumps and shock forces. The obtained results are
comparable throughout world. It is usually done by Lanzoni VPPS 2000 apparatus (Figure
2).
The observation period started in the beginning of January 1998 and lasted till the end
of 2000, with glass replacement each day and 24 hour duration of sedimentation period.
Pollen grains identification and counting were performed on 2 cm2 surface.
Figure 1. Gravimetric Durham
apparatus for
aerosedimentation
30
Figure 2. Sedimentation aeropallinologic apparatus - Lanzoni VPPS 2000
1.3. Methodology of aeropallinological research
Aeropallinological research was performed in six cities of R. Macedonia: Skopje, Dojran,
Ohrid, Prilep, Debar and Pehchevo. Selection of the cities was based on many criteria,
such as: climate-vegetation-soil characteristics, horticultural wealth, economic and tourist
importance as well as characteristic location in R. Macedonia (Figure 3).
Durham sedimentation method was applied during aeropallinological examination. The
observation period started in the beginning of January 1998 and lasted till the end of
2000, with glass replacement each day and 24 hour duration of sedimentation period.
Pollen grains identification and counting were performed on 2 cm2 surface.
Among basic analyzes for quality-quantity relations in pollen spectrum, pollen calendars
were constructed for each city, according to the 10 day-interval average values of dominant
taxa in the pollen aerosediment, and data were shown on standard column chart as the
most appropriate one, according to EPI recommendations.
Dynamics of the total daily PG number was analyzed and compared with the meteorology
data (Republic Hydrometeorology Institute - Meteorology stations: Zajchev Rid, Dojran,
31
Ohrid, Prilep, Mavrovi Anovi and Berovo). Skopje meteorology station was located at
region Zajchev Rid, Debar data were taken from meteorology station in Mavrovi Anovi,
and Pehchevo data were taken from the station in Berovo.
Data obtained were statistically analyzed by analysis of variance (ANOVA), regression
correlation analysis, cluster analysis and t-test.
Figure 3. Map of climate regions and location of apparatus
for aeropallinological monitoring
1.4. Influence of aeropollution on pollen grains concentration and
dissemination
Aeropollution. The term “aeropollution” means wide spectrum of chemical and biological
components in outdoor and indoor atmosphere. Aeropollutant is every substance which
modifies natural contents of the atmospheric air.
International meteorology organization research (Intergovernmental Panel on Climatic
Change) (1992) and ecology associations focused on: increased SO2 concentration in the
atmosphere, gases of “green house”, CFC presence as well as new technologies as factors
which have influence on pollen spectrum. They are producing changes in timing and
magnitudes of pollen period and have implications on pollenosis appearance.
32
Under the influence of UV waves, aeropollution (SO2, NO2, CO, diesel particulates,
heavy metals) changes the surface structure of pollen grains, increases the number of
cytosol allergy proteins, and pollen becomes intensively allergenic. Total PG number
in the air is associated with total aerosediment amount and the correlation is significant
(Figure 4). In conditions of unavailable fundamental research, the data obtained through
continuous monitoring and some researches give opportunity to determine the association
between aerosediment amount and PG number for some area. Statistical analysis of these
parameters in 2000 for the city of Skopje showed high degree of statistical association
and coefficient of positive correlation (0,97). These data are expected and logical and
significant correlation enables PG number assessment according to the aerosediment
amount. This assessment could be valuable guide to the pollen potential evaluation of
some area but comparative advantages of aeropallinologic methods are irreplaceable.
Figure 4. Correlation between total monthly PG number and total monthly aerosediment
amount (mg/m2) registered in Skopje, 2000
Nevertheless, statistically significant correlation was not determined in the case of
ambrosia (Figure 5). The answer is somewhere between the presence of ambrosia PG
in summary pollen structure on one side to the gravimetric and other characteristics of
ambrosia PG on the other side.
33
Figure 5. Correlation between total monthly ambrosia PG number and total monthly
aerosediment amount (mg/m2) registered in Skopje, 2000
The anatomy of nasal cavities enables deposition of inhaled particles, larger than 10
mcm, they are caught on the nasal filter and there they express effects, such as pollen
rhinitis. After raining, pollen grains release submicron pollen particles (leucoplasts)
which penetrate in lower airways and cause spreading allergic inflammation. Under the
influence of UV waves, aeropollution (SO2, NO2, ozone) changes the surface structure
of pollen grains, increases the number of cytosol allergy proteins, and pollen becomes
intensively allergenic. The problems of aeropollution and its effects on the processes of
allergic senzibilisation and inflammation are global ones. Table 1 shows the results of
aerosediment measurements in the Republic of Macedonia, performed by the Republic
Institute for Health Protection, Skopje (2003). It is obvious that large number of samples
(20%) had aerosediment values above the maximum permitted concentration.
34
Institute for
Health Protection
Number of
measurement
sites
Number
of
samples
Average annual
concentration
(mg/m2)
MinimumMaximum
(mg/m2)
SKOPJE
VELES
v. Ivankovci
PRILEP
T.U.Krushevo
OHRID
T.E.Struga
BITOLA
KOCHANI
KUMANOVO
STRUMICA
TETOVO
SHTIP
R. MACEDONIA
30
7
1
5
2
3
2
4
4
4
4
4
6
76
338
82
12
60
24
29
24
46
48
48
47
47
70
870
182.1
176.7
191.0
177.45
119.5
229.9
248.86
114.58
72.67
135.0
290.0
126.16
243.9
177.52
32.1-707.2
0.3-1508.0
6.0-686.1
127.0-229.3
95.75-136.25
26.61-616.62
33.6-818.2
27.15-325.53
11.83-242.08
16.0-457.1
117.0-682.0
11.58-379.40
35.38-659.31
41.56-572.85
Number
of samples
above
MPC*
42
14
2
13
0
6
10
2
0
3
17
1
60
170
* MPC-Maximum Permitted Concentration (300 mg/m2);
Table 1. Hygiene quality of air in R. Macedonia during 2003 - aeropollutant aerosediment
Statistical analysis showed significant correlation between total PG number and
aerosediment concentration in 2003 in the city of Skopje (Figure 6).
Figure 6. Correlation between total PG number and aerosediment
concentration in 2003 in the city of Skopje
35
Multicenter strategy is indispensable in order to solve the problem with the allergic diseases
due to their high prevalence both in our country and in the world. The importance of such
strategy is emphasized because of the wide range of industrial and biologic pollutants
which are detected as allergogens and because of their synergistic actions.
The motive for performing such study is related either to the critical notification of
disadvantages linked to the first epidemiological and aeropallinological examinations in
our country or to the necessity for representative pollenosis data for the whole country.
Therefore, besides Skopje, cities of Dojran, Ohrid, Prilep, Debar and Pehchevo were
included in our research and pollen monitoring and clinical-epidemiological research for
the whole country showed the true significance of a multicenter study.
1.5. Results
1.5.1. Skopje.
Skopje apparatus was located on flat roof on the building of the
Institute of Occupational Health at 7,5 m height above the ground level, coordinates:
λ=21°27′09′′; ϕ=42°01′16′′; and Ζ=275 m above the sea level.
The city of Skopje is characterized by rich horticultural diversity. During the examined
period, the highest values were detected for: Betula (birch), Pinaceae (pine), Cedrus
(cedar), Platanus (plane), Cupressaceae (cypress), Quercus (oak), and Fraxinus (ash) as
dendrofloral taxas, and Poaceae (cereal), Urticaceae (nettle), Plantago (plantain), and
Chenopodiaceae/Amaranthaceae (orach/barren) as greens.
The highest concentrations of: Cedrus (cedar), Betula (birch), Platanus (plane), Acer
(maple), Populus (polar), Morus (mulberry) and Fraxinus (ash), and low concentrations
of Fagus (beech) were registered in Skopje in comparison with other examined cities.
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Table 2. Taxas
SKOPJE
Trees
Cereal
Orach
Wormwood
Nettle
Plantain
Ambrosia
Pollen %
88,4
6,1
1,1
0,2
1,5
1,1
0,2
Average annual relative presence of pollen grains of seven taxa in the city of Skopje
1.5.2. Dojran. Sampling apparatus in Dojran was located at the Barracks court with
coordinates λ=22°42′44′′; ϕ=41°10′42′′ and Ζ=160 m above the sea level.
The city of Dojran is characterized by the presence of taxa of riverside and swamp
vegetation. During the investigation period, the highest values were detected for:
36
Cupressaceae (cypress), Pinaceae (pine), Cedrus (cedar), Quercus (oak), Ulmus (elm),
Platanus (plane), and Juglans (walnut) as dendrofloral taxas, and Poaceae (cereal),
Urticaceae (nettle), Asteraceae, Plantago (plantain), and Rumex (sorrel) as greens.
The highest concentrations of Ulmus (elm) and Sambucus (elder), typical only for the
region of Dojran were registered, followed by high concentrations of Rosaceae (rose),
Fabaceae, Olea (olive), Myrtus (greek tea), and Koelreuteria, as well as Urticaceae
(nettle), Chenopodiacea/Amaranthaceae (orach/barren) and Apiaceae. The highest
concentrations of Morus (mulberry), Platanus (plane), Cupressaceae (cypress), Juglans
(walnut) and low concentrations of Tilia (lime) were registered at this location. Here,
pollen period starts earlier and finishes later in comparison with other locations.
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Table 3. Taxa
DOJRAN
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
70,9
8,6
4,4
0,9
8,4
0,5
0,1
Average annual relative presence of pollen grains of seven taxa in the city of Dojran
1.5.3. Ohrid. Sampling apparatus in Ohrid was located on the plain roof of the Medical
Center building at 8,5 m from the surface with the following coordinates: λ= 20° 49′20′′;
ϕ=41° 06′56′′ and Ζ=705 m above the sea level.
In the city of Ohrid, the highest values of pollen grains from dendrofloric taxa were
detected for Pinaceae (pine), Cupressacea (cypress), Betula (birch), Quercus (oak),
Juglans (walnut) and Corylus (hazel), whereas the most prevalent grass and weed pollens
were: Poaceae, Asteraceae, Plantago (plantain), Rumex (sorrel) and Urticaceae (nettle)
pollen grains.
This city is characterized by a rich horticultural diversity, but also by a presence of swamp
and water vegetables and higher pollen grains concentration of Asteraceae. In this city,
compared to others, the highest concentrations were registered for Pinaceae (pine) and
Sambucus (elder), and the lowest for Fagus (beech).
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Table 4. Taxa
OHRID
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
83,9
8,3
0,2
0,9
0,5
0,9
0,1
Average annual relative presence of pollen grains of seven taxa in the city of Ohrid
37
1.5.4. Prilep.
Sampling apparatus in Prilep was located on the plain roof of the
Medical Center building, 8,5 m from the surface with the following coordinates: λ=21°
34′07′′; ϕ=41° 20′39′′ and Ζ=660 meters above the sea level.
The highest values of pollen grains were detected for Cupressaceae (cypress), Quercus
(oak), Pinaceae (pine), Tilia (lime) and Corylus (hazel) of dendrofloric taxaes, as well as for
Poaceae (cereal), Plantago (plantain), Rumex (sorrel), Chenopodiaceae/Amaranthaceae,
Urticaceae (nettle) and Asteraceae of grass and weed pollens in the city of Prilep, in the
examined period.
This city, compared to others, is characterized with higher concentrations of Corylus
(hazel), Tilia (lime), Populus (poplar), Quercus (oak) and Koelreuteria, as well as high
prevalence of grass and weed taxa, with dominance of Poaceae (cereal), Rumex (sorrel),
Chenopodiacea/Amaranthaceae and Plantago (plantain). The most important taxa
registered in the city of Prilep and their seasonal and concentration characteristics are
presented in the pollen calendar for Prilep.
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Table 5. Taxa
PRILEP
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
70,7
16,6
1,8
0,6
1,6
4,1
0,1
Average annual relative presence of pollen grains of seven taxa
in the city of Prilep
1.5.5. Debar.
Sampling apparatus in Debar was located on the plain roof of the
Medical Center building, 8,5 m from the surface with the following coordinates: λ= 20°
32′ 03′′; ϕ=41° 31′ 19′′; Ζ= 675 meters above the sea level.
The highest values of tree pollens were detected for Cupressaceae, Pinaceae (pine), Tilia
(lime) and Quercus (oak), as well as for Poaceae (cereal), Urticaceae (nettle), Plantago
(plantain) and Asteraceae of grass and weed pollens in the city of Debar, in the examined
period.
This city, compared to others, is characterized with the highest concentrations of Salix
(willow), Tilia (lime), Corylus (hazel) and Castanea (chestnut), as well as Urticaceae
(nettle) and Plantago (plantain), also with presence of higher concentrations of pollen
grains of Fabaceae and Ericaceae, compared to other cities, and lower of Platanus
(plane).
38
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Taxa
DEBAR
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
70,8
15,6
0,9
1,3
5,6
3,2
0,1
Table 6. Average annual relative presence of pollen grains of seven
taxa in the city of Debar
1.5.6. Pehchevo.
Sampling apparatus in Pehchevo was located on the plain roof of
the Health Center building, 8 m from the soil surface with the following coordinates: λ=
22° 52′ 30′′; ϕ=41° 45′ 37′′; Ζ= 1000 meters above the sea level.
During the investigation period, the highest values of tree pollen grains were detected for
Pinaceae (pine), Cupressacea (cypress), Betula (birch), Quercus (oak), Fagus (beech)
and Salix (willow), as well as Poaceae (cereal), Urticaceae (nettle), Plantago (plantain)
and Artemisia (mugwort) of grass and weed pollens in the city of Pehchevo.
This city, compared to others, is characterized with the higher prevalence of weed pollens,
such as nettle and plantain, as well as higher pollen grains concentrations for Pinaceae
(pine), Fagus (beech), Betula (birch) and Alnus (alder), but lower concentrations for Tilia
(lime).
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Taxa
PEHCHEVO
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
78,8
10,3
0,8
1,1
4,5
2,0
0,2
Table 7. Average annual relative presence of pollen
grains of seven taxa in the city of Pehchevo
The pollen period begins earliest in the city of Dojran and the latest in the city of Pehchevo
as a result of the climate and geographical conditions.
39
1.5.7. Concentration and distribution of pollen grains in R. Macedonia
The pollen specter found in the examined cities showed rich qualitative and quantitative
composition. There are 98 registered taxa in R. Macedonia (59 families), 51 of them (27
families) are representatives of the dendroflora.
From the total number of registered pollen grains in R. Macedonia (521127 pollen grains),
most of them belong to the dendroflora taxa, predominantly: Cupressaceae (cypress 23,6% of the total registered pollen grains), Pinaceae (pine - 17,25%), Betula (birch 8,5%) and Quercus (oak). They participate with more than 60% in the total amount of
detected tree pollens. Dominant taxa from the group of grasses and weeds were Poaceae
(10,45%), followed by: Urticaceae (nettle-4,39%), Chenopodiaceae/ Amaranthaceae (fat
hen-1,94%), and Plantago (plantain-1,94%).
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Table 8. Taxa
Trees
Grasses
Oraches
Wormwood
Nettles
Plantain
Ragweed
Pollen%
77,2
10,4
1,5
0.8
3,7
2,0
0,1
Average annual relative presence of pollen grains of
seven taxa in the Republic of Macedonia
1.5.8. Sensitization-relation to pollen grains
Considering the sensitization prevalence to pollen allergens that was 27,5% in adults, the
highest prevalence was registered for weed pollens (19,4%), with the prevalence of 13,0%
for fat hen (Chenopodium sp.) as the most potent allergen (Table 8). Its participation in
examined population with manifested seasonal allergic rhinitis was 30,5%, whereas in
allergic asthma it was 58,3%. The sensitization prevalence in the group of grasses was
18%, and 11,9% in the group of trees.
The highest prevalence of pollen sensitization was registered in examinees with allergic
conjunctivitis (87,2%).
40
Figure 7. Atopy in examined population
Taxon
Dendroflora
Trees
Poaceae
Grasses
Chenopodiaceae
Fat Hen
Artemisia
Mugwort
Urticaceae
Nettle
Plantago
Plantain
Ambrosia
Ragweed
Table 9. Pollen%
Poisitive SPT %
77,2
11,9
10,4
18
1,5
13,0
0,8
11,4
3,7
7,5
2,0
4,8
0,1
4,1
Average annual relative presence of pollen grains of seven taxa
and positive skin prick tests in the Republic of Macedonia
41
1.5.9. Sensitization-relation to pollen grains in the examined cities
Skopje
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
88,4
6,1
1,1
0,2
1,5
1,1
0,2
Positive SPT in %
5,5
13
15
15
8,5
6,5
6,5
Dojran
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
70,9
8,6
4,4
0,9
8,4
0,5
0,1
Positive SPT in %
21,3
25,5
11,7
11,7
5,3
5,3
4,3
Ohrid
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
83,9
8,3
0,2
0,9
0,5
0,9
0,1
Positive SPT in %
19
10
5
4
8
3
2
Prilep
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
70,7
16,6
1,8
0,6
1,6
4,1
0,1
Positive SPT in %
9,3
35,6
27,1
20,3
11,0
8,5
5,9
Debar
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
70,8
15,6
0,9
1,3
5,6
3,2
0,1
Positive SPT in %
6,8
7,8
7,8
6,8
3,9
1,9
1,9
Pehchevo
Dendroflora
Poaceae
Chenopodiaceae
Artemisia
Urticaceae
Plantago
Ambrosia
Pollen in %
78,8
10,3
0,8
1,1
4,5
2,0
0,2
Positive SPT in %
9,3
17,8
11,2
10,3
8,5
3,7
3,7
Table 10. Average annual relative presence of pollen grains of seven taxa
and positive skin prick tests in the six examined cities
42
Figure 8. Average annual relative presence of pollen grains of seven taxa
and positive skin prick tests in the city of Ohrid
OH_POL vs. OH_KT (Casewise MD deletion)
OH_KT = 4,9621 + ,17136 * OH_POL
Correlation: r = ,90767
24
20
16
12
OH_KT
8
4
0
-10
10
30
50
70
90
OH_POL
Figure 9. Correlation between average annual relative presence and
ensitization to the adequate pollen allergens in the city of Ohrid
(r= 0,90; r<0,01)
43
Regression
95% confid.
1.5.10. Analysis of aeropallinological monitoring and sensitization effect
among adult population in R. Macedonia
Analyzing the pollen microflora and sensitization of the examined adult population in
R. Macedonia (Table 9), it is evident that tree taxaes are with the biggest average annual
relative prevalence in the air (77,2%), while the sensitization to the tree allergens in the
examinees is only 18,9%. On the other hand, the grass taxa have the highest prevalence
of positive skin tests (Poaceae) with 17,9%, participating in the average annual relative
prevalence in the air with 10,4% (right next to the tree taxa). The taxa Chenopodiaceae,
Artemisia, Urticaceae, Plantago and Ambrosia have higher prevalence of positive skin
tests related to their prevalence in the air. Besides that, the statistical analysis of the average
annual relative prevalence of pollen grains for all 7 taxa and sensitization to them, show
no relevant statistical correlation (r=0,245; for p>0,05).
The analysis of average relative pollen grains prevalence and positive skin tests in
examinees from different cities shows that the highest air prevalence have the tree pollen
grains (over 70%) in all 6 cities (Table 10), followed by grasses (Poaceae) ranging from
6,1% in Skopje to 16,6% in Prilep. The tree taxa do not dominate with their sensitization
prevalence in the examined cities except in Ohrid with 19,0% (Table 10; Graph 6). There
is the highest prevalence of the grass pollen taxa sensitization in Prilep (35,6%), followed
by Dojran (25,5%), Pehchevo (17,8) and Debar (7,7%). In the city of Skopje the highest
sensitization prevalence is registered for Chenopodiaceae and Artemisia with 15,0%.
There is no correlation found between average annual relative presence and sensitization
to the pollen allergens for the centers in Dojran, Skopje, Prilep, Debar and Pehchevo. This
correlation is registered (Figure 9) only for the city of Ohrid (r=0,90, p<0,01).
The basic approach in the examination is evaluation and correlation of two connected
segments: aeropallinological monitoring and clinical results.
A rich pollen specter, with total number of 98 taxa by 59 families, is registered using
the aeropallinological monitoring. The dendroflora containing 51 taxa (27 families) has
a dominant place in the total number of taxa. Most of the pollen grains belong to the
dendroflora taxa but the most dominant are Cupressaceae (cypress)-23,6%, and cereals
(fam. Poaceae) in the group of the grasses (10,4%). The constructed pollen calendars
for each center separately, show the pollen taxa types, the period of appearance and their
maximal concentrations. The pollen period in Dojran is the earliest one compared to the
latest one in Pehchevo, considering the climate characteristics.
As a result of the climate-vegetation characteristics Macedonian pollen calendar has some
similarities with the pollen calendar of Bulgaria. The differences of the pollen calendars
in the Mediterranean countries and the Nordic region are significant, both in qualitative
and quantitative point of view, timing and the magnitudes of the pollen periods and the
present taxa.
Considering the distribution by cities in Macedonia, it is registered that in Prilep seasonal
allergic rhinitis (SAR) has the highest prevalence (29,7%), whereas in Skopje it is the
44
lowest (8,5%). If we compare this prevalence for the city of Skopje with the results in
1996, when the prevalence of SAR was 7,1%, it is evident that the prevalence has slightly
increased. The reasons for the different prevalence of SAR, the highest in the city of Prilep,
are not quite clear. From the aeropallinological point of view, Prilep is characterized with
higher concentrations of Corylus (hazel), Tilia (lime), Populus (poplar), Quercus (oak)
and Koelreuteria compared to the other cities, as well as high prevalence of grass and
weed pollens, with predominance of Poaceae (cereal), Chenopodiacea/Amaranthaceae
(fat hen) and Plantago (plantain). It is possible that these original pollen allergogenic
composition and concentrations are one of the factors for the high SAR prevalence,
although some other factors such as genetic, meteorologic, climate and geographic should
be taken into account.
It is registered that the younger age and urban environment are factors in favor for SAR
in adults, and lung problems are statistically significantly related to SAR (p<0,01). This
relation points out to the necessity of integral approach during evaluation of upper and
lower airways.
If the SAR prevalence in adults in Skopje (8,5%) is compared to the one registered in
children, it is obvious that SAR is more present in the youth than in the adult population.
The reason for this may be in the sensitivity of the child organism to the intensive urban
pollution in the context of aero-biological pollution of the city of Skopje, having in mind
that perhaps the genetic predisposition for SAR is manifested earlier compared to the
other cities in the Republic of Macedonia. The early sensitization in children is supported
by the presence of high pollen grains concentrations that are severe allergenic.
On the other hand, the prevalence of the perennial allergic rhinitis in children is 8,3%
which is very similar to the seasonal allergic rhinitis, and it is the highest in Skopje
(10,6%) and lowest in Debar (4,8%).
The atopy prevalence is 34,8% which is an expected value, according to the literature
data. The highest sensitization prevalence is registered for weeds as a group (19,4%),
followed by grasses with 17,9% in adults. The same is with the SAR, weeds with 7,6%
and grasses 6,8%. These data confirm the fact that weeds and grasses have the greatest
allergenicity in the examined population.
However, the aeropallinological data show that tree pollens taxa are with the highest
concentrations in the Republic of Macedonia (77,2%), but sensitization to these pollens is
found in 10,8% of the examined subjects. This fact shows that allergenic concentration is
not the only factor for pollen sensitization.
It is evident that allergenicity of the weed and grass pollens is much more expressed than
tree pollen taxa. This is proved by the data that if the weeds as a group are distributed
due to single taxa (Chenopodiaceae, Artemisia, Urticacae, Plantago, Ambrosia), higher
prevalence of skin prick tests are registered related to average relative air prevalence,
respectively.
45
According to these data, statistical analysis has also shown no correlation on the country
level (totally and each city separately) between the annual relative prevalence of pollen
grains of 7 taxa and sensitization to them in the examined population, except for the city of
Ohrid where such correlation is found (r=0,90, p<0,01). In the city of Ohrid the highest is
the average annual relative prevalence of the tree pollen taxa (83,9%), but the sensitization
to them is also the highest (19,0%), followed by grass and weed pollens. Which is the
reason for this, it is not yet clear enough, having in mind that the unique geographicclimate factors have their own influence. The high concentration of the dendrofloric taxa
in Ohrid is the result of the rich alohtone horticulture; together with the high relative
humidity contributing to the accelerated sedimentation of the grass and weed pollen grains
sedimentation and making the lowest average annual relative prevalence compared to the
other cities. So, the lower pollen grains concentrations of grasses and weeds decrease
the relative sensitization in skin prick tests contributing to obtaining positive correlation.
However, further aero-biological and epidemiological research in the city of Ohrid is
needed, in order to receive the necessary answers to all open questions.
1.5.11. Proposal of the List of allergens for clinical use
By the clinical aspect of view, the highest sensitization was obtained for weed and grass
pollen grains. In the pollen structure grasses are ranged as second, right behind the tree
pollen taxa with average annual relative air prevalence of 10,4%. Therefore, if allergologicaerobiologic assessment is in question, the priority would be determining of the grass and
weed taxa air concentration in the Republic of Macedonia, and then of the tree taxa as
well. From the practical point of view, using the integration of the aerobiological and
epidemiological data, a List of allergens for practical use in allergy centers is proposed
(Table 11).
Table 11. Proposal of the List of allergens for practical use in the allergy centers
WEED POLLEN
Latin terminology
Planatago lanceolata
Urtica dioica
Parietaria officinalis
Rumex sp.
Artemisia vulgaris
Ambrosia sp.
Taraxacum officinale
Solidago sp.
Amarantus sp.
Chenopodium sp.
Salsola kali
English terminology
Plantain
Nettle
Pellitory
Dock (Sorrel)
Mugwort (Wormwood)
Ragweed
Dandelion
Golden Rod
Pigweed
Fat Hen (Orache)
Salsola
46
GRASS POLLEN
Latin terminology
Poa pratensis
Triticum sativa
Phleum pratense
Agrostis alba
Alopecurus pratensis
Secale cereale
Cynodon dactylon
Lolium perenne
Festuca pratensis
Anthoxanthum odoratum
Bromus sp.
Arrhenatherum elatior
Dactylis glomerata
English terminology
Smooth-Stalked meadowgrass
Wheat
Timothy
Bent grass
Meadow Foxtail
Rye Cultivated
Bermudagrass
Perennial ryegrass
Meadow fescue
Sweetvernalgrass
Brome
Tall Oatgrass
Cocksfoot Rough
TREE POLLEN
Latin terminology
Fagus sylvatica
Quercus robur
Castanea sativa
Betula pendula
Corylus avellana
Alnus sp.
Platanus orientalis
Morus alba
Salix alba
Populus alba
Tilia cordata
Juglans regia
Fraxinus excelsior
Aesculus hippocastanum
Olea europaea
Sambucus nigra
Robinia pseudoacacia
Acer negundo
Humulus lupulus
Pinus nigra
Cupressus sempervirens
English terminolgy
Beech
Oak-Common
Shanich chesnut
Birch (Silver)
Hazelnut (Hazel)
Alder
Planetree
Mulberry White
Willow White
Poplar
Lime
Walnut
Ash
Horse -Chesnut
Olive
Elder
False Acacia
Maple
Common hop
Pine black
Cypress
47
1.6. Pollen calendar(s)
It is necessary to construct aeropallinology calendar resulting from climate, vegetation
and topography characteristics of certain region as well as from its orography and
hydrography. Our country has specific climate features, rich and specific vegetation and
has unique aerobiologic characteristics.
Therefore, continual monitoring and reporting on pollen appearance in the air have longterm tradition in many countries and their pollen calendars differ from each other and
have great differences between separate areas, too.
European monitoring system (European Pollen Information - EPI) provides regional,
national and international coordination of aeropallinology centers by follow-up of pollen
grains distribution and by provision of prediction models.
Our aeropallinologic data aim to provide and to predict majority of main aeropallinologic
allergens in order to control the environment which is an important procedure, incorporated
in the principles of prevention and therapy of allergic diseases. The data obtained in
researches performed in our country will contribute to fulfil the gap in EPI information.
One of the possible ways in solving this problem is establishment of monitoring network
for contents and concentration follow-up of air allergens. It is important to increase the
number of monitoring objects and to implement contemporary methods in air microflora
research in order to receive relevant data.
The reported results could be used in theoretical interpretations of phenology, pollen
production, different factors influencing changes on pollen contents and pollen quantity.
Pollen calendar construction and modified set of allergen-diagnostics preparations are
important for clinical allergology in allergic respiratory diseases examination as well
as for their adequate prophylaxis and treatment. Also, it will help tourists and foreign
business partners to choose place and time for accommodation in R. Macedonia.
48
1.6.1. Pollen calendar of the city of Skopje
49
Concentration of the tree, grass, and weed pollens in the city of Skopje
in the period January-December (I - XII), 2000
50
1.6.2. Pollen calendar of the city of Dojran
51
Concentration of the tree, grass, and weed pollens in the city of Dojran
in the period January-December (I - XII), 2000
52
1.6.3. Pollen calendar of the city of Ohrid
53
Concentration of the tree, grass, and weed pollens in the city of Ohrid
in the period January-December (I - XII), 2000
54
1.6.4. Pollen calendar of the city of Prilep
55
Concentration of the tree, grass, and weed pollens in the city of Prilep
in the period January-December (I - XII), 2000
56
1.6.5. Pollen calendar of the city of Debar
57
Concentration of the tree, grass, and weed pollens in the city of Debar
in the period January-December (I - XII), 2000
58
1.6.6. Pollen calendar of the city of Pehchevo
59
Concentration of the tree, grass, and weed pollens in the city of Pehchevo
in the period January-December (I - XII), 2000
60
1.7. Conclusions
1. The constructed pollen calendars for each city separately have shown different pollen
taxa, period of their appeal, and their maximal concentrations. It is registered that
pollen calendar in the city of Dojran is the earliest and the one in Pehchevo is the
latest which is, of course, reflection of the climate characteristics of those regions;
2. The highest sensitization prevalence of the examined population has been noted for
weed pollens (19,4%), followed by the grass pollens with 17,7%. Similar is with the
sensitization among the individuals with SAR (weed 7,6% and grass 6,8%);
3. The tree pollen taxa have the highest air concentrations in the Republic of Macedonia
(77,2%), but sensitization to them is only 10,8%. Weed and grass pollen allergenicity
is far more expressed, which make them much more important in the aerobiology
specter of the Republic of Macedonia;
4. The correlation between the average annual relative pollen prevalence and positive
skin prick tests is found in the city of Ohrid (r=0,90, p<0,01), having the highest
annual relative prevalence of the tree pollen taxa (83,9%), as well as the sensitization
to them (19,0%), followed by grass and weed pollens;
5. A high prevalence of pollenoses has been registered in the city of Prilep (SAR-29,7%)
which is a result of the high grass pollen grains concentration;
6. The registered high SAR prevalence in the examined children in the city of Skopje
reveals the connection between aero-pollution and the high allergen concentration
and alohtone pollen grains;
7. Integrating of the aerobiological and epidemiological data, a List of allergens for
practical use in allergy centers is proposed, in order to help in diagnostics, therapy and
prevention of pollenoses;
8. A continuous monitoring with a multi-centric approach is necessary, including
strategic following of invasive and allergenic species and restrictive implementation
of allergenic and alohtone species (not to cultivate birch, linden and fetid tree);
9. It is necessary to incorporate the preventive measures in the public health programs
(measures, principles and tools for elimination or reduction of the contact with
allergens, sensitizing substances, irritants and other environmental provocative and
factors in favor, staying outdoors when the concentrations are low, professional
orientation, pre- and postnatal prevention etc.).
61
1.8. References:
1. Frankland A W, Aerobiology in Medicine, Grana 30; 1991: 19-23.
2. D’Amato G, Spiksma M Th M, Bonini S. Allergenic Pollen and Pollenosis in Europe.
Blackwell, Oxford, 1991: 1-222.
3. European Allergy White Paper. The USB Institute of Allergy, Belgium, 1997
4. Yii-Panula E, Rantio-Lentimaki A. Birch pollen antigenic activity of settled dust in
rural and urban home. Allergy 1995: 50, 303-307.
5. Majd A, Ghanati F. The effect of air pollution on pollen grain allergenisity of Pinus
elderica (Pinaceae) pollen. Grana 1995: 34, 208-211.
6. Milkovska S. Aeropalinoloski istrazuvanja na teritorijata na Republika Makedonija
i nivnoto znacenje za alergizacijata na respiratorniot sistem. Univerzitet “Sv. Kiril i
Metodij”, Prirodno-matematicki fakultet, Institut za biologija, Skopje, 2002.
7. Charpin J, Surinyach R, Frankland AW. Atlas of European Allergenic Pollens. Paris:
Sandoz 1974, 1-229.
8. Davies R, Webb T. The contemporary distribution of pollen in eastern North America:
A comparison with the vegetation. Qut Res 1975; 3: 395-434.
9. Jankova R. Aeropalinologicni proucvanija na nekoi objekti v Blgarija v†v vr†zka s
polenovata alergija. Disertacionen trud. Sof. Uni. B.F. Sofia, 1979.
10.Spieksma F, Nolard N, Frenguelli G, et al. Pollens de l’air en Europe. Bruxelles 1993,
1-83.
11.Emberlin J. The effects of patterns in climate and pollen abundance on allergy.
Allergy1994; 49 (18): 15-20.
62
2.0. Indoor aeroallergens
2.1. Moulds
Moulds (fungi) can act as both indoor and outdoor airborne allergens. Penicillium,
Aspergilus and Candida can be found indoors, while Alternaria and Cladosporium can
be found both indoors and outdoors (Figure 10 and 11). Among these, Alternaria (Figure
12) is of special importance, being established as a risk factor for asthma in various
populations, as well as a risk factor for asthma death in the United States.
Dark, humid, and poorly ventilated areas are optimal for indoor fungal growth. Moulds
also grow well within the systems used for cooling, heating, and humidification, with
house humidifiers providing a special risk for indoor fungal growth and air contamination.
Outdoor moulds are particularly prevalent in the dry and windy conditions, where they
usually grow on grasses and grains. They usually peak in the summer months and early
fall, but their dispersion and airborne prevalence largely vary depending on climate.
Table 12 presents the mold species and its airborne prevalence in R. Macedonia.
Species
Growth area
Prevalence in R. Macedonia
Alternaria alternata
Aspergillus niger
Aspergillus fumigatus
Botrytis cinerea
Humid walls, grains
Foods, grains
Foods, grains
Grains
Dispersed by wind;
no growth in R. Macedonia
Dispersed by wind
Grains, grasses
Dispersed by wind
Dispersed by wind
Humid walls, grains
Foods
Grasses
Foods
Dispersed by wind
High
Very high
Very high
High
Chaetomium glabosum
Eoicoccum purpurascens
Fusarium spp.
Neurospora sitophila
Paecilmyces margundii
Cladosporium cladosporoides
Penicillium notatum
Phoma betae
Rhizopus nigricans
Sporobolumyces roseus
Table 12. Mold species and its airborne prevalence in R. Macedonia
63
Low
Low
High
Low
Low
High
Very high
High
Very high
Low
Figure 10. Mold fruiting structures and spores of
Penicillium notatum
Adapted from: Moulds. Available at: http://www.
denniskunkel.com/DK/DK/Fungi_and_Slime_
Moulds/
Figure 11. Aspergillus fumigatus spores
Adapted from: Moulds. Available at: http://www.
denniskunkel.com/DK/DK/Fungi_and_Slime_
Moulds/
Figure 12. Filamentous structure of Alternaria
alternata
Adapted from: Alternaria alternata. Available at:
http://www.alamy.com/stock_photography/
64
In the study of allergic sensitization to mold allergens, carried out at the Institute of
Occupational Health Skopje in 2001 including 46 subjects with respiratory allergic diseases
(allergic rhinoconjunctivitis and/or asthma) and 32 healthy subjects, we found similar
prevalence in both groups (17.4% and 25.0%, respectively). The highest prevalence in
both subjects with respiratory allergies and healthy subjects was found for sensitization
to Neutrospora sitophila (10.8% and 8.6%, respectively) and Penicillium notatum (15.6%
in both groups) (Figure 13).
Figure 13. Allergic sensitization to mold allergens in subjects with
respiratory allergies and healthy subjects
2.1.1. Results of current study of sensitization to moulds in adults
in R. Macedonia
Sensitization to Alternaria was detected in 3.6% of the examined adults (Figure 14).
Figure 14.
Sensitization to Alternaria in the examined adults
65
The highest prevalence of subjects sensitized to Alternaria was detected among adults
in Skopje (5.5%), and the lowest one among adults in Dojran (1.1%) (Figure 15). The
difference is probably due to the different climate conditions in certain centers.
Figure 15. Sensitization to Alternaria among adults in certain centers
Prevalence of sensitization to Alternaria in the adults with perennial allergic rhinitis,
perennial allergic conjunctivitis, and allergic asthma was 14.9%, 12.8%, and 25.0%,
respectively (Figure 16).
Figure 16. Sensitization to Alternaria in all examined adults, and in the
Subjects with perennial allergic rhinitis, perennial allergic
conjunctivitis, and allergic asthma
66
Sensitization to Penicillium notatum was detected in 3.9% of the examined adults (Figure
17).
Figure 17. Prevalence of the sensitization to Penicillium in examined adults
As with Alternaria, the highest prevalence of adults sensitized to Penicillium was observed
in Skopje (5.7%), and the lowest one in Debar (2.0%) (Figure 18).
Figure 18. Sensitization to Penicillium among adults in certain centers
Prevalence of sensitization to Penicillium in the adults with perennial allergic rhinitis,
perennial allergic conjunctivitis, and allergic asthma was 14.9%, 11.2%, and 16.7%,
respectively (Figure 19).
67
Figure 19. Sensitization to Penicillium in all examined adults, and in the subjects with
perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma.
2.2. House dust mites
House dust (domestic) mite allergens are considered as the most important indoor
sensitizing agents worldwide. Sensitization to house dust mites may be manifested by
allergic asthma, allergic rhinoconjunctivitis and/or atopic dermatitis.
House dust is composed of several organic and inorganic compounds, including fibers,
mold spores, insect and insect feces, mammalian danders, and mites and mites feces.
Dust mites feed on organic material in households, particularly the skin that is shed from
humans and pets. They can be found in carpets, upholstered furniture, pillows, mattresses,
comforters, and stuffed toys. While they thrive in warmer temperatures (22-26oC) and
high humidity (higher than 55%), they can be found year-round in many households.
There are 2.000 to 15.000 mites per gram of mattresses dust.
The principal mite species include: Dermatophagoides pteronyssinus, Dermatophagoides
farinae, Dermatophagoides microceras, and Eurogluphus mainei. Dermatophagoides
pteronyssinus (Figure 20, A and B) is dominant mite in constantly damp climates (Europe,
including R. Macedonia, and the Pacific Northwest).
68
A.
B.
Figure 20. A. and B. Dermatophagoides pteronyssinus
(B. Isolated by S. Milkovska, 1996)
Adapted from: Cvetanov V, et al. Alergiski bolesti-Lekuvanje
[Allergic diseases – Treatment, in Macedonian]
Skopje: Medis-informatika 1998, p. 21.
In 1967 it was considered that allergenicity to house dust is associated with house dust
mite allergens. House dust mite allergens are present in various parts of mite bodies,
secretion, and excretion, constituting the main source of dust-derived allergens. The house
dust mite allergens have been identified as proteolytic enzymes from mite feces, such as
cysteine proteases (group I allergens: D. pteronyssinus I, D. farinae I, and D. microceras
I), serine proteases (group III allergens), and amylase (group IV allergens). The group II
allergens are derived mainly from mite bodies (D. pteronyssinus II, and D. farinae II).
The predominant allergens in house dust are from the groups I and III. A concentration
of mite allergen above 0.5 mcg of D. pteronyssinus I per gram of house dust seems to be
a significant risk factor for mite sensitization in susceptible individuals.
Mite sensitization is considered as a major risk factor for development of respiratory
allergic diseases. Prevalence of mite sensitization is estimated to 100 million individuals
worldwide. Results from the ECRHS local data sets showed that mite sensitization
was found to be the allergen most strongly associated with asthma or bronchial
hyperresponsiveness in 16 centers from Europe, North America, and Australia, mite
and cat equally in one, cat in eight, timothy in eight, and Cladosporium in two. Mite
sensitization was also found to be the most important individual allergen in the subjects
with allergic asthma in our previous study of asthma in 1995.
Many published studies suggested strong link between mite sensitization and childhood
asthma. According to the results of the prospective studies which investigated childhood
asthma pathogenesis, a positive correlation between risk of childhood asthma and level
of exposure was observed. The study of childhood asthma carried out in R. Macedonia
at the end of the 1990s showed significant association between the level of exposure and
severity of bronchial hyperresponsiveness, severity of asthma, and course of the disease.
The mean concentration of mite allergen was found to be 11.8 mcg per gram of house
dust that was 20 times higher concentration in respect to concentration of mite allergen
considered as a risk factor for allergic sensitization in susceptible individuals.
69
2.2.1. Results of the current study of mite sensitization in adults
in R. Macedonia
Sensitization to Dermatophagoides pteronyssinus was detected in 13.9% of the examined
adults (Figure 21).
Figure 21. Sensitization to Dermatophagoides pteronyssinus in the examined adults
Prevalence of mite sensitization among adults in certain centers varied from 14.4% in
Skopje to 11.6% in Debar (Figure 22).
Figure 22. Prevalence of mite sensitization among adults in certain centers
Mite sensitization was the most important individual allergen in the adults with respiratory
allergic diseases (Figure 23).
70
Figure 23. Prevalence of mite sensitization in all examined adults, and in subjects with
perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma.
2.3. Pets
Household warm-blooded animals and birds release allergens in secretions, excretions,
and danders.
2.3.1. Senzitation to cats
Cat allergens are potent sensitizing agents. The main cat allergen (Fel d1) is found in cat
pelt, especially in the facial area, sebaceous secretions, and urine.
The cat allergen is carried on small particles (3-4 mm in diameter) that easily become
airborne and enable rapid onset of the respiratory symptoms in sensitized subjects
entering an indoor environment containing a cat. Although households with a cat contain
high concentration of the cat allergen, homes without a cat may also contain its sufficient
concentration to trigger symptoms in highly sensitized subjects. The clothes of cat owners
constitute the vehicle of passive transport of cat allergen to cat-free environments.
Results of the published studies indicated approximately 6 million individuals in the USA
which are sensitized to cat fur. The ECRHS data set from Sweden and the Netherlands
suggested significant association of cat sensitization and bronchial hyperresponsiveness
and asthma. On the other side, the ECRHS data set from Spain indicated that cat sensitization
was a predictor of airflow limitation (lower FEV1 value) that was independent of smoking
and bronchial hyperresponsiveness.
71
2.3.1.1. Results of the actual study of cat sensitization in adults in R. Macedonia
Sensitization to cat fur was detected in 5.5% of the examined adults (Figure 24).
Figure 24. Sensitization to cat fur in all examined adults
Prevalence of cat sensitization among adults in certain centers varied from 7.4% in Skopje
to 2.4% in Debar (Figure 25).
Figure 25. Cat sensitization among examined adults in certain centers
Prevalence of cat sensitization in the adults with perennial allergic rhinitis, perennial
allergic conjunctivitis, and allergic asthma was 34.0%, 16.7%, and 21.6%, respectively
(Figure 26).
72
Figure 26. Prevalence of cat sensitization in all examined adults, and in subjects with
perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma
2.3.2. Senzitation to dogs
Dogs produce two important allergens, Can f1 and Can f2, found in dog hair and dander.
The dog allergens characteristics are similar to cat allergens but they have lower allergenic
potential. There is a slight degree of cross-reactivity between dog and cat allergens.
Sensitization to dog hair is registered in up to 30% of atopics in developed countries.
2.3.2.1. Results of the actual study of sensitization to dog hair
in adults in R. Macedonia
Sensitization to dog allergens was detected in 2.8% of the examined subjects (Figure 27)
Figure 27. Sensitization to dog hair in all examined adults
73
Prevalence of sensitization to dog hair among adults in certain centers varied from 4.2%
in Skopje to 1.0% in Debar that probably depended on the prevalence of pets ownership
in certain centers (Figure 28).
Figure 28. Sensitization to dog hair among adults in certain centers
Prevalence of sensitization to dog hair in the adults with perennial allergic rhinitis,
perennial allergic conjunctivitis, and allergic asthma was 23.1%, 18.4%, and 10.0%,
respectively (Figure 29).
Figure 29. Prevalence of sensitization to dog hair in all examined adults, and in subjects
with perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma
74
2.3.3. Sensitization to birds
Sensitization to birds kept as indoor pets (parrots, canaries, pigeons) is considered as
sensitization to allergens of mites which feed in their feather.
According to the published data, the prevalence of sensitization to feathers is not high.
However, exposure to feathers may trigger severe nasal, ocular and/or asthma symptoms
in sensitized individuals.
2.3.3.1. Results of the actual study of sensitization to
feathers in adults in R. Macedonia
Sensitization to feathers was detected in 3.9% of the examined subjects (Figure 30).
Figure 30. Sensitization to feathers in all examined adults
Prevalence of sensitization to feathers among adults in certain centers varied from 4.4%
in Skopje to 1.4% in Debar (Figure 31).
75
Figure 31. Sensitization to feathers among adults in certain centers
Prevalence of sensitization to feathers in the adults with perennial allergic rhinitis,
perennial allergic conjunctivitis, and allergic asthma was 23.1%, 18.4%, and 10.0%,
respectively (Figure 32).
Figure 32. Prevalence of sensitization to feathers in all examined adults, and in subjects with
perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma
76
2.3.4. Senzitation to cockroach
Sensitization to cockroach (Figure 33, A and B) is considered as an important trigger of
asthma symptoms in sensitized subjects in the USA, the UK, and Australia. Most species of
cockroaches live in tropical climates, but central heating has enabled them to thrive outside
their normal habitat. The most common species are the American cockroach (Periplaneta
americana), Australian cockroach (Periplaneta australasiae), Asian cockroach (Blatella
orientalis), etc. The German cockroach (Blatella germanica) lives in Europe and in R.
Macedonia.
A.
Figure 33. A. and B. Cockroach
Adapted from: Cockroach. Available at: http://en.wikipedia.org/wiki/
B.
Allergens from the Blatella germanica and Periplaneta americana are characteristic, and
the presence in house dust can be measured by using specific monoclonal antibodies.
2.3.4.1. Results of the actual study of sensitization to cockroach
allergens in adults in R. Macedonia
Sensitization to cockroach allergens was detected in 3.2% of the examined subjects
(Figure 34).
Figure 34. Sensitization to cockroach in all examined subjects
77
Prevalence of sensitization to cockroach among adults in certain centers varied from 4.4%
in Skopje to 1.4% in Debar (Figure 35).
Figure 35. Sensitization to cockroach among adults in certain centers
Prevalence of sensitization to cockroach in the adults with perennial allergic rhinitis,
perennial allergic conjunctivitis, and allergic asthma was 11.6%, 10.0%, and 10.0%,
respectively (Figure 36).
Figure 36. Prevalence of sensitization to cockroach in all examined adults, and in subjects
with perennial allergic rhinitis, perennial allergic conjunctivitis, and allergic asthma
78
2.4. Conclusions
1. Sensitization to moulds was not frequent in the examined adults, however, they
were considered as an important risk factor for perennial allergic rhinitis and allergic
asthma.
2. Our data confirm the importance of mite sensitization as a risk factor for respiratory
allergic diseases. The prevalence of mite sensitization in the examined adults was
found to be 13.9%, which is approximately 200,000 subjects with mite sensitization in
R. Macedonia. Mite sensitization was detected in 90% of the subjects with perennial
allergic rhinitis and in above 60% of the subjects with allergic asthma.
3. Prevalence of sensitization to pet allergens in R. Macedonia was lower than in the
developed countries that is probably due to the lower prevalence of pets ownership.
However, sensitization to pet allergens was considered as an important risk factor for
respiratory allergic diseases.
4. The initial results of sensitization to cockroach allergens in adults in R. Macedonia
have suggested that it must be taken into consideration in allergologic evaluation of
the subjects with respiratory allergic diseases.
2.5. References:
1. Global Initiative for Asthma. Risk factors. National Institutes of Health, National
Heart, Lung, and Blood Institute 2004; p. 27-41.
2. The UCB Institute of Allergy. Allergies. Brussels 1999; p. 20-29.
3. Custovic A, Simpson A, Woodcock A. Importance of indoor allergens in the induction
of allergy and elicitation of allergic disease. Allergy 1998; 53: 115-120.
4. Nelson HS. The importance of allergens in the development of asthma and the
persistence of symptoms. J Allergy Clin Immunol 2000; 105: 628-632.
5. Neukirch C, Henry C, Leynaert B, et al. Is sensitization to Alternaria alternata a risk
factor for severe asthma? A population-based study. J Allergy Clin Immunol 1999;
103: 709-711.
6. Harrison PT. Creature comfort-living mites and moulds. Clin Exp Allergy 1999; 29:
148-149.
7. Kungulovski Gj. Oral report, 1999.
8. Moulds. Available at: http://www.denniskunkel.com/DK/DK/Fungi_and_Slime_
Moulds
9. Alternaria alternata. Available at: http://www.alamy.com/stock_photography/
10.Voorhorst R, Spiksma F, Varekamp H, et al. The house dust mite (Dermatophagoides
pteronyssinus) and the allergens it produces: identity with the house dust allergens. J
Allergy 1967; 39: 325-339.
11.Janson C, Anto P, Burney P et al. The European Community Respiratory Health
Survey: what are the main results so far? Eur Respir J 2001; 18:598-611.
12.Plaschke PP, Janson C, Norrman E, et al. Onset and remission of allergic rhinitis and
asthma and the relationship with atopic sensitization and smoking. Am J Respir Crit
Care Med 2000; 162: 920-924.
79
13.Abramson M, Kutin JJ, Raven J, et al. Risk factors for asthma among young adults in
Melbourne, Australia. Respirology 1996; 1: 291-297.
14.Chinn S, Burney P, Sunyer J, et al. Sensitization to individual allergens and bronchial
responsiveness in the ECRHS. European Community Respiratory Health Survey. Eur
Respir J 1999; 14: 876-884.
15. Bjornsorn E, Norback D, Janson C, et al. Asthmatic symptoms and indoor levels of
micro-organisms and house-dust mites. Clin Exp Allergy 1995; 25: 423-431.
16. Chinn S, Jarvis D, Luczynska C, Burney P. Individual allergens as risk factors for
bronchial responsiveness in young adults. Thorax 1998; 53: 662-667.
17.Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova
N. Alergiski bolesti-Lekuvanje [Allergic diseases – Treatment, in Macedonian]
Skopje: Medis-informatika 1998, 21-25.
18.Karadzinska-Bislimovska J, Cvetanov V, Petrovska J, et al. Respiratory symptoms
and positive skin prick tests in a prospective asthma study in Republic of Macedonia
(initial results). Eur Respir J 1999; 14 (30): 78.
19.Sporik R, Holgate S, Platts-Miles TAE. Exposure to house-dust mite allergen
(Der
p 1) and the development of asthma in childhood. A prospective study. Engl J Med
1990; 323: 502-507.
20.Maceska-Badzakova G. Faktori koi vlijaat vrz evolucijata na astmata vo detskata
vozrast [The factors which determine the evolution of childhood asthma, in
Macedonian]. Ph.D. thesis. University “Sv. Kiril i Metodij”, Faculty of Medicine,
Skopje, 1999.
21.Trandafilovski P, Maceska-Badzakova G. Astmata i vaseto dete [Asthma and your
child, in Macedonian]. Bitola: Kiro Dandarot 2002,41-48.
22.Partti-Pellinen K, Marttila O, Makinen-Kiljunen S, et al. Occurrence of dog, cat and
mite allergens in public transport vehicles. Allergy 2000; 55: 65-68.
23.Pope A, Patterson R, Burge H. Indoor allergens: assessing and controlling adverse
health effects. National Academy of Sciences. Washington: National Academy Press;
1993.
24.Cockroach. Available at: http://en.wikipedia.org/wiki/
25.Soriano JB, Anto JM, Sunyer J, et al. Risk of asthma in the general Spanish population
attributable to specific immunoresponse. Spanish Group of the European Community
Respiratory Health Survey. Int J Epidemiol 1999; 28: 728-734.
80
Part III
Epidemiological survey
82
A cross-sectional study (study of prevalence) was carried out in six centers in R. Macedonia,
including Skopje, Dojran, Ohrid, Prilep, Debar, and Pehchevo, in the period FebruaryJune 2002. The study included 1121 randomly selected subjects (i.e. approximately 0.6%
of the population in R. Macedonia), 722 adults (283 males and 439 females, mean age
39,6 ± 13,5) and 399 children (196 boys and 203 girls, mean age 11,01 ± 2,61).
Evaluation of the examined adults on site included completion of a questionnaire and
skin prick tests (SPT) to common inhalant allergens. The interviewer-led questionnaires
for adults and children were designed using the models of the ECRHS and ISAAC
questionnaire. The questionnaires included questions about allergic and respiratory
symptoms, life style, housing, smoking habit, environmental and workplace exposures,
medication use, and family history of allergic and respiratory disorders (Appendix 2).
SPT to 13 common inhalant allergens were performed on the volar part of the forearm
using allergen extracts (Bencard Allergie GmbH, Germany)) of tree pollens, grass
pollens, mugwort, goosefoot, plantain, Ambrosia eliator, Penicillinum notatum, Alternaria
alternata, Dermatophagoides pteronyssinus, cat fur, dog hair, feathers, and cockroach.
All tests included positive (1 mg/mL histamine) and negative (0.9 % saline) controls.
Following the recommendations of the European Academy of Allergology and Clinical
Immunology (EAACI), the SPT were considered positive if the mean wheal diameter 20
min after allergen application was larger than 3 mm.
Lung function tests were performed in the Institute of Occupational Health, SkopjeWHO Collaborating Center in the examined adults aged 20-44 who reported symptoms
suggestive of asthma. Spirometry, including measures of forced vital capacity (FVC),
forced expiratory volume in one second (FEV1), FEV1/FVC ratio, maximal expiratory
flow at 50 %, 25% and 25-75% of FVC (MEF50, MEF25 and MEF25-75, respectively),
was performed recording the best of three measurements. The results were expressed
as percentages of the predicted values, according to the European Community for Coal
and Steel (ECCS) norms. Histamine challenge was performed according to the European
Respiratory Society (ERS)/ American Thoracic Society (ATS) recommendations. The test
was considered positive if provocative concentration 20 - PC20 (i.e. the concentration of
histamine causing a 20% fall in FEV1) was equal or less than 4 mg/mL. In the subjects
with reduced lung function, bronchodilator test with inhaled salbutamol was performed.
According to the British Thoracic Society (BTS) recommendations, the test was considered
positive if the increase of the FEV1value after bronchodilator application was equal or
more than 12% compared to the baseline value.
Evaluation of the examined children included completion of a questionnaire on allergic
and respiratory symptoms, birth weight, presence of siblings, type of feeding in the
infancy, life style, housing conditions, environmental exposures, medication use, and
family history of allergic and respiratory diseases (Appendix 3). The interviewer-led
questionnaire was completed on site by the children’ parents.
The data obtained were statistically processed by descriptive and inferential methods
(χ2-test, Fisher’s exact-test, Mann-Whitney U-test, t-test for independent samples, and
linear regression) using statistic program SPSS 11.
83
1.0. Diagnostic criteria for certain allergic entities
Atopy in adults was defined as at least one positive SPT to common inhalant allergens.
Allergic rhinitis in adults was defined by positive history of one or more rhinitis symptoms
associated with positive SPT to common inhalant allergens.
Saesonal allergic rhinitis in adults was defined by positive history of rhinitis symptoms
associated with positive SPT to seasonal inhalant allergens.
Perennial allergic rhinitis in adults was defined by positive history of rhinitis symptoms
associated with positive SPT to domestic inhalant allergens.
Seasonal allergic rhinitis in children was defined by positive history of seasonal rhinitis
symptoms, whereas perennial allergic rhinitis in children was defined by positive history
of persistent rhinitis symptoms.
Allergic conjunctivitis in adults was defined by positive history of one or more conjunctivitis
symptoms associated with SPT to common inhalant allergens.
Asthma in the age group 20-44 was defined by history of one or more asthmatic symptoms
or use of asthma medications associated with positive histamine challenge or positive
bronchodilator test in the subjects with reduced lung function.
Atopic dermatitis in children was defined as an itching rash coming and going for at least
six months.
Hypersensitivity to drugs, food and insect sting in adults and children was defined by history
of adverse reaction after drug intake, food consumption, and Hymenoptera insect sting.
1.1. Characteristics of the examined subjects
1.1.1. Characteristics of the examined adults
The group of examined adults included 722 randomly selected subjects, 283 males (38.6%)
and 439 females (61.4%). Sex distribution of the examined adults is shown in Figure 37.
84
Figure 37. Sex distribution of the examined adults
The examined adults were aged between 18 and 78 years, mean age 39.56 ± 13.5. Age
distribution of the examined adults is shown in Figure 38.
Figure 38. Age distribution of the examined adults
Distribution of the examined subjects by certain centers is shown Table 39.
85
Figure 39. Distribution of the examined adults by certain centers
Macedonians and Albanians were the majority of the examined adults (79.7% and 13.6%,
respectively). Distribution of the examined adults by ethnicity is shown in Figure 40.
Figure 40. Distribution of the examined subjects by ethnicity
86
There was higher prevalence of subjects with urban than with rural residence (85.4% vs.
14.6%) (Figure 41).
Figure 41. Distribution of the examined adults by residence
Distribution of the examined subjects by educational level and employment status is
shown in Tables 42 and 43.
Figure 42. Distribution of the examined adults
by educational level
Figure 43. Distribution of the examined adults
by employment status
87
Prevalence of daily smokers was 34.2% (Figure 44). The highest prevalence of daily
smokers was registered among examined subjects in Skopje (45.7%) and the lowest one
among examined subjects in Dojran (25.6%) (Figure 45).
Figure 44. Distribution of the examined adults by smoking status
Figure 45. Prevalence of smokers among examined subjects in certain centers
Living in a house was the dominant housing type (Figure 46), and wood heating was the
dominant heating type in the examined adults (Figure 47).
Figure 46. Distribution of the examined adults
by housing type
Figure 47. Distribution of the examined adults
by heating type
Housing in the environment rich with green plants was reported by 67.2% of the examined
adults (Figure 48). The highest prevalence of subjects with reported green plants outdoors
was registered in Dojran and Pehchevo (92.3% and 84.3%, respectively) (Figure 49).
88
Figure 48. Distribution of the examined adults
by presence of the green plants outdoors
Figure 49. Green plants outdoors/ prevalence
among examined subjects in certain
centers
Presence of green plants at home was reported by 77.2% of the examined adults (Figure
50). The highest prevalence of subjects with reported green plants indoors was registered
in Pehchevo and Ohrid (85.9% and 84.3%, respectively) (Figure 51).
Figure 50. Presence of green plants indoors
in the examined adults
Figure 51. Presence of green plants indoors/
prevalence among examined adults
in certain centers
Pets ownership was reported by 35.3% of the examined adults (Figure 52). The highest
prevalence of pets owners was registered in Dojran and Skopje (45.4% and 40.5%,
respectively) (Figure 53).
Figure 52. Distribution of the examined adults
by pets ownership
Figure 53. Pets ownership/ prevalence among
examined adults in certain centers
Exposure to environmental air pollutants (e.g. traffic and/or industrial pollution) was
reported by 38.3% of the examined adults (Figure 54). The highest prevalence of subjects
exposed to air pollutants was registered in Skopje, and the lowest in Dojran (45.2% vs.
14.6%) (Figure 55).
89
Figure 54. Distribution of the examined adults by
prevalence exposure to environmental
air pollution
Figure 55. Environmental air pollution
among examined adults in
certain enters
Exposure to workplace air pollutants was reported by 43.8% of the examined adults
(Figure 56). The highest prevalence of the subjects with reported workplace exposure
to air pollutants was registered in Skopje (57.5%) and the lowest one in Dojran (24.1%)
(Figure 57).
Figure 56. Distribution of the examined adults
by exposure to workplace air pollutants
Figure 57. Exposure to workplace air pollutants/
prevalence among examined adults in
certain centers
1.1.2. Characteristics of the examined children
The study included 399 children aged 0-15 years, 196 boys (48.9%) and 203 girls (51.1%).
Sex distribution of the examined children is shown in Figure 58.
Figure 58. Sex distribution of the examined children
90
The mean age of the examined children was 11,0 ± 2,6 years. Approximately 40% of the
examined children were younger than 7 years (Figure 59).
Figure 59. Age distribution of the examined children
Figure 60 shows the distribution of the examined children by certain centers.
Figure 60. Distribution of the examined children by certain centers
As in the examined adults, the majority of the examined children were Macedonians
(78.7%), followed by Albanians (14.5%). Distribution of the examined children by
ethnicity is shown in Figure 61.
Figure 61. Distribution of the examined children by ethnicity
91
There was a higher prevalence of children with urban than with rural residence (81.9%
and 18.1%, respectively) (Figure 62).
Figure 62. Distribution of the examined children by residence
Living in a house was the dominant housing type (Figure 63), and wood heating the most
dominant heating type in the examined children (Figure 64).
Figure 63. Distribution of the examined children
children by housing type
Figure 64. Distribution of the examined
by heating type
Maternal smoking during pregnancy was reported by 12.1% of the examined children
(Figure 65). The highest prevalence of maternal smoking during pregnancy was registered
among examined children in Dojran and Skopje (17.6% and 15.6%, respectively), and the
lowest one among examined children in Pehchevo (2.0%) (Figure 66).
Figure 65. Distribution of the examined children by
maternal smoking during pregnancy
92
Figure 66. Maternal smoking during
pregnancy in certaon centers
Breast-feeding in the infancy was reported by 91.0% of the examined children (Figure
67). The highest prevalence was registered among examined children in Dojran (Figure
68). The majority of the examined children was breastfed during the period of infancy
(Figure 69).
Figure 67. Distribution of the examined children by feeding in the infancy
Figure 68. Breast-feeding in the infancy
prevalence among examined
children in certain centers
Figure 69. Duration of breast-feeding (months)
Birth weight in the majority of the examined children was 3,000-4,200 g. (Figure 70).
Figure 70. Distribution of the examined children by birth weight (g.)
Sibship was reported by 55.0% of the examined children (Figure 71).The highest preevalence was registered in Ohrid (66.6%) (Figure 72).
93
Figure 71. Distribution of the examined
children by sibship
Figure 72. Sibship prevalence among
examined children in certain centers
A day-care attendance during the preschool period was reported by 42.8% of the
examined children (Figure 73). The highest prevalence of children that had attended a
day-care was registered in Skopje (57.1%) (Figure 74).
Figure 73. Distribution of the examined
children by a day-care attendance
Figure 74. A day-care attendance/ prevalence
among children in certain centers
Presence of the green plants outdoors was reported by 79.7% of the examined children
(Figure 75). The highest prevalence was registered among examined children in Dojran
(Figure 76).
Figure 75. Distribution of the examined children
by presence of green plants outdoors
Figure 76. Green plants outdoors - prevalence
among examined children
in certain centers
Presence of green plants indoors was reported by 71.4% of the examined children
(Figure 77). The highest prevalence was also registered in Dojran (92.7%) (Figure 78).
94
Figure 77. Distribution of the examined children
by presence of green plants indoors
Figure 78. Green plants indoors prevalence among
examined children in certain centers
Pets ownership was reported by 34.4% of the examined children (Figure 79). As in the
adults, the highest prevalence was registered in Dojran (Figure 80).
Figure 79. Distribution of the examined
children by pets ownership
Figure 80. Pets ownership/ prevalence among
examined children in certain centers
Exposure to environmental tobacco smoke was reported by 60.7% of the examined
children (Figure 81). The highest prevalence was registered in Pehchevo (Figure 82).
Figure 81. Distribution of the examined
children by exposure to
environmental tobacco smoke
Figure 82. Exposure to environmental tobacco
smoke/prevalence among examined
children in certain centers
Exposure to environmental air pollutants (traffic pollution, industrial pollution) was
reported by 20.1% of the examined children (Figure 83). As in the examined adults, the
highest prevalence of children exposed to environmental air pollutants was registered in
Skopje (34.2%), and the lowest one in Dojran (5.9%) (Figure 84).
95
Figure 83. Distribution of the examined
children by exposure to
environmental air pollutants
Figure 84. Exposure to environmental air
pollutants/prevalence among
examined children in certain centers
References:
1. Stikova E. Zdravstvena ekologija [Medical Ecology, in Macedonian]. Skopje:
Faculty of Stomatology 2006, 47-48.
2. The European Academy of Allergology and Clinical Immunology. Position paper:
Allergen standardization and skin tests. Allergy 1993;48 Suppl 14:48-82.
3. 185. Quajner PhH, ed. Standardization of Lung Function Tests – 1993 Update. Report
Working Party for the European Community for Steel and Coal. Official Statement of
the European Rrespiratory Society. Eur Rrespir J 1993; 16 Suppl: 1-100.
4. Sterk PJ, Fabbri LM, Quanjer PhH, et al. Airways Responsiveness. Standardized
challenge testing with pharmacological, physical and sensitizing stimuli in adults.
Report Working Party for the Standardization of Lung Function Tests. European
Community for Steel and Coal. Official Statement of the European Respiratory
Society. Eur Respir J 1993; 6(16):58-83.
5. American Thoracic Society. Guidelines for Metacholine and Exercise Challenge
Testing -1999. Am Respir Crit Care Med 2000;161(1):309-329.
6. British Thoracic Society and Association of Respiratory Technicians and Physiologists.
Guidelines for the measurement of respiratory function. Respiratory Medicine 1994;
88: 165-194.
96
2.0. Allergic rhinitis - ICD - 10; J 30.4
2.1. Defintion
Allergic rhinitis (AR) is defined as an inflammation of nasal mucosa in which many cells
and celular elements are involved.
The inflammation leads to increased nasal response to different specific and nonspecific
stimuli and to symptom complex that consists of any combination of sneezing, nasal
itching, rhinorrhea, and nasal blockage.
2.2. Classification
For a period of time AR has been subdivided, based on time of exposure, into seasonal
and perennial AR. According to the new classification, based on duration of symptoms,
AR is subdivided into intermittent and persistent AR. Intermittent AR is characterized by
symptoms occurrence in less than four days per week or in less than four weeks per year.
Persistent AR is characterized by symptoms occurrence in a longer period (e.g. in more
than four days per week or in more than four weeks per year).
Seasonal AR (SAR, J 30.1) is defined as an inflammation of the nasal mucosa characterized
by intermittent nasal symptoms that occur in sensitized subjects following exposure to
outdoor allergens (pollens and certain moulds).
Perennial AR (PAR, J 30.3) is defined as an inflammation and hypertrophy of the nasal
mucosa characterized by nasal symptoms that persist round-year.
Occupational AR, which can be seasonal, perennial, or sporadic, is defined as an
inflammation of the nasal mucosa caused by IgE-mediated reaction to the allergen from
the workplace.
According to the classification based on severity, AR is subdivided into mild and moderatesevere depending on symptoms and quality of life.
2.3. Pathogenesis
2.3.1. Seasonal Allergic Rhinitis (SAR)
The inflammation of the nasal mucosa in SAR results from an IgE-mediated response to
extrinsic allergens. An inflammatory infiltrate is made up of different cells. The cellular
response includes chemotaxis, selective recruitment and trans-endothelial migration of
cells (T-lymphocytes, eosinophils, neutrophils); release of cytokines (IL 4, IL 5, IL 13);
activation and differentiation of various cell types including mast cells, T-lymphocytes,
eosinophils, and epithelial cells; prolongation of their survival; and release of mediators by
97
activated cells among which histamine and cysteinyl-leukotrienes are the most important.
The response includes early or immediate phase, that occurs in minutes following the
allergen exposure, and late phase, that occurs over 4-8 hours and may persist for hours
or days.
SAR is commonly caused by allergy to seasonal pollens and outdoor moulds.
Tree pollens, which vary by geographic location, are typically present in high counts
during spring, although some species produce their pollens in fall. Common tree families
associated with SAR include birch, lime, alder, hazel, oak, olive, and willow. Grass pollens
also vary by geographic location. Most of the common grass species are associated with
SAR, including Zae mays, Secale cereale, Poa pratensis, and Triticum spp. A number
of these grasses are cross-reactive, meaning that they have similar antigenic structure.
Consequently, an individual which is sensitized to one species is also likely to be sensitive
to other species. The grass pollens are most prominent from late spring during fall. Weed
pollens also vary geographically. Common weeds associated with SAR include mugwort,
plantain, goosefoot, nettle, and ragweed. Many of the weeds are most prominent in the
late summer and fall.
Outdoor moulds, such as Alternaria and Cladosporium are also associated with SAR. Their
airborne prevalence vary depending on climate and season. Alternaria and Cladosporium
are particularly prevalent in the dry and windy conditions. Aspergilus and Penicillium
can be found both outdoors and indoors (particularly in humid households), with variable
growth depending on the season and climate.
Cold air, physical exercise, and emotional stress are considered as contributing factors in
the development of SAR. A number of environmental and workplace air pollutants also
play a role enhancing the formation of IgE and allergic inflammation. Indoor air pollution,
particularly tobacco smoke, is of great importance since subjects in industrialized
countries spend over 80% of their time indoors. Outdoor pollutants, including pollutants
of automobile origin, ozone, oxides of nitrogen, and sulfur dioxide, may also be involved
in the aggravation of nasal symptoms.
2.3.2. Perennial Allergic Rhinitis (PAR)
Similarly to SAR, inflammation of the nasal mucosa caused by IgE-mediated reaction to
extrinsic allergens, including early and late response, is the basis of the pathogenesis of
PAR.
PAR is usually caused by allergens found at home. Domestic allergens, such as allergens
from the house dust (Dermatophagoides pteronyssinus), indoor moulds (Alternaria,
Penicillium), pets (dog hair, cat fur, feathers), and insects (cockroach) are the most
important allergens in the development of PAR.
98
Nonspecific stimuli, such as cold air, physical exercise, environmental and workplace
air pollutants, strong smells, and emotional factors contribute to its development and
severity.
2.4. Clinical manifestations
2.4.1. Seasonal Allergic Rhinitis (SAR)
Sneezing, nasal itching, and watery rhinorrhea, often accompanied by nasal congestion
are the typical symptoms of SAR. The eyes, ears, sinuses, and throat can also be involved.
Systemic effects, including fatigue, sleepiness, and malaise, can occur as a result of the
inflammatory response. These symptoms often contribute to impaired quality of life. In
about 10 – 20% of the subjects with SAR accompanied asthma is present, and in about
1% the disease is associated with skin and gastrointestinal manifestations.
- Seasonal occurrence of the symptoms, following the exposure to certain allergens (pollens or moulds) is typical for SAR.
- Severity of the symptoms depends upon the pollen concentration.
- Severity of the symptoms usually decreases with age.
- Occurrence of the symptoms out of certain season usually is caused by transport of the
pollen grains from other areas.
2.4.2. Perennial Allergic Rhinitis (PAR)
- Hypersecretion of thick mucus or nasal blockage commonly dominate in the clinical
picture of PAR (runners or blockers), whereas sneezing and nasal itching are less
expressed.
- Symptoms occur at a consistent level thorough the year, usually being more severe in
the fall-winter period.
- Sinusitis occurs quite frequently in the subjects with PAR. Sinonasal polyposis, as well
as otitis media can also be associated with PAR. PAR is associated with asthma and is
considered to be a risk factor for asthma.
2.5. Diagnosis
Diagnosis of AR is based on history, physical examination, functional assessment, and
skin and laboratory tests.
99
2.5.1. Clinical history
Clinicl history is essential for an accurate diagnosis of rhinitis, assessment of its severity,
and likely response to treatment. Important elements include an evaluation of the nature,
duration, and time course of symptoms, possible triggers for symptoms, response to
medications, comorbid conditions, family history of allergic diseases, environmental
and occupational exposures, and effects on quality of life. A thorough history may help
identify specific triggers, suggesting an allergic etiology for rhinitis.
2.5.2. ENT status
The physical examination is focused on the nose, but examination of eyes, ears,
oropharynx, neck, lungs, and skin is also important. Looking for physical findings that
may be consistent with a systemic disease that is associated with rhinitis (e.g. sarcoidosis,
hypothyroidism, ciliary dyskinesia syndrome) is recommended. The nasal examination
includes rhinoscopy and nasal endoscopy. Anterior rhinoscopy using a speculum and
mirror usually gives limited information. Nasal endoscopy is more useful.
The mucosa of the nasal turbinates is swollen and has a pale, bluish-gray color. While
pale, boggy, blue-gray mucosa is typical for AR, mucosal examination findings cannot
definitely distinguish between allergic and nonallergic causes of rhinitis. Thin and watery
secretions are frequently associated with SAR, while thick and purulent secretions are
usually associated with sinusitis. By examination of the nasal cavity may also be detected
septal deviation, polyps, tumors, foreign bodies, etc. Polyps are firm gray masses that
are often attached by a stalk which may not be visible. Polyps do not shrink after nasal
decongestant application, while the surrounding nasal mucosa shrinks.
2.5.3. Functional diagnostics
2.5.3.1. Rhinomanometry
Rinomanometry is a routinely applicable functional method for assessment of nasal
patency (nasal resistence) through measurements of nasal airflow and differential pressure
which can produce qualitative (Figure 85) and quantitative parameters for evaluation.
100
A. Normal rhinogram
B. Obstructed nasal breathing
Figure 85. Normal and pathological rhinomanometric results
Rhinomanometric parameters for quantitative evaluation of nasal function for the Rhinotest
MP 500 (Figure 86) are the flow parameters, percent of flow increase upon doubling the
differential pressure (aerodinamical assessment), flow ratio (functional comparison of
both nasal sides) and resistance parameters. Decongestion test and allergen specific nasal
provocation test can be applied as well.
Figure 86. Rhinotest MP 500 device
2.5.3.2. Acustic rhinometry
Acustic rhinomanometry is a method for assessment of parameters of nasal turbinates that
enables quantification of abnormalities. The method is based on analyses of the reflected
sound wave that was emitted into nose.
101
2.5.4. Skin tests (immediate hypersensitivity testing)
Testing for reaction to specific allergens can be helpful to confirm the diagnosis of AR and to
determine specific allergic triggers. If specific allergic triggers are known, then appropriate
avoidance measures can be recommended and allergen-specific immunotherapy can be
performed.
The allergens may be introduced percutaneously (prick tests) or intradermally. Skin
prick tests (SPT), performed according to the actual recommendation of the European
Academy of Allergology and Clinical Immunology (EAACI) are usually used for allergy
testing. Drugs, such as antihistamines and corticosteroids, older age, seasonal variations
of allergen, and skin changes, such as urticaria, dermographism, and atopic dermatitis,
can change the skin reaction to introduced allergen.
2.5.5. Laboratory tests
Measurement of the total level of IgE in the blood (regardless of specificity) is
neither sensitive nor specific for AR, so this test is not recommended in the diagnostic
procedure.
Measurement of the level of specific IgE to a particular antigen in the blood by
radioallergosorbent test (RAST) or CAP specific IgE assay is a useful test for demonstration
of allergic sensitization. Since specific IgE is detected in different tissues (i.e. skin and
blood) there is no correlation between in vivo and in vitro tests in approximately 30% of
the cases.
Measurement of the markers of allergic inflammation, such as measurement of the
eosinophil count in the nasal smear and in the blood, as well as the levels of inflammatory
mediators (leukotrienes, prostaglandins, histamine) in the blood and urine, may help in
establish the diagnosis of AR.
While radiographic studies (radiography, CT scanning, and MRI) are not needed to
establish the diagnosis of AR, they can be helpful for evaluating possible structural
abnormalities or to help detect complications or comorbid conditions, such as sinusitis or
adenoid hypertrophy.
2.5.6. Differential diagnosis
Other problems that should be considered in the subjects with chronic nasal symptoms
include vasomotor rhinitis, rhinitis medicamentosa (e.g. due to topical decongestants,
antihypertensives, cocaine abuse), infectious rhinitis, hormonal rhinitis (e.g. related to
pregnancy, hypothyroidism, oral contraceptive use), immotile cilia syndrome (ciliar
dyskinesis), nasal polyps, and granulomatous rhinitis (e.g. sarcoidosis, Wegener
granulomatosis).
102
2.6. Management of Allergic Rhinitis
The management of AR consists of environmental control measures, pharmacological
treatment, allergen-specific immunotherapy, and other types of therapy.
2.6.1. Environmental control measures
Environmental control measures involve both the avoidance of allergen to which the
patient has IgE-mediated hypersensitivity and avoidance of nonspecific triggers. However,
global environmental control without identification of specific triggers is inappropriate.
2.6.1.1. Seasonal Allergic Rhinitis (SAR):
- To consider pollen counts when planning outdoor activities. It is helpful to limit the
outdoor activities when pollen and mold counts are at their highest;
- To keep doors and windows of the house and car shut as much as possible during the
pollen season;
- To take a shower after outdoor exposure for removing pollen grains that are stuck to
the hair and skin;
- To use an air conditioner to cool the home instead of coolers or fans that bring in
outside air.
2.6.1.2. Perennial Allergic Rhinitis (PAR):
-
-
-
-
-
-
-
No furry or feathered pets at home;
Remove the carpets or clean carpets and rugs by vacuum cleaning;
Wash pillows, sheets, and blankets weekly in hot water;
Cover mattress and pillows with impermeable covers;
Reduce excessive humidity and to removal standing water;
Exterminate cockroaches by insecticides;
Avoid situations that may aggravate symptoms of PAR, such as exposure to tobacco
smoke, strong perfumes, and rapid changes in temperature;
- Keep doors and windows shut during the pollen season since the exposure to pollens
may aggravate symptoms of PAR.
2.6.2. Pharmacological treatment
The goals for successful pharmacological treatment of AR are to:
- Achieve and maintain control of symptoms;
- Prevent exacerbations, chronicity, and complications;
- Improve quality of life;
- Avoid adverse effects from rhinitis medications.
103
Pharmacological treatment of AR includes antihistamines, decongestans, anticholinergics,
and anti-inflammatory medications. The most important AR medications are presented
in Appendix 4. The effects of certain medications on rhinitis symptoms are shown in
Appendix 5.
2.6.2.1. Antihistamines
Antihistamines are often preferred for the first-line therapy of AR, especially for seasonal
symptoms, because of their excellent efficacy and safety profile.
- All antihistamines are efficacious in controlling sneezing, itching, and r h i n o r r h e a ,
but do not significantly improve nasal congestion;
- They compete with histamine for histamine receptor type 1 (H1) receptor sites in the
blood vessels, gastrointestinal (GI) tract, and respiratory tract, which, in turn, inhibits
physiologic effects that histamine normally indices at the H1 receptor sites;
- Second-generation antihistamines (also reffered to as the nonsedating antihistamines)
are usually administered. The older, first-generation antihistamines, are effective in
reducing most symptoms of AR, but they produce a number of adverse effects (e.g.
sedation, impairment of cognition, anticholinergic effects);
- There are systemic and topical preparations of antihistamines.
2.6.2.2. Decongestants
Decongestants stimulate vasoconstriction by directly activating α adrenergic receptors of
the respiratory mucosa. They are used alone or in combination with antihistamines to treat
nasal congestion. Decongestants should be administered with precautions in subjects with
hypertension, cardiac disease, diabetes, glaucoma, GI obstruction, urinary obstruction,
elderly patients, pregnancy and lactation. They may also produce anxiety and insomnia.
Local decongestants should not be used as a long-term treatment since they may cause
rebound effect or atrophy of the nasal mucosa (i.e. rhinitis medicamentosa).
2.6.2.3. Anticholinergics
Anticholinergics, such as ipratropium bromide, may be helpful for decreasing symptoms
of a runny nose.
2.6.2.4. Anti-inflammatory medications
Anti-inflamatory medications, including cromones, leukotriene receptor antagonists, and
corticosteroids) control inflammation of the nasal mucosa.
104
Cromones, such as disodium cromoglycate and nedocromil sodium, produce mast cell
stabilization and antiallergic effects that inhibit degranulation of mast cells. Used as local
preparations they are effective for prophylaxis of AR, just before exposure to a known
allergen (e.g. pollen, animal, occupational). Cromones produce modest effect compared
with that of intranasal corticosteroids, their protective effect lasts 4-8 hours and thus
frequent dosing is necessary. Cromones have an excellent safety profile and are thought
to be safe for use in children and pregnancy.
Leukotriene receptor antagonists, such as montelukast, selectively prevent action
of leukotrienes released by mast cells and eosinophils. When used as a single agent,
montelukast produces modest improvement of symptoms, similar in degree to secondgeneration antihistamines.
Local corticosteroids are highly efficacous in treating AR. They control the four major
symptoms of AR (i.e. sneezing, itching, rhinorrhea, and nasal obstruction). They are
effective as monotherapy and studies have shown that nasal corticosteroids are more
effective than monotherapy with nasal cromones or antihistamines. Greater benefit
may occur when local corticosteroids are used with other classes of medications (e.g.
antihistamines). They are safe and are not associated with systemic adverse effects. Local
adverse effects of nasal corticosteroids are limited to minor irritation of the nose or throat
and nasal bleeding, which resolve with temporary discontinuation of the medication.
Safety during pregnancy has not been established, but clinical experience suggests that
their use is not associated with adverse fetal effects.
Due to the possibility of serious systemic adverse effects systemic corticosteroids are
recommended only as a short-course treatment in subjects with severe AR symptoms.
2.6.2.5. Specific immunotherapy
Allergen-specific immunotherapy (ASIT), also referred to as desensitization, allergy
vaccination (AV) or allergy shots, for the first time was used in the treatment of AR by Noon
and Freeman in 1911. Since then, a considerable body of clinical research has established
the effectiveness of ASIT in reducing symptoms and medication requirements. ASIT has
been considered as an established treatment of SAR, PAR, allergic rhinoconjunctivits,
asthma, and insect sting allergy. The success rates have been demonstrated to be as high
as 80-90% for certain allergens.
In 1997 the initiative of J. Bousquet and R. Lockey, resulted in publishing Allergen
Immunotherapy: therapeutic vaccines for allergic diseases. The WHO Position Paper that
includes recommendations for indications, contraindications, and standardized therapeutic
protocols. ASIT as a therapeutic modality in the treatment of allergic diseases has been
used in R. Macedonia for a long period of time and its principles have been incorporated in
the Macedonian National Consensus for Allergic Rhinitis and in the Macedonian National
Consensus for Asthma and Chronic Obstructive Pulmonary Disease, both published in
1999.
105
Definition. SIT is defined as a high allergen dose vaccination strategy, which reprogrammed
the peripheral tolerance against allergen.
The classic subcutaneous immunotherapy (SCIT) consists of a series of injections (shots)
with an increasing concentration of allergen extracts reaching the dose that is effective
for reducing the symptoms associated with exposure to certain allergen. The treatment
usually begins with a weak solution that is applied once or twice a week. The strength of
the solution is gradually increased with each dose. Once the strongest dose is reached,
the injections are given once a month. At this point, the sensitivity to certain allergen is
decreased and the maintaince level is reached.
Mechanism. Controversy remains about the mechanism of ASIT. There is no conclusive
evidence as to exact mechanism of ASIT, though there are several theories. The most
plausible current theory emphasizes the balance between effector and regulatory T cell
population, which regulates peripheral tolerance (Figure 87).
Figure 87.
Current concept of regulatory T-cell induction underlying ASIT
Adapted from Schmidt CB & Blaser K. New insights into the mechanisms of allergenspecific immunotherapy. Curr Opin Allergy Clin Immunol 2005; 5 (6): 525-530.
Allergic diseases result from an unbalanced response of the specific immune system,
generating allergen-specific antibodies, which mediate various clinical symptoms. The
generation of allergen-specific IgE by B ly depends on the generation of IL-4 producing
Th 2 cells. The existence of allergen-specific Th 2 cells is not sufficient for allergy
pathogenesis, because these cells are also found in healthy individuals. In contrast,
allergen-specific regulatory T cells (T regs) occur at a higher frequency than their effector
counterparts in healthy individuals, and are capable of suppressing the proliferation and
cytokine expression of Th 1 and Th 2 cells, also acting on APC. T regs are defined on the
basis of their function, in contrast to Th 1 and Th 2 cells, which are characterized by their
gene products. Allergen-specific T regs are induced after the initiation of ASIT, and are
assumed to suppress Th 2 cells directly mediating allergic inflammation.
106
Goal. The basic goal of ASIT is to achieve allergic tolerance and to reduce symptoms of
the disease by decreasing the level of specific IgE directed against certain allergen. ASIT
represents the only curative treatment of specific allergy, i.e. the only treatment that can
modify the natural course of the disease.
Indications. ASIT should be administered with allergens to which the patient is known
to be sensitive and that are present in the patient’s environment and cannot be easily
avoided. ASIT may be considered more strongly with severe disease, poor response to
other management options, and the presence of comorbid conditions or complications.
The value of the ASIT for pollens, dust mites, cats, and Hymenoptera venom is well
established. The value of the ASIT for dogs and moulds is less well established. ASIT is
not a useful method for the treatment of food allergy.
ASIT with undefined allergens, such is house dust, should not be performed.
Before starting the ASIT the allergic sensitization to certain allergen in each patient has to
be demonstrated by history, positive SPT and/or increased specific IgE levels, and nasal
provocation test.
The most important indications for ASIT include:
- Cases of SAR with poor response to other management options;
- Cases of SAR with prolonged exposure to pollens (3-5 months);
- Cases of PAR caused by mite sensitization with poor response to other m anagement
options;
- Cases of clinical manifested insect sting allergy and demonstrated allergic sensitization to Hymenoptera venom.
Contraindications
ASIT should only be performed in selected patients by individuals who have been
appropriately trained, who institute appropriate precautions, and who are equipped for
potential adverse effects. A number of potential contraindications for ASIT exist and need
to be considered.
The most important contraindications for ASIT include:
-
-
-
-
-
-
Cases of SAR in which adequate allergen avoidance may be achieved;
Cases of SAR characterized by sporadic exposure to allergen;
Nasal polyposis;
Cardiovascular diseases;
Treatment with β blockers;
All conditions in which administration of adrenaline is contraindicated (arterial hypertension, arrhythmias);
- Autoimmune diseases;
- Pregnancy;
- Uncontrolled asthma.
107
Duration. Administration of the ASIT is a long-term process. A noticeable improvement
often is not observed for 6-12 months. If helpful, therapy should be continued for 35 years. ASIT is not without risk because severe systemic allergic reactions (i.e. lifethreatening anaphylactic shock) can occur. For these reasons, the risk and benefits of
ASIT in each patient should be carefully considered in respect to the risks and benefits of
the other management options.
ASIT modalities. In the last decades many treatment schedules, aimed at satisfactory
protection, minimal side-effects, optimal convenience, and minimal costs, have been
developed.
There are several ASIT protocols in which the initial phase (i.e. the period in which the
maintenance dose should be reached) is markedly shortened. The patients who underwent
these ASIT protocols had to be hospitalized due to the possibility of adverse effects. In the
rush ASIT protocol the maintenance dose is reached within 4 - 7 days, whereas in the
ultrarush ASIT protocol the maintenance dose is reached within 2 days.
Sublingual immunotherapy (SLIT)
Although SCIT has proven efficacy and a good safety record, disadvantages include
requirement for injections, which are especially problematic in children, as well as the
need for injections administering at the doctor’s office. These factors provide a rationale
to seek alternative treatment approaches, and SLIT shows considerable promise in this
regard.
SLIT technique involves putting large doses of allergen extracts under the tongue, where
the allergen is adsorbed and subsequently induces immune response that may promote
peripheral tolerance. One of the main advantages of this technique is the ability to have
patients self-administrate the extracts at home.
Oral allergen extracts have been used in randomized clinical trials, which began to appear
in the literature around 1985. There has been a considerable clinical experience with
SLIT until today. The published data indicate the efficacy of SLIT in treatment of AR,
asthma, and insect sting hypersensitivity, as well as a good safety profile in both adults and
children. The questions that have to be answered to optimize this therapy include defining
the optimal dose and administration schedule for each extract, determining how long-term
efficacy is best achieved, and working toward a better understanding of the local immune
response and immunologic mechanisms underlying the SLIT-induced tolerance.
2.7. Frequency of allergic rhinitis
The prevalence of AR varies among and within countries that is due to geographic
differences in the types and potency of different allergens, as well as to type and design
of the study. However, published data indicate AR prevalence from 3.8 to 20.6% of the
108
general population (13-15% in Finland, 4-8.6% in Switzerland, 9.6% in the UK, 8.7%
in Germany). Recent US figures have suggested a 20% cumulative prevalence rate (i.e.
approximately 40 million people in the USA). Scandinavian studies indicate prevalence
rate of 15% in men and 14% in women.
An increasing AR prevalence in the last three decades has been reported by a number of
studies. The studies from Switzerland, England and Sweden reported that prevalence of
AR doubled in the period of a decade.
AR occurs in subjects of all races. In childhood, AR is more common in boys than in girls,
but in adulthood the prevalence is approximately equal between men and women.
In 80% of cases, the symptoms of AR occur before the age of 25. The prevalence of AR
has been reported to be as high as 40% in children, subsequently decreasing with age. In
the geriatric population, rhinitis is less common allergic in nature.
AR often coexists with other disorders, such as asthma, and may be associated with asthma
exacerbations. It is also associated with allergic conjunctivitis, otitis media, eustachian
tube dysfunction, sinusitis, nasal polyps, and atopic dermatitis.
2.7.1. Results from our epidemiological study
of allergic rhinitis in R. Macedonia
Epidemiological observations of AR and aeropalinological measurements in R. Macedonia
have started in the early 1990s. During 1993, 556 cases of SAR and 127 cases of PAR
(ratio 4.4 / 1.0) at the Institute of Occupational Health Skopje were rregistered.
In the middle 1990s the first epidemiological survey of AR on a cohort of 113 randomly
selected subjects aged over 18, was carried out. Evaluation of the examined children
included completion of a questionnaire and SPT to common aeroallergens. The prevalence
of AR was found to be 11.5%. In that period a survey of occupational AR had also been
conducted.
The Project “Epidemiological characteristics of allergic rhinitis in R. Macedonia in
correlation to pollen microflora” started in the late 1990s. AR was detected in a group
of 1121 randomly selected subjects (722 adults and 399 children) from six centers
in R. Macedonia. Evaluation of the examined adults for AR included completion of a
questionnaire and SPT to common aeroallergens, while the diagnosis of AR in the
examined children was questionnaire-based.
Prevalence of chronic rhinitis, AR and nonallergic rhinitis (NAR) was 30.2%, 20.8%, and
9.3%, respectively (Figure 88).
109
Figure 88. Prevalence of chronic rhinitis, AR, and NAR in all examined subjects
Prevalence of SAR and PAR in all examined subjects was 13.5% and 7.3%, respectively
(Figure 89).
Figure 89. Prevalence of AR, SAR, and PAR in all examined subjects
2.7.2. Prevalence of rhinitis in examined adults
Prevalence of rhinitis in examined adults was 34.4%. Prevalence of AR and NAR was
23.1% and 11.3%, respectively. Prevalence of SAR and PAR in examined adults was
16.5% and 6.7%, respectively (Figure 90).
110
Figure 90. Prevalence of AR, SAR and PAR in examined adults
The increasing trend of AR prevalence in the last decades, reported by many authors, was
also confirmed in the actual study. The prevalence of AR in adults in the period 19952003 has doubled, particularly due to the increase of the prevalence of SAR (Figure 91).
Figure 91. Prevalence of AR, SAR and PAR in examined adults in 1995 and 2003
Prevalence of AR was slightly higher in women than in men (24.4% vs. 21.2%). (Figure
92). Prevalence of both SAR and PAR was slightly higher in women (17.1% vs. 15.2%
and 7.2% vs. 6.0%, respectively). Non-significant sex distribution of AR was obtained in
our previous study, as well as in the many studies carried out worldwide.
111
Figure 92. Sex distribution of AR in examined adults
The highest prevalence of AR in examined adults was registered in the age group 31-40
(29.5%) (Figure 93). Data from the reviewed studies indicate higher prevalence of AR in
younger age groups. The highest prevalence of SAR in England and Wales was registered
in the age group 5-15, in Denmark in the age group 10-19, and in the USA in the age of
24. Prevalence of SAR in the European countries is lower than in the USA and Australia.
This could be a result of the higher allergic potential of the allergens in these countries.
Figure 93. Age distribution of AR in examined adults
2.7.2.1. Prevalence of allergic rhinitis in examined adults from certain centers
The highest AR prevalence in examined adults was registered in Prilep (35.4%) and the
lowest in Ohrid and Skopje (20.0% and 16.5%, respectively). The highest SAR prevalence
in examined adults was also registered in Prilep (29.7%) and the lowest one in Debar and
Skopje (9.7% and 8.5%, respectively). The highest prevalence of PAR was registered
among examined adults from Debar (13.6%) and the lowest one among examined adults
from Ohrid (1.0%) (Figure 94).
112
Figure 94. AR, SAR, and PAR prevalence among examined adults from certain centers
The highest prevalence of SAR was registered among examined adults from Prilep (29.7%),
that is one of the highest SAR frequencies reported in the literature. Aeropalinological
measurements showed the highest concentrations of airborne grass and weed pollens in
Prilep. The highest prevalence of allergic sensitization to tree, grass, and weed pollens
among examined adults was registered also in Prilep (25.4%, 41.5%, and 43.2%,
respectively). The period in which the skin prick tests were performed (April-May), that
is a period of the highest pollination of the most grass species, also play a role for the
obtained results.
113
2.7.2.2. Distribution by sensitization to common aeroallergens
The importance of mite sensitization as a risk factor for AR and asthma has been indicated
in many reviewed studies and was confirmed in our study. The highest sensitization to
common aeroallergens among subjects with AR was registered for goosefoot pollen,
Dermatophagoides pteronyssinus, mugwort pollen, and cat fur (Table 13).
Allergen
Tree pollens
Grass pollens
Weed pollens
Goosefoot
Mugwort
Nettle
Plantain
Ambrosia
Penicillium
Alternaria
Cat
Dog
Feathers
Dermatophagoides
pteronyssinus
Cockroach
Positive SPT in the
examined adults
(%)
10.8
17.9
19.4
13.6
11.9
7.5
5.1
4.4
3.9
3.6
5.5
2.8
3.9
Positive SPT in the
examined adults with AR
(%)
25.4
41.5
43.2
30.5
26.3
18.6
12.7
11.0
4.2
4.2
10.2
6.8
6.8
13.9
26.3
3.2
3.4
Table 13. Distribution of the adults with AR by sensitization to common aeroallergens
2.7.2.3. Sex distribution
The non-significant role of the gender in AR development has been reported by many
studies that is in agreement with the results of our study. The prevalence of AR in adults
was non-significantly higher in women, whereas in children it was non-significantly
higher in boys.
2.7.2.4. Allergic rhinitis and respiratory symptoms
Many studies indicated strong link between AR and respiratory symptoms that was
confirmed by results of our study. AR was significantly associated with respiratory
symptoms in both examined adults (P < 0.01) and examined children (P < 0.01).
114
2.7.2.5. Allergic rhinitis and atopy
Atopy is defined as a predisposition for production of IgE antibodies following the
exposure to extrinsic allergens. Prevalence of atopy worldwide varies from 10 to 50% of
the general population. Atopy may be demonstrated by in vivo or in vitro tests, as well
as by positive personal or family history of allergic diseases. Prevalence of atopy in our
study was 34.8% and it was non-significantly higher in males (38.7% vs. 31.6%).
We found significant association between AR and positive family history of allergic
diseases in examined children. In examined adults this association was statistically nonsignificant.
2.7.2.6. Allergic rhinitis and environmental factors
Although the significant association between AR and any individual environmental factor
was not registered it could be noted that the frequency of AR and SAR is higher among
examined adults exposed to traffic pollutants, and the frequency of PAR is higher among
examined adults who own pets (Figure 95).
Figure 95. Prevalence of AR, SAR, and PAR in examined adults exposed
to certain environmental factors
According to data from the population-based study carried out in the UK including 2000
subjects, exposure to dust and pets ownership were considered to be the most important
triggers of respiratory allergic diseases. The role of exposure to pets allergens as a risk
factor for respiratory allergies was also reported in the Turkish study carried out in 2003.
According to the results of actual study, the avoidance of exposure to pets should be
recommended.
Many studies have indicated increasing trend of AR incidence and prevalence in
industrialized countries in the last three decades. An increased concentration of traffic
pollutants is considered as one of the most important factors for such changes in AR
frequency. The urban-type pollutants, such as ozone and nitric oxides, may also play a
115
role in the development and severity of rhinitis symptoms. Data from the Italian study,
carried out in the period 1998-2000 which included 18,873 examined subjects aged 2044 from continental and Mediterranean region, showed that exposure to nitric dioxide
in subjects living in warm climate regions increased the risk for AR. Data from the
English study revealed that exposure to sulfur dioxide and ozone may worsen the rhinitis
symptoms.
2.7.3. Prevalence of allergic rhinitis in examined children
The present study was the first epidemiological observation of AR in children in R.
Macedonia. The epidemiological diagnosis of AR was questionnaire-based.
Figure 96. Prevalence of rhinitis symptoms, AR, SAR, and PAR in examined children
Rhinitis symptoms were reported by 22.6% of the examined children. Prevalence of AR,
SAR, and PAR was 16.5%, 8.3%, and 8.3%, respectively (Figure 96). Data of the actual
study indicated higher prevalence of AR in adults than in children. In the reviewed studies
higher AR prevalence in children is reported. The English study indicated the highest
AR prevalence in the age group 5-15. The study from Denmark reported the highest AR
prevalence in the age group 10-19 affecting 15-20% of the school-children with higher
prevalence in boys.
The AR prevalence in children was higher in the girls than in the boys (17.3% vs. 15.8%)
(Figure 97).
116
Figure 97. Sex distribution of AR in examined children
The highest AR prevalence in examined children was registered in Skopje and Prilep
(21.1% and 20.4%, respectively) and the lowest one in Debar (8.4%). The highest and
the lowest prevalence of SAR was registered in Skopje and Debar (10.6% and 3.6%,
respectively). The highest and the lowest prevalence of PAR was also registered in Skopje
and Debar (10.6% and 4.8%, respectively) (Figure 98).
Figure 98. Prevalence of AR, SAR and CAR in examined children from certain centers
We found significant association between AR in examined children and respiratory
symptoms (P < 0.01). Significant association between AR in examined children and
endogenous factors was registered for family history of allergic diseases (P < 0.01),
whereas the association with other endogenous factors was not statistically significant.
117
2.7.3.1. Association between allergic rhinitis in examined
children and environmental factors
Statistical significance between AR, SAR, and PAR in examined children was not
registered with any individual environmental factor. However, more frequent occurrence
of these diseases was noted in children with certain exposure (Figure 99). AR occurred
more frequently among children that reported exposure to environmental air pollutants and
cat ownership. According to our findings exposure to traffic pollutants and cat ownership
may play a role in PAR development, whereas housing in environment rich with plants
and trees may be important for development of SAR.
Figure 99. Prevalence of AR, SAR, and PAR in children exposed
to certain environmental factors
Results from the studies that investigate the effect of environmental factors to respiratory
allergies are controversial. The study carried out in the United Arab Emirates that included
2,200 children aged 6-12 years had indicated pets ownership as a risk factor for allergic
sensitization and AR. On the contrary, Swedish follow-up study carried out on a sample
of 3,000 children aged 7-9 and 12-13 years had showed that exposure to pets allergens in
the first year of life led to lower prevalence of AR and asthma. The Dutch contribution to
ISAAC, carried out on a sample of 3,000 children, reported non-significantly lower risk
of sensitization to pollens in children exposed to pets allergens in the first two years of
life.
The study from Austria indicated lower prevalence of allergic sensitization, SAR, and
asthma in children with farming exposure. The German study, carried out on a sample of
317 children at the age of 9, showed significant association between pollens sensitization
and the air level of nitric dioxide. Similar findings (i.e. significant association between AR
and level of traffic air pollutants) were reported by the study carried out among teenagers
in Taiwan.
Many studies indicate that AR prevalence in developing countries in both children and
adults is recently increasing following the urbanisation and industrialisation. Possible
explanations, beside the exposure to pollution from industrial and motor vehicle exhaust
118
emission, may be the changes in diet that cause a loss of protection against allergic diseases
caused by Lactobacillus, contained in fermented milk usually drunk in African rural
areas, as well as the decrease in worm infections (e.g. Ascaris lumbricoides), considered
responsible for protection against development of allergies by some authors.
Furthermore, some authors report an adverse effect of childhood immunisations, as well
as the use of antibiotics on the allergic diseases development. Some authors also report
that sibship size is inversely related to the prevalence of childhood allergic diseases. A
potential explanation may be that having more siblings contribute to a higher infectious
burden, thereby directing the development of the immune system in a nonatopic (Th1)
direction.
The hygienic hypothesis, being on the scene long time ago, assumes all these elements.
John Bostock, the doctor who first identified hay fever, noted that it was a condition of the
educated and he could not report any case among poor people.
2.7.4. Occupational allergic rhinitis
A significant association between AR, SAR, and PAR and any individual workplace factor
was not found in our study. However, higher prevalence of AR and SAR was registered
in subjects with workplace exposure to dusts. The prevalence of AR, SAR, and PAR was
non-significantly higher in subjects that reported higher level of humidity at the workplace
(Figure 100).
Figure 100. Prevalence of AR, SAR and PAR in examined adults
with harmful work environment
Workplace-associated worsening of the rhinitis symptoms was reported by 33.3% of the
adults with AR. Despite the fact that our the questionnaire was not designed for detection
119
of the occupational AR, the prevalence of occupational AR in the examined adults may
be estimated to 7.6%. that was consistent with the published data. The prevalence of
occupational AR in published literature varies from 1.7 to 20%. It seems that the prevalence
of occupational AR is quite underdiagnosed since in many cases the workplace relatedness
of rhinitis symptoms is not registered by both patients and doctors.
The findings of our previous study, carried on a sample of 198 subjects and based on
the completion of a questionnaire (Appendix 6), SPT, and lung function tests, showed
prevalence of occupational AR of 10.1%. The highest prevalence of occupational AR was
registered in the tea and spice processors (15.5%). Occupational AR was significantly
associated with respiratory symptoms (P < 0.001), whereas the age over 45, high dust
level, and physical exercise were considered as contributing factors in its development.
2.7.5. Conclusions
1. The prevalence of AR in all examined subjects was 20.8%.
2. The prevalence of AR in examined adults was 23.1%, being slightly higher in women
(24.4%) than in men (21.2%). The prevalence of SAR in examined adults was 16.5%
(15.2% in men and 17.1% in women), while the prevalence of PAR was 6.7% (6.0%
in men and 7.2% in women).
3. The prevalence of AR showed trend of increase that was more expressed for SAR
than for PAR.
4. The highest AR prevalence among examined adults was registered in Prilep (35.4%).
The highest prevalence of SAR was registered also in Prilep (29.7%), whereas the
highest prevalence of PAR was registered in Debar (13.6%). In respect to the age, the
highest AR prevalence was registered in the age group 31-40.
5. The weed pollens were the most important aeroallergens in the adults with SAR. The
goosefoot and the mugwort pollen were the most important individual aeroallergens.
6. Significant association was found between AR in adults and respiratory symptoms.
The association between AR and other endogenous and exogenous factors was not
statistically significant.
7. Although no significant association was found, exposure to traffic pollution and pets
ownership could play a role in AR development.
8. The prevalence of occupational AR was estimated to be 7.6%. Although no significant
association between AR and any workplace factor was registered, workplace exposure
to dusts and humidity could play a role in AR development.
9. The prevalence of AR in examined children was 16.5%, being slightly higher in the
boys (17.3%) than in the girls (15.8%). The prevalence of both SAR and PAR in
examined children was 8.3%.
10.AR in examined children was closely related to positive family history of allergic
diseases and to respiratory symptoms. Association between AR and other endogenous
and exogenous factors was not statistically significant.
120
2.7.6. References:
1. Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemioloski karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseases in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
2. Cvetanov V, Caev V, Gjorcev A, Dokic D, Nikolovski Lj, Ezova N, Risteska-Kuc S,
Milkovska S. Makedonski nacionalen konsenzus za alergiski rinitis [Macedonian
National Consensus for Allergic Rhinitis, in Macedonian]. Skopje: Macedonian
Society for Basical and Clinical Immunology and Allergology, 1999, 20-22.
3. Mileva Z. Alergicen rinit. Vo: Nasev G, Mileva Z. Naracnik na
obstopraktikuvastija
lekar [Allergic Rhinitis. In: Nasev G, Mileva Z: Manual for the general practitioner,
in Bulgarian]. Sofia: Znanie EOOD 2003, 474-476.
4. Dokic D. The upper airways: The guardian of the lower airways. Summer School
Sofia 2002.
5. Ezova N, Cvetanov V, Milkovska S, et al. Karakteristiki na alergiskiot rinitis vo R.
Makedonija [Characteristics of allergic rhinitis in R. Macedonia, in Macedonian].
Mak Med Pregled 2003; 56: 142-143.
6. Kay AB. Principles and Practice of Diagnosis and Treatment of Allergic Disease.
In: Kay AB (ed). Asthma and Allergic Rhinitis. Evolving Concepts in Management.
Oxford: Blackwell Science Ltd, 1997; 31-50.
7. Bousquet J, Vignola AM, Demoly P. Allergic inflammation of the upper and lower
airways: a continuum of disease? In: Chung F, Fabbri LM, editors. Asthma. European
Respiratory Society: European Respiratory Monograph 2003; 8 (23): 211-220.
8. Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova N.
Alergiski bolesti-lekuvanje [Allergic Diseases – Management, in Macedonian].
Skopje: MEDIS-informatika 1998; 163-173.
9. Pepys J. Skin testing. Br J Hosp Med 1975; 14: 412-417.
10.Cvetanov V, Risteska-Kuc S, Ezova N, Micajkov I. Rinomanometrija: znacenje,
primena i osnovni principi [Rhinomanometry: importance, use, and basic
principles, in Macedonian]. Mak Med Pregled 1994; 5-6: 181-185.
11.Mileva Z, ed. Svremenno lecenie na alergicnite bolesti [Current management of
allergic diseases, in Bulgarian]. St. Zagora: Znanie EOOD 1999; 142-148.
12.Gavrilovski M, Dokic D. Imunoterapija [Immunotherapy, in Macedonian]. Skopje:
EDIT 1992; 20-30.
13.Bousquet J, van Cauwenberge P, Ait Khaled N, et al. Pharmacologic and anti-IgE
treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy
2006; 61: 1086-1096.
14.Gjorcev A, Stefanovski T, Dimitrovski M, Cvetanov V, Trandafilovski P, Nikolovski
Lj, Dokic D. Makedonski nacionalen konsenzus za dijagnoza i lekuvanje na astma
i hroni~na obstruktivna belodrobna bolest [Macedonian National Consensus for
Diagnosis and Management of Asthma and Chronic Obstructive Pulmonary
Disease, in Macedonian]. Skopje: Evropa 92, 1998; 58-59.
15.WHO position paper. Allergen immunotherapy: Therapeutic vaccines for allergic
diseases. Geneva 1997.
16.Schmidt CB, Blaser K. New insights into the mechanisms of allergen-specific
immunotherapy. Curr Opin Allergy Clin Immunol 2005; 5 (6): 525-530.
17.Bousquet J. Sublingual Immunotherapy: Validated! Allergy 2006: 61(81): 5-6.
121
18.Cvetanov V. Objektivizacija na primenata na specificnata imunoterapija [Evaluation
of the effects of specific immunotherapy, in Macedonian]. In: II Congress of the
Macedonian Respiratory Society. Mak.Med Pregled 1997; 51(28): 23.
19.Cvetanov V. Bazicni principi za sproveduvanje na alergiska specificna imunoterapija
[Basic principles of allergen-specific immunotherapy, in Macedonian]. In:
Symposium for specific immunotherapy 2001; 7-19.
20. van Cawenberge P, et al. Consensus statement on the treatment of allergic rhinitis.
European Academy of Allergology and Clinical Immunology. Allergy, 2000; 55(2):
116-134.
21.Brown CW, Hawkins L. Allergy prevalence and causal factors in the domestic
environment: results of a random population survey in the United Kingdom. Ann
Allergy Asthma Immunol. 1999; 83(3): 240-4.
22.Mungan D, Celik G, Bavbek S, Misirligil Z. Pet allergy: how important for Turkey
where there is a low pet ownership rate. Allergy Asthma Proc 2003; 24 (2): 137-42.
23. Kilpeläinen M, Terho EO, Helenius H, Koskenvuo M. Home dampness, current
allergic diseases, and respiratory infections among young adults. Thorax 2001; 56:
462-467.
24.de Marco R et al. The impact of climate and traffic-related NO2 on the prevalence of
asthma and allergic rhinitis in Italy. Clin Exp Allergy 2002; 32 (10): 1405-12.
25.Hajat S, Haines A, Atkinson RW, et al. Association between air pollution and daily
consultations with general practitioners for allergic rhinitis in London, United
Kingdom. Am J Epidemiol. 2001; 153 (7): 704-14.
26. Kanceljak-Macan B. Suvremeni pogledi na alergijske bolesti [Current views on
allergic diseases, in Croatian]. Arh Hig Rada Toksikol 2004; 55: 123-134.
27.Leino T, Tammilehta L, Hytonon M, et al. Occupational skin and respiratory diseases
among hairdressers. Scand J Work Environ health 1988;24 (5): 398-406.
28.Kanerva L, Vaheri E. occupational allergic rhinitis in Finland. Int Arch Occup Environ
Health 1993; 64 (8): 565-8.
29. Cvetanov V. Profesionalen alergicen rinit. Vo: Mileva Z, ed. Klinicna alergologija
[Occupational allergic rhinitis. In: Mileva J, ed. Clinical Allergology, in
Bulgarian]. Sofia: Znanie 2001; 337-338.
30. Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Clinical effects of specific
immunotherapy: A two-year double-blind placebo controlled study with a one year
follow-up. Macedonian Academy of Sciences and Arts. Contributions, Sec Biol Med
Sci, XXVI 2, 113-129.
31. Dokic D, Schnitker J, Narkus A, Cromwell O, Frank E. Spezifische Immuntherapie
mit einem neu entwickelten Hausstaub-milbenallergoid (AcaroidR). Allergo J 2005;
14: 337-343.
122
3.0. Allergic conjunctivitis - ICD - 10; H 10.8
Conjunctivitis is one of the most common nontraumatic eye complaints. The term
describes any inflammatory process that involves the conjunctiva. Classification usually
is based on cause, including viral, bacterial, fungal, parasitic, chlamydial, chemical, and
allergic agents.
3.1.
Classification and definition
According to the actual classification there are five types of allergic ocular diseases, including
allergic conjunctivitis (that may be seasonal or perennial), atopic keratoconjunctivitis,
vernal keratoconjunctivitis, and giant papillary conjunctivitis.
Allergic conjunctivitis (AC) is conjunctival inflammation caused by IgE-mediated
mechanism and manifested by redness, pruritus, tearing, discharge, and photophobia.
AC is the most common type of allergic ocular disease that often accompanies allergic
rhinitis (allergic rhinoconjunctivitis). It may be divided into seasonal and perrenial AC
(intermittent and persistent AC) as in the subdivision of allergic rhinitis. Seasonal AC
(SAC) occurs during certain season (spring and/or summer), whereas the symptoms of
perrenial AC (PAC) persist during the whole year. Seasonal rhinoconjunctivitis (hay
fever) is the most common allergic disease worldwide, affecting 15-20% of the general
population.
Atopic keratoconjunctivitis (H 10.1; H 16.2) involves associated corneal affection,
typically occuring in male teenagers who have a history of childhood atopic dermatitis.
The condition resembles vernal keratoconjunctivitis but is not seasonal.
Vernal keratoconjunctivitis (H 16.2) is presumed to be a hypersensitivity to exogenous
antigens and usually affects young boys. The condition occurs during the warm months
of the year, particularly in hot climates. Characteristic laboratory finding is blood
eosinophilia and increased total IgE level. In 75% of the cases vernal keratoconjunctivitis
is accompanied with other allergic diseases, whereas the family history of allergic diseases
is positive in 60% of these subjects.
Giant papillary conjunctivitis (H 10.8) occurs mainly in soft contact lens wearers who
develop a syndrome of excessive pruritus, mucous production, and increasing intolerance
to contact use.
3.2. Pathogenesis
Type I immunological reaction according to Gell and Coombs is the underlying mechanism
of AC.
123
Complexes of the aeroallergens and specific IgE antibodies cause degranulation of the
mast cells from conjunctival substantia propria and inflammatory mediators (histamine,
prostaglandines, leukotrienes) release. The multiple effects of inflammatory mediators,
including plasma exudation, eosinophils and neutrophils migration, and sensory nerve
activation, lead to clinical manifestations of the disease.
3.3.
Clinical manifestations
Redness, itching and burning or a foreign-body sensation, tearing, discharge, and
photophobia are manifestations of both allergic and nonallergic conjunctivitis.
The symptoms of SAC usually occur in spring or summer, during certain types of pollen
domination. The symptoms of PAC persist throughout the whole year. Dermatophagoides
pteronyssinus, pets, and moulds allergens are the most important allergens in subjects
with PAC.
3.4.
Diagnosis
Diagnosis of AC is based on history, physical examination, and allergologic evaluation.
In addition, measurement of IgE level in tears, as well as conjunctival biopsy can be
performed.
History of acute or subacute episodes of redness, itching, discharge, tearing, and sensitivity
to light, that may be seasonal or persistent, suggests AC. Furthermore, positive personal
and/or family history of allergic diseases is reported by a number of subjects with AC.
Physical examination of the eye usually shows palpebral edema and moderate conjunctival
injection. Clear, watery discharge with or without a moderate amount of mucous production
is typical. In subjects with AC there is no associated corneal involvement (Figure 101).
The visual acuity is not affected.
Figure 101. Typical signs of AC
Adapted from Kanski JJ. Clinical Ophthalmology. Oxford: Butterworth-Heinemann
International Edition 1997; p. 84.
124
Allergologic evaluation includes identification of the allergen by skin prick tests or
laboratory methods. Specific IgE antibodies may also be detected in the tears of the
subjects with AC.
3.5.
Treatment
The treatment of AC includes nonpharmacological measures and medication use.
Non-pharmacological treatment includes measures for control of the environment but in
most cases these measures have a limited effect. Pharmacological treatment includes use of antihistamines and anti-inflammatory drugs.
Antihystamines are basic medications in the pharmacological treatment of AC. These
medications reduce symptoms of AC by blockage of the histamine receptors (H1
receptors), but they have no effect on the other inflammatory mediators. Local and systemic
preparations of antihistamines may be used in the AC treatment. Local decongestants may
also be used for reduction of the symptoms of AC.
Cromones, such as disodium cromoglycate and nedocromil sodium, are the most important
anti-inflammatory agents in the AC treatment. By stabilizing the mast cell membrane
these medications inhibit mast cell degranulation and mediators release. The mast cell
stabilizers are recommended for prevention of the symptoms following allergen exposure.
Non-steroidal anti-inflammatory agents (NSAIDs) also exhibit anti-inflammatory effect
by inhibition of the prostaglandine synthesis. Corticosteroids are recommended only
in treatment of severe symptoms that failed to respond to conventional therapy. The
medications used in the AC treatment are shown in Appendix 4.
3.6.
Environmental control
Measures of the environmental control, i.e. avoidance of allergens and irritants, are
effective in treatment of both allergic rhinitis and AC.
3.7.
Frequency of allergic conjunctivitis
Epidemiological characteristics of AC are usually investigated within the epidemiological
observations of allergic rhinitis. The results of numerous studies have shown that allergic
rhinitis is accompanied by AC in approximately 70% of the cases.
Prevalence of AC in the general population of the USA and the UK is estimated to 5-22%.
Approximately 15% of the population in the USA (more than 22,000 000 individulas)
will have an AC episode at some time.
125
AC prevalence is usually higher in females than in males. The disease occurs in all ages
and no racial predilection exists. Its occurence is more frequent in hot climate areas.
It seems that air pollution, particularly traffic pollution, contributes to development of
AC.
3.8.
Results of our epidemiological study of AC in R. Macedonia
Until today no previous epidemiological study of AC in R. Macedonia has been carried
out. The diagnosis of AC in the actual study was based on the presence of one or more
conjunctivitis symptoms and positive skin prick tests to common aeroallergens. Since
in the examined children skin prick tests was not performed and completion of the
questionnaire was not sufficient to confirm allergic background of the disease, AC was
observed in the examined adults.
Conjunctivitis symptoms in the last 12 months were reported by 30.1% of the examined
adults. Prevalence of AC and nonallergic conjunctivitis (NAC) was 12.9% and 17.2%,
respectively (Figure 102) that is within the range of the published data.
Figure 102. Prevalence of conjunctivitis symptoms, NAC and AC in examined adults
The prevalence of perennial AC was higher than the prevalence of seasonal AC (7.8% vs.
5.3%). (Figure 103).
126
Figure 103. Prevalence of AC, SAC, and PAC in examined adults
3.8.1. Sex and age distribution
The allergic conjunctivitis prevalence was slightly higher in females than in males (13.0%
vs. 12.0%) (Figure 104).
Figure 104. Sex distribution of the subjects with AC
Results from the reviewed studies indicated higher AC prevalence in the younger age
groups. Our data showed the highest AC prevalence in the age group 21-30 (19.6%) and
decreasing prevalence in the older age groups (Figure 105).
127
Figure 105. Age distribution of the subjects with AC
3.8.2. Prevalence of allergic conjunctivitis among
examined adults in certain centers
Similarly to allergic rhinitis, the highest and the lowest AC prevalence was registered in
Prilep and Pehchevo (26.0% and 8.3%, respectively). The AC prevalence in Skopje was
8.5% (Figure 106).
Figure 106. Prevalence of AC in the examined adults from certain centers
3.8.3. Distribution by sensitization to common aeroallergens
The highest prevalence of sensitization to common aeroallergens in the subjects with AC
was registered for pollens, Dermatophagoides pterronysinus, and pets (87.2%, 31.9%,
and 19.1%, respectively) (Figure 107). The most important individual pollen allergens
were goosefoot and mugwort pollens (47.8% and 31.1%, respectively).
128
Figure 107. Sensitization to common aeroallergens in the subjects with AC
3.8.4. Association with allergic rhinitis and asthma
Allergic rhinitis was registered in 76.1% of the subjects with AC that is complementary
to published data. The prevalence of allergic rhinoconjunctivitis in the examined adults
was 7.3% (Figure 108).
Figure 108. Prevalence of allergic rhinitis (AR), AC, and allergic rhinoconjunctivitis
The published data suggest no close relation of AC to asthma that was confirmed by
findings in our study. The prevalence of AC with asthma in the examined adults was 1.5%
(Figure 109).
129
Figure 109. Prevalence of AC, asthma and AC with asthma
3.8.5. Allergic conjunctivitis and endogenous factors
The importance of endogenous factors in the AC development was confirmed by its close
relation to positive family history of allergic rhinitis (P < 0.05). Positive family history of
allergic rhinitis was reported by 62.5% of the subjects with AC (Figure 110).
Figure 110. Prevalence of the subjects with AC and positive family history of allergic rhinitis
3.8.6. Allergic conjunctivitis and environmental factors
The increasing prevalence of allergic diseases in the last decades may be due to the
environmental changes. According to the results from published studies, traffic pollution
and workplace air pollutants, may play a role in the AC development, contributing to the
processes of allergic sensitization and conjunctival inflammation. Air pollutants can also
worsen the symptoms of manifested AC. In present study exposure to dusts was reported
by 68.1% of the subjects with AC, to smoke in 36.9%, and to workplace pollutants in
17.3% (Figure 111).
130
Figure 111. Prevalence of the subjects with AC exposed to air pollutants
3.8.7. Allergic conjuncivitis and residence
According to many studies, urban residence is a risk factor for development of allergic
diseases. In our study the AC prevalence was significantly higher in the subjects living in
urban areas than in rural ones (14.8% vs. 7.2%, P < 0.05). (Figure 112).
Figure 112. Prevalence of AC in the subjects with urban and rural residence
Association between AC and other exogenous factors, such as active smoking, exposure
to environmental tobacco smoke (ETS), exposure to traffic pollutants, pets ownership,
and green plants outdoors, was not statistically significant.
3.8.8. Conclusions
1. Prevalence of AC in the examined adults was 12.9%, slightly higher in females than
in males, that was in agreement with the results in the literature.
2. Prevalence of SAC was nonsignificantly lower than prevalence of PAC.
3. The highest prevalence of AC was registered in the age group 21-30.
131
4. Similarly to allergic rhinitis, the highest prevalence of AC was registered in the
examined adults from Prilep.
5. Sensitization to pollens, Dermatophagoides pteronyssinus and pets was the most
important aeroallergens in the subjects with AC. The most important individual
pollens were goosefoot and mugwort pollen.
6. There was a strong link between AC and allergic rhinitis. Association between AC
and other allergic diseases was nonsignificant.
7. AC was closely related to positive family history of allergic rhinitis. Association
between AC and other endogenous factors was nonsignificant.
8. AC was significantly associated with urban residence. Association between AC and
other exogenous factors was nonsignificant.
3.8.9. References:
1. Kanski JJ. Clinical Ophthalmology. Oxford: Butterworth-Heinemann International
Edition 1997; 83-86.
2. Stites D, Stobo J, Vivian Wells J. Osnovna i klinicka imunologija [Basic and clinical
immunology, in Serbian]. Beograd : Savremena administracija 1989; 435-455.
3. Groneberg DA, Bielory L, Fischer A et al. Animal models of allergic and inflammatory
conjinctivitis,. Allergy 2003; 58 (11): 1101-1110.
4. Woerly G, Loiseau S, Loyens M et al. Inhibitory effects of ketotifen on eotaxindependent activation of eosinophils: consequences for allergic eye diseases. Allergy
2003; 58 (5): 397-395.
5. Johanson SOG, Hourihane JO’B, Bousquet J et al. A revised nomenclature for allergy.
Allergy 2001; 56 (9): 813-822.
6. Canonica GW. Expanding the Anti-Allergy Therapeutic Horizon. Allergy 2002; 75
(57): 5-7.
7. Ruffili A, Bonini S. Suspectibility genes for allergy and asthma. Allergy 1997; 52:
256-273.
8. D’Amato G, Holgate ST. Introduction. Eur Resp Mon 2002; 7 (21): b-c.
9. D’Amato G, Liccardi G. The increasing trend of seasonal respiratory allergy in urban
areas. Allergy 2002; 71 (57): 35-36.
10.Allergic conjunctivitis Referral Guideline. Allergy/Immunology August 2001.
11.Schäfer T, Ring J. Epidemiology of allergic diseases. Allergy 1997; 52 (38): 14-22.
12.Allergy Statistics. National Institute of Allergy and Infectious Diseases, National
Institute of Health January 2002.
13.American Academy of Allergy, Asthma and Immunology (AAAI). The Allergy
Report: Science Based Findings on the Diagnosis & Treatment of Allergic Disorders
1996-2001.
14.Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemioloski karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseses in R. Macedonian, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
15.Spasovska O, Cvetanov V, Karadzinska-Bislimovska J, et al. Prevalencija na
alergiskiot konjunktivitis vo R. Makedonija i negovata asociranost so drugite alergiski
zaboluvanja [Prevalence of allergic conjunctivitis in R. Macedonia and its association
with other allergic diseases, in Macedonian]. Mak Med Pregled 2003; 56: 142.
132
4.0. Asthma - ICD - 10; J. 45
4.1.
Definition
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular
elements play a role. The chronic inflammation causes an associated increase in airway
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest
tightness, and coughing, particularly at night or in the early morning. These episodes are
usually associated with widespread but variable airflow obstruction that is often reversible
either spontaneously or with treatment (Global Initiative for Asthma – GINA Updated
2004).
4.2.
Risk factors
Asthma develops as a result of the interplay between host and environmental factors.
It is still not completely possible to distinguish which factors are true causes of the
development of asthma and which are triggers of asthma attacks. The major risk factors
for asthma according to Sheffer are shown on Scheme 3.
Figure 113. Risk factors for asthma
Sex, atopy, family history of asthma, ethnic group, early life risk factors like prematurity
and bottle feeding in the first 4-6 months, and childhood and adulthood respiratory trouble,
are considered as endogenous risk factors for asthma. On the other hand, exposure
to allergens, active and passive smoking, indoor and outdoor air pollution, workplace
exposure, lifestyle, and diet and alcohol consumption are the main environmental risk
factors for asthma.
133
4.2.1. Genetics of asthma
Despite intensive effort and the advances of molecular biology over the last few years,
no genes involved in asthma pathogenesis have been clearly identified. According to the
actual knowledge several genes or gene groups, which expression is variable, may be
involved in the asthma pathogenesis. Recent studies indicate that separate genetic factors
for bronchial hyperresponsiveness and for tendency to over-produce IgE exist, but they
are linked by a phenomenon of coheredity. A locus which regulates the IgE production
has been found in the chromosome 5q31-q33. The results of other studies indicate that
certain asthma phenotype characteristics are associated with other chromosomal regions,
such as 6r21.3 and 14q11.
4.2.2. Atopy
Atopy, defined as a personal or familial tendency to produce IgE antibodies in response
to low doses of allergens, usually proteins, and to develop typical symptoms such as
asthma, rhinoconjunctivitis, or eczema/dermatitis, is considered as a major risk factor
for asthma. The prevalence of atopy worldwide varies from 10 to 45%, depending upon
race, gender, age, and environmental factors. The results of the multicentric study in R.
Macedonia carried out in 1995 by Institute of Occupational Health showed prevalence of
atopy among adults of 38%.
4.2.3. Allergens
The inhalant allergens, causative factors of the respiratory allergic disorders, are usually
classified as common and occupational allergens. The common inhalant allergens are
presented in the outdoor and indoor atmosphere of certain geographic area, while the
occupational allergens are associated with certain workplace. Tree, grass, and weed
pollen, as well as some types of moulds are the main outdoor allergens. House dust mite
(Dermatophagoides pteronyssinus), pet, and mold allergens are considered as the most
important indoor allergens.
4.2.4. Air pollution
Air pollution may cause adverse respiratory effects by mechanisms of sensitization and
irritation. Nitrogen dioxide (NO2), sulphur dioxide (SO2), ozone, diesel exhaust particles,
and outdoor allergens are considered as the most important outdoor air pollutants.
A number of compounds and mixtures, such as tobacco smoke, combustion products
(carbon monoxide, nitrogen dioxide, sulphur dioxide), cleansing agents, volatile organic
compounds (formaldehyde, alkanes, aldehydes), and indoor allergens are identified as
relevant indoor pollutants that may cause respiratory impairment. A large group of air
pollutants associated with the workplace has a special importance as an occupational
asthma has become the most important work-related respiratory disorder in developed
countries.
134
There are suggestions that a substantial increase of incidence and prevalence of respiratory
allergic disorders in the last three decades is partially due to the increased levels of air
pollution in an urban environment. Anyway, the role of air pollution in the determination
of asthma still remains unclear. Adjuvant effect of the pollutants in the process of allergic
sensitization and its role in maintenance of the chronic airway inflammation are possible
proasthmogenic effects of the air pollutants.
4.3.
Pathogenesis and classification of asthma
It is now widely accepted that chronic inflammation including both central and peripheral
airways (chronic eosinophil bronchitis) plays a key role in asthma. It is characterized
by epithelial desquamation, infiltration of the airway wall by inflammatory cells with
predomination of T helper 2 lymphocytes (Th2 ly), eosinophils and mast cells, increased
smooth muscle mass, hypertrophy of mucous glands and goblet-cell hyperplasia, as well
as subepithelial fibrosis. Structural changes of the airway wall (also referred to as airway
wall remodeling) lead to a thickened airway wall and a markedly reduced airway caliber
(Figure114).
Figure 114. Normal and asthmatic bronchiole
Adapted from: Asthma. Available at www.nlm.nih.gov/medlineplus/
Airway inflammation in asthma, extremely complex in origin, regulation and outcomes,
involves a cascade (“allergic cascade”) of events including many different kind of cells,
cytokines, as well as over 100 inflammatory mediators. Inflammation, remodeling and
altered neural control of the airways are responsible for variable airflow obstruction and
increased airway responsiveness. The recurrent episodes of symptoms and reversible
airflow limitation that characterize asthma represent an acute inflammatory response
acting upon structurally and functionally altered airways.
It seems that the mast cells play a key role in development of the acute symptoms (early
asthmatic reaction) (Figure 115), while eosinophils and Th2 ly are involved in the chronic
inflammation that is associated with bronchial hyperresponsiveness (late asthmatic
reaction).
135
Figure 115. Early asthmatic reaction
Adapted from: Mast cell degranulation. Available at: en.wikipedia.org/wiki/
In about 80% of childhood asthma and about 40-50% of the adult form the allergic cascade
is initiated by inhalation of detectable common allergen and IgE-mediated activation of
the inflammatory cells, followed by increased level of specific IgE antibodies directed
against common allergens. This subgroup of asthma is defined as allergic asthma (J 45.0).
In the other cases, defined as nonallergic asthma (J 45.1), the cascade is not initiated
by inhalation of detectable allergen and there is no evidence of specific IgE antibodies
directed against common allergens. There are several theories about initiation of the
cascade in nonallergic asthma, such as inhalation of as-yet undetected allergen, local IgE
production, triggering by infection, etc. Occupational asthma presents variant form of
asthma caused by specific agent from the workplace.
4.4.
Clinical manifestations
Asthma is a chronic disease characterized by recurrent acute or subacute episodes
(asthma exacerbations) of wheezing, breathlessness, chest tightness, and coughing, with
symptom-free intervals in the majority of the patients. In small amount of patients there
are persistent asthma symptoms with episodes of worsening. Asthma symptoms usually
occur at night or in the early morning with variable frequency and severity. Asthma, both
allergic and nonallergic, is frequently accompanied by upper airways diseases, such as
rhinitis, sinusitis, and sinonasal polyposis.
136
Triggers that precipitate asthma exacerbations include respiratory viral infections,
allergen exposure, air pollutants, physical exercise, cold air, weather changes, drugs such
as nonsteroid anti-inflammatory drugs (NSAIDs) and β blockers, gastroesophageal reflux
disease (GERD), and extreme emotional expression. Usually, asthma exacerbations
are precipitated by several triggers that vary from person to person and from time to
time. However, there are variants with predomination of one trigger such as seasonal
(pollen) asthma, Candida asthma, exercise-induced asthma (EIA), and aspirin-induced
asthma. Work-related asthma (WRA) is a variant of asthma that includes two subtypes,
occupational asthma (OA) and work-aggravated asthma.
On the basis of severity (the level of airflow limitation and its variability), asthma is
subdivided into four grades: Intermittent, Mild Persistent, Moderate Persistent, and
Severe Persistent.
4.5. Diagnosis and assessment
The diagnosis of asthma is focused on the history of asthma symptoms and on lung function
testing that confirms reversible airflow limitation and increased airway responsiveness.
Diagnostic procedure also includes determining of allergic status and measuring of the
markers of airflow inflammation.
4.5.1. The characteristic symptoms of asthma are recurrent episodes of wheezing and
breathlessness, often associated with chest tightness and cough, which are partially or
completely reversible, either spontaneously or after bronchodilator administration.
4.5.2. Lung function testing includes tests which confirm the presence of reversible
airflow limitation, such as bronchodilator test, serial spirometry, and serial peak expiratory
flow rate (PEFR) measurement. For patients with symptoms consistent with asthma, but
normal lung function, measurement of airway responsiveness to non-specific stimuli, such
as metacholine, histamine, exercise, or cold air, may help establish asthma diagnosis.
Specific challenge with agent to whom the patient is sensitized is a gold standard for
diagnosis of allergic and occupational asthma, that is not performed in every day practice
due to the complex protocol and possibility of adverse effects.
4.5.3. Atopic status is evaluated by in vivo (skin prick tests) and in vitro tests (total
and specific IgE measurement). These tests add little to the asthma diagnosis, but they
can help in risk factors or triggers identification so that adequate environmental control
measures can be recommended.
4.5.4. Markers of the chronic airway inflammation, i.e. measurement of the level of
nitric oxide (NO) in exhaled breath, of the eosinophil count in the blood and sputum, and
of the level of eosinophil cationic protein (ECP) in the blood and sputum, may help in
establish asthma diagnosis.
137
4.6.
Management
The goals for successful management of asthma are to achieve and maintain control of
symptoms; to prevent asthma exacerbations; to maintain pulmonary function as close to
normal levels as possible; to maintain normal activity levels, including exercise; to avoid
adverse effects from asthma medications; to prevent development of irreversible airflow
limitation; and to prevent asthma mortality.
Asthma management includes non-pharmacological and pharmacological treatment.
4.6.1. Patients education to control their own condition is the basic non-pharmacological
measure in asthma management. Measures for reducing exposure to environmental and
occupational allergens, air pollutants, foods and drugs, improve the control of asthma
and reduce medication needs. Allergen-specific immunotherapy, used in selected patients
with allergic asthma, also presents a type of non-pharmacological treatment of asthma.
4.6.2. Pharmacological treatment includes chronic treatment of asthma and treatment
of the acute exacerbations.
Chronic treatment of asthma should be tailored according to the severity of disease with a
stepwise approach that means increasing the number, dosing and frequency of medications
with increasing asthma severity, considering the presence or absence of control of the
disease. The mainstay of the chronic asthma therapy consists of using agents that induce
bronchodilatation (bronchodilators or relievers) and that control chronic inflammatory
process (anti-inflammatory agents or controllers).
4.6.2.1. Bronchodilators. The group of bronchodilators includes short- and long-acting
β2–agonists, anticholinergics, and theophylline. Short-acting β2–agonists are the best
relievers, while long-acting β2–agonists and slow-release theophylline are best used in
conjunction with inhaled corticosteroids in the treatment of moderate and severe persistent
asthma.
4.6.2.2. Anti-inflammatory agents. The group of anti-inflammatory agents includes
corticosteroids, cromolines and antileukotrienes. Inhaled corticosteroids (ICS) by
inhibiting eosinophilic inflammation and mediator/cytokine expression remain the basic
controller in the chronic asthma treatment.
Currently available pharmacological agents when taken regularly enable achieving good
control of the disease in most patients with asthma.
The treatment of acute exacerbations of asthma also rests on the use of bronchodilators
(short-acting β2–agonists) and anti-inflammatory agents (corticosteroids) administered
orally or parenteraly.
The present asthma medications, the doses of ICS, and the actual combined asthma
medications are shown in Appendices 7, 8, and 9.
138
4.7. Prevention of asthma
4.7.1. Primary prevention includes measures of prenatal prophylaxis such as maternal
smoking during pregnancy, as well as of measures in infancy and childhood such as
reduction of the exposure to indoor pollutants (indoor allergens, passive smoking), and
adulthood (smoking cessation, environmental and workplace control).
4.7.2. Secondary prevention could be used to prevent development of symptomatic
disease in sensitized, but still asymptomatic subjects including measures for environmental
and workplace control, treatment of allergic rhinitis and atopic dermatitis, and orientation
to occupations with reduced exposure to allergens.
4.7.3. Tertiary prevention is used in the subjects with symptomatic disease and includes
nonpharmacological and pharmacological treatment of asthma.
4.8.
Multinational, national, and regional epidemiological
studies of asthma
The prevalence of asthma showed increasing trend in both developed and developing
countries in the last three decades. The largest increase has been detected in the younger
age group and in Anglo-Saxon countries. A World Health Organization (WHO) estimate,
published on the Internet in January 2000, showed that 100 –150 million individuals
all over the world suffered from asthma. The yearly direct and indirect medical costs
associated with asthma in the European Union countries was estimated to 2.000-3.000
euros per patient.
The social and economic burden of this condition is heavy. Asthma costs of the society
may be largely reduced through national and international concerted actions. In 1995, the
Global Initiative on Asthma (GINA) was implemented by the WHO, and it was revised
in 1998, 2002, and 2004, according to the actual knowledge. In the same period several
national guidelines were developed. The Macedonian National Consensus for Asthma
and Chronic Obstructive Pulmonary Disease was developed in 1999.
In the 1980s and 1990s a number of regional, national, and multinational epidemiological
studies of asthma were carried out. The studies which have contributed with standardized
definitions to improve the knowledge in the epidemiology of asthma include the European
Community Respiratory Health Survey (ECRHS), the International Study of Asthma and
Allergies in the Childhood (ISAAC), the Swiss Studies on Air Pollution and Lung Diseases
in Adults (SAPALDIA), the Italian Studies on Respiratory Diseases (the Po Delta study,
the Pisa and Cascina study), the Obstructive Lung Disease in Northern Sweden Study
(OLIN), etc.
The ECRHS was a cross-sectional study carried out in the first half of the 1990s. The
database of the ECRHS included about 140,000 participants aged 20-44 from 48 centers
from 22 countries (Europe, North America, and Australia). The reason for undertaking
139
the ECRHS was a rapid increase in the prevalence of asthma that had been reported from
many different countries. The increase was over a too short time period to be explained
by genetic factors and therefore, was related to environmental changes.
In stage I subjects were sent the ECRHS screening questionnaire asking about symptoms
suggestive of asthma, use of medication for asthma, and presence of hay fever and nasal
allergies. In stage II, a smaller random sample of subjects who had completed the screening
questionnaire were invited to attend a more detailed interviewer-led questionnaire,
skin prick tests, blood tests for measurement of total and specific IgE, spirometry, and
metacholine challenge. The symptomatic subjects with positive metacholine challenge
and/or subjects using asthma medications were considering having asthma.
Over 100 papers written in English, as well as a large number of papers in languages other
than English, have been published by the ECRHS. About 20 papers have been based on
analyses of the complete data set (central analyses) and the rest from analyses of data
from one or several of the centers (local analyses).
According to the ECRHS protocol several national (Bulgaria, Chile) and regional surveys
(St. Petersburg, Manisa) were carried out.
The ISAAC is a cross-sectional study of childhood asthma started in the first half of the
1990s including children aged 6-7 and adolescents aged 13-14 years in 56 countries all
over the world, including R. Macedonia. The ISAAC consisted of three phases. In phase
I subjects completed a questionnaire on asthma symptoms, as well as nasal and skin
disorders. In phase II clinical evaluation which included lung functional testing, carbachole
challenge, and allergologic evaluation by in vivo and in vitro tests was performed. Phase
III started in 2001 with an ecologic evaluation as a basic field of research.
The Global Allergy and Asthma European Network (GA2LEN) is a consortium of leading
European research centers committed to establish a European research area of excellence
in the field of allergy and asthma. The network intends to harmonize diagnostic and
therapeutic procedures, accelerate the application of research results to clinical practice,
patients’ needs and policy development, as well as to promote training and integration
between public and private sectors. One of the work packages within GA2LEN project
was designed to identify all European birth cohorts (started between 1985 and 2004)
on asthma and atopic diseases, to create a common database of the different study
characteristics which would allow comparison of study methods including design and
assessment of outcome as well as exposure parameters.
4.9.
Epidemiological studies of asthma in R. Macedonia
An epidemiological survey of adult asthma in R. Macedonia was carried out in 1995 by
the Institute of Occupational Health, Skopje in collaboration with Occupational Health
Services in R. Macedonia. The polycentric study including 556 randomly selected adults
(302 men and 254 women, aged 18-74) from 11 centers (Skopje, Kumanovo, Tetovo,
140
Shtip, Veles, Kichevo, Kavadarci, Prilep, Struga, Ohrid, and Bitola) was performed.
Evaluation of the examined subjects included a questionnaire for respiratory and allergic
symptoms, lung function testing, skin prick tests to 11 common aeroallergens, and acetyl
choline challenge by indications.
The most important data obtained from the survey included:
-
-
-
-
-
Prevalence of asthma – 3.2%;
Non-significant sex distribution of the disease;
Higher asthma prevalence in the older age groups;
Atopy detected in 72.2% of the subjects with asthma;
Mite sensitization was the most important allergen in the subjects with allergic
asthma(61.1%);
- Prevalence of active smokers in the subjects with asthma – 38.8%.
Several surveys of occupational asthma in certain industries in R. Macedonia were also
carried out by the Institute of Occupational Health, Skopje. The data obtained indicated
prevalence of occupational asthma of 1.6% among herbal tea processors, 5.2% among
grain workers, 5.7% among rice workers, and 6.2% among tanners.
Epidemiological survey of asthma including school children (aged 7 to 18) from Skopje,
carried out in 1993, showed prevalence of asthma of 2.75%. The data obtained in the
Macedonian part of the third phase of the ISAAC (December 2001-March 2002) with
school children from Skopje aged 13-14, showed prevalence of asthma ever and wheezing
in the last 12 months of 1.7% and 8.8%, respectively.
4.10.
Results from our epidemiological survey
of asthma in R. Macedonia
The present survey of adult asthma was carried out as a continuum of its epidemiological
evaluation in R. Macedonia. The survey was performed according to the ECRHS
protocol.
A cross-sectional survey included subjects aged 20-44 (368 subjects, 138 men and 230
women) that was about one third from the subjects included in the Project (1121 subjects)
(Figure 116).
141
Figure 116. Distribution of the examined subjects by certain centers
In the first phase (February - June 2002) all examined subjects underwent completion of
a questionnaire and skin prick tests (SPT) to common aeroallergens. An interviewer-led
questionnaire included the questions from the ECRHS screening questionnaire, as well
as the questions about family history of asthma and allergic diseases, current smoking
and smoking history, environmental and workplace exposure, and medication use. The
battery of allergens for the SPT contained 13 commercial allergen extracts (tree pollen,
grass pollen, mugwort, goosefoot, plantain, ragweed, Penicillium notatum, Alternaria
alternata, Dermatophagoides pteronyssinus, cockroach, cat fur, dog hair, and feathers
mixed) selected as a result of a 3-year aeropalinological follow-up.
In the second phase (October - Novemeber 2003) the examinees with symptoms suggestive
for asthma underwent spirometry, including vital capacity (VC), forced expiratory volume
in one second (FEV1), and mean expiratory flow at 75%, 50%, and 25% of VC (MEF75,
MEF50, and MEF25, respectively), and histamine challenge. Histamine challenge was
considered positive if provocative concentration equal or less than 4 mg/mL caused a
20% fall of FEV1 (PC20 ≤ 4 mg/mL). In the subjects with asthma-suggested symptoms
and reduced lung function bronchodilator test with inhaled salbutamol was performed.
The bronchodilator test was considered positive if the increase of FEV1 15 minutes
after salbutamol application was equal or more than 12% of the baseline value. The
symptomatic subjects with positive histamine challenge or positive bronchodilator test
were considered having asthma.
The data obtained were statistically processed using the Statistical Package for the Social
Sciences (SPSS) Release 11.0.
4.10.1. Prevalence of respiratory symptoms and asthma
The prevalence of respiratory symptoms in the last 12 months, wheezing, wheezing with
dyspnea (W/D 12), asthma attacks, and use of asthma medications was 22%, 12.2%,
142
6.8%, 4.1%, and 2.2%, respectively. Positive histamine challenge was obtained in 4.9%,
positive bronchodilator test in the subjects with reduced lung function in 0.5%. The
prevalence of asthma was 5.4% (Figure 117 and 118).
Figure 117. Prevalence of asthma symptoms, asthma medications use,
and asthma in examined subjects
Figure 118. Prevalence of asthma in examined subjects
The prevalence of asthma was within the range of its prevalence in the Central and
South Europe countries. It was higher than the asthma prevalence in Asia and Africa,
and lower than in English speaking (Anglo-Saxon) countries (Table 14).
143
Country
Algeria
India
Greece
Bulgaria
Italy
Macedonia
Portugal
Spain
USA
Sweden
New Zealand
United Kingdom
Asthma prevalence
3.0%
3.5%
2.0 - 4.5%
4.7%
3.3 - 5.1%
5.4%
4.,3 - 6.0%
2.1 - 6.3%
6.1 - 10.2%
5.8 - 10.8%
8.0 - 12.5%
7.5 - 15.0%
Table 14. Asthma prevalence in the age group 20-44 in the certain countries
The prevalence of wheezing, wheezing with dyspnea, asthma attacks, and asthma
medication use in the last 12 months was also similar to its prevalence in the Central and
South Europe countries, two to threefold lower than in the Anglo-Saxon countries.
The use of asthma medications (relievers and/or controllers) in the last 12 months was
reported by 2.2% of the examined subjects (39% of the subjects with asthma). The asthma
medications use among subjects with asthma varied from 30% in Estonia to 85% in the
United Kingdom (Figure 119).
Figure 119. Prevalence of the asthma medications use in subjects with asthma
The ICS use was reported by 20% of the subjects with asthma. Its use in the European
countries varied from 17% in Italy to 49% in the United Kingdom. The use of the inhaled
bronchodilators (salbutamol) was reported by 33.3% of the subjects with asthma, whereas
the use of the oral bronchodilators (theophylline) by 14.8%. Data obtained suggested
insufficient use of the ICS that was confirmed by high frequency of asthma symptoms
reported by patients with asthma (Figure 120).
144
Figure 120. Frequency of asthma symptoms in subjects with asthma
The asthma prevalence in our study was higher than its prevalence in the study carried out
in 1995 (5.4% vs. 3.2%) (Figure 106). It has to be mentioned that the survey carried out
in 1995 included subjects aged 18 to 74 (Figure 121).
Figure 121. Prevalence of asthma in R. Macedonia in 1995 and 2003
The increasing prevalence of asthma has been reported by a number of regional and
national studies in the last decades. The prevalence of asthma in the USA has increased
for over 60% in the last 20 years. According to the UCB data, the prevalence of asthma
in the West European countries doubles every 10 years. Increasing prevalence of asthma
is also registered in the countries of Asia, Africa, Central and South America. Such
increase, registered in a too short time period could not be explained by genetic factors
and must, therefore, be related to environmental factors such as outdoor and indoor air
pollution, diet, lifestyle, etc.
145
4.10.2. Sex distribution
We found non-significantly higher asthma prevalence of asthma in males (6.4 vs. 4.9%)
(Figure 122).
Figure 122. Sex distribution of asthma
Data from a number of studies indicate sex difference of the prevalence of asthma and
bronchial hyperresponsiveness. The prevalence of bronchial hyperresponsiveness in
childhood is higher in boys, in the middle age it is higher in women, while in the elderly
it is similar in both sexes. On the other hand, according to data from the ECRHS the
prevalence of sensitization to common aeroallergens is higher in men that is consistent
with the results of our study.
4.10.3. Prevalence of asthma in certain centers
Asthma prevalence varied from 3.3% in Dojran, 4% in Pehchevo, 4.8% in Prilep, 5.9% in
Ohrid and Debar to 6.3% in Skopje (Figure 123).
Figure 123. Prevalence of asthma in certain centers
146
The highest asthma prevalence among examined subjects in Skopje, the capital of R.
Macedonia, could be explained by characteristics of the lifestyle and high concentrations
of air pollutants from industry and traffic. Table 15 shows data from the Republic Institute
for Health Protection, Skopje about concentration of the air pollutants in the area of Skopje
in 2003.
Air pollutant
Number of
checking
points
Number
of
samples
Mean
conc.
Min - max
concentration
MPL*
Number of
samples with
level over
MPL*
Air sediment
(mg/m2)
30
338
182,1
32,1 - 707,2
300,0
42
CO (mg/m3)
4
168
3,5
0,2-13,8
3
56
SO2 (mg/m3)
7
2485
0,0166
0 - 0,2649
0,150
4
Smoke (mg/m3)
7
2506
0,0205
0,0006-0,2550
0,050
219
*MPL: Maximal Permitted Level
Table 15. Concentration of the air pollutants in the area of Skopje in 2003
The prevalence of asthma in Skopje was within the range of its prevalence in the centers
of Central and South Europe (Table 16).
Center
Algeria
Bombay
Turin
Basel
Bordeaux
Coimbra
Skopje
Huelva
Portland
Stockholm
Cambridge
Auckland
Wellington
Melbourne
Prevalence of asthma
3.0%
3.5%
4.5%
5.4%
5.5%
6.0%
6.3%
6.3%
7.1%
7.6%
8.4%
10.1%
11.3%
11.9%
Table 16. Prevalence of asthma in certain cities
147
4.10.4. Distribution by atopic status and sensitization
to common aeroallergens
Allergic asthma was registered in 60% and nonallergic asthma was registered in 40% of
the subjects with asthma (Figure 124). The results obtained are in agreement with the
results from the ECRHS, as well as to the results from our previous study (1995). The
prevalence of atopy was higher in men, in all examined subjects, as well as in subjects
with asthma.
Figure 124. Distribution of the subjects with asthma by atopic status
Dermatophagoides pteronyssinus and goosefoot (58,3%), followed by mugwort (50%),
plantain (33,3%) and Alternaria (25%) were the most important individual air allergens
in the subjects with allergic asthma (Figure 125).
Figure 125. Prevalence of the sensitization to individual air allergens
subjects with allergic asthma
in the
Similar prevalence of mite sensitization (61.1%) was registered in our previous study
(1995), as well as in 16 centers where the ECRHS was carried out. Our data confirmed
the role of weed pollen and Alternaria as potent allergens. We found lower prevalence of
the subjects sensitized to pet allergens compared to the ECRHS data that was probably
due to the lower frequency of pet ownership in R. Macedonia than in the West European
countries.
148
4.10.5. Allergic Rhinitis and its Impact to Asthma (ARIA)
In the majority of the subjects with asthma (70.4%), concurrent rhinitis was registered.
Rhinitis accompanied both allergic and nonallergic asthma. The prevalence of asthma
with rhinitis was 3.8% (Figure 126).
Figure 126. Prevalence of rhinits, asthma, and asthma with rhinitis in the examined subjects
Data from our study showed that in the majority of the subjects with asthma (71.0%)
rhinitis preceded asthma, in 21.0% occurrence of asthma and rhinitis at the same time
was registered, and in 8.0% rhinitis developed after the asthma occurrence (Figure 127).
Figure 127. Occurrence of rhinitis in the subjects with asthma accompanied by rhinitis
Data from our study that had investigated the same association carried out in 2002
indicated prevalence of rhinitis in patients with allergic and nonallergic asthma of 73.1%
and 63.4%, respectively. Results reported in the consulted studies showed prevalence of
rhinitis in patients with asthma of 50 to 90%, and prevalence of asthma in patients with
rhinitis of 20 to 40%.
The association between upper and lower respiratory airways has been confirmed by
numerous epidemiological studies. Cross-sectional studies have shown that the coexistence
149
of rhinitis and asthma is quite common and longitudinal studies have shown that subjects
with both allergic and nonallergic rhinitis frequently develop asthma, and that rhinitis
usually precedes asthma. Many clinical observations have also shown the occurrence of
BHR in rhinitics as well as the comorbid role of sinusitis in asthma. Furthermore, it has
been repeatedly shown, that an effective treatment of rhinitis have a beneficial effect on
bronchial symptoms as well as on the occurrence of respiratory infections.
The WHO experts team in 2001 published an extensive position paper devoted to the
relationship between rhinitis and asthma and its therapeutic implications, called Allergic
Rhinitis and its Impact on Asthma (ARIA). On the other hand, the acronym CARAS
(Combined Allergic Rhinitis and Asthma Syndrome) has been used by World Allergy
Organization (WAO) for indicating the concept “one airway, one disease”. At present,
the hypothesis of the unity of the airways is supported by many data and new therapeutic
rationales are put forth.
4.10.6. Association with endogenous factors
We found significant association between asthma and positive family history of asthma and
atopy. The prevalence of asthma among atopics was 13.2%, whereas atopy was detected in
60% of the patients with asthma. Presence of asthma in the first degree relatives (parents
and siblings) was reported in 54.8% of the subjects with asthma (Figure 128).
Figure 128. Positive family history of asthma (the first degree relatives) in the subjects with asthma
Data from the ECRHS indicate close relation between asthma and parental asthma, and
even more so if both parents have asthma. The odds ratios for asthma in subjects with
maternal and paternal asthma were 3.2 and 2.9, respectively. If both parents had asthma,
the odds ratio for asthma increased to 7.0.
We found no significant association between asthma and sex, family history of allergic
diseases, and family history of allergic rhinitis. Association between asthma and ethnic
group was also nonsignificant. On the other hand, the study carried out in Israel as a part
150
of the ISAAC showed that in school-children aged 13-14, the prevalence of “current
asthma” and “ever asthma” was higher among Jews than among Arabs. Epidemiological
investigations of childhood asthma in the USA showed higher prevalence of asthma in
blacks than in whites (9.1% vs. 6.4%). Possible explanation for ethnic differences in
asthma prevalence might be a genetic predisposition, poor access to the care system,
difference in family structures, and associated social risk factors.
4.10.7. Association with environmental factors
We found no significant association between asthma and urban residence, active smoking,
exposure to traffic pollution, as well as with housing conditions such as heating conditions
(exposure to combustion products), high indoor humidity, green plants outdoors (exposure
to pollens), and pets ownership (Figure 129). We found significant joint effect of urban
residence, active smoking, exposure to traffic pollution, and green plants outdoors (P <
0.05).
Figure 129. Prevalence of asthma in the subjects living in urban zone, active smokers, subjects
exposed to traffic pollution, pet owners, and subjects having green plants outdoors
The role of outdoor and indoor air pollution in asthma development is complex and
still unclear. The highest increase of asthma prevalence in the West European countries
occurred in the period characterized by reduced levels of the conventional outdoor air
pollutants (carbon monoxide, sulfur dioxide) and increased levels of nitric oxides, diesel
exhaust, and ozone. At the same time, a number of studies emphasize the importance
of indoor air pollutants in asthma development. However, future prospective studies
will further clarify the role of certain exposures for individuals with different genetic
predisposition.
4.10.8. Association with workplace exposure
Worsening of the symptoms at the workplace was reported by 24.7% of the subjects with
asthma. The prevalence of work-related asthma (WRA) was 1.4% (Figure 130).
151
Figure 130. Prevalence of work-related asthma in examined subjects
We found nonsignificant association between asthma and certain workplace hazards, such
as exposure to dusts, chemical agents, high air humidity and temperature. The joint effect
of these factors on asthma development was also nonsignificant (Figure 131).
Figure 131. Prevalence of asthma in the subjects with workplace exposure to dust,
high air humidity, chemical agents, and high temperature
Prevalence of asthma in office workers was 4.8%, whereas its prevalence in workers with
specific exposure at the workplace was 5.8% (Figure 132).
152
Figure 132. Prevalence of asthma in unexposed and exposed workers
The highest prevalence of asthma among exposed workers was detected in pharmaceutical
industry workers (8.7%), textile workers (7.2%), and chemical industry workers (6.2%)
(Figure 133).
Figure 133. Prevalence of asthma in all examined subjects, and in pharmaceutical
industry, textile, and chemical industry workers
Many studies have shown the relationship between workplace exposure and asthma.
WRA, that includes occupational asthma (OA) and work-aggravated asthma, is a growing
problem, becoming the most common work-related respiratory disease in many countries.
The prevalence of WRA ranges from 10 to 25% of the cases with adult asthma. In the
Norwegian general population, the prevalence was 0.9%, and it increased to 28.0%
considering only subjects with asthma that is similar to the results of our study. The risk
of asthma attributable to occupational exposure was studied in analyses of the Spanish
ECRHS data set and the data set from New Zealand. The proportion of asthma attributed
to occupational exposure was estimated to be 5-7% in Spain and 2-3% in New Zealand. In
both these investigations, a higher risk for asthma was found in farmers, painters, plastic
153
workers, cleaners, and agricultural workers. After creating a job exposure matrix, asthma
found to be associated with high dose exposure to biological and mineral dust, as well as
exposure to gases and fumes.
4.10.9. Conclusions
1. Prevalence of asthma in the age group 20-44 was 5.4%, 6.4% in males and 4.9%
in females, which translated to approximately 100,000 subjects with asthma in R.
Macedonia. The asthma prevalence in R. Macedonia was within the range of the
South European countries, such as Italy, Greece, Bulgaria, Spain, and Portugal.
2. The highest asthma prevalence was registered in Skopje (6.3%), and the lowest one in
Dojran (3.3%). The asthma prevalence in Skopje was within the range of South and
Central European centers, such as Turin, Basel, Bordeaux, Coimbra, and Huelva.
3. This study has indicated higher asthma prevalence than it has been detected in our
study carried out in 1995 (5.4% vs. 3.2%). Increasing prevalence of asthma is a global
problem, and it is registered in a number of studies undertaken all over the world.
4. We noted relatively low use of anti-inflammatory medications among asthma patients,
approximately threefold lower than its use among subjects with asthma in the United
Kingdom.
5. Allergic asthma was detected in 60%, and nonallergic asthma in 40% of the subjects
with asthma.
6. Sensitization to Dermatophagoides pteronyssinus and goosefoot pollen were the most
important common allergens in the subjects with allergic asthma. Mite sensitization
was the most important common allergen in our previous study (1995), as well as in
a number of studies from different countries.
7. We found asthma / rhinitis association in 70% of the subjects with asthma that
confirmed “the united airway disease” concept. In the majority of subjects with asthma
accompanied by rhinitis, asthma development was preceded by rhinitis.
8. We found significant association of asthma with atopy and family history of asthma.
Allergic rhinitis was detected in about half of the atopic subjects and asthma was
detected in about 15% of the atopic subjects. Paternal asthma was reported by half of
the subjects with asthma. Association between asthma and other endogenous factors,
such as sex, ethnic group, and family history of allergic diseases, was nonsignificant.
9. Association between asthma and individual exogenous factors was nonsignificant.
We found significant joint effect of some environmental factors (urban residence,
active smoking, exposure to traffic pollution, and green plants outdoors) on asthma
development.
10.Prevalence of WRA was 1.4%, (24.7% of the subjects with asthma). Asthma prevalence
was higher in exposed workers than in office workers. The highest prevalence among
workers with specific exposure at the workplace was found in pharmaceutical, textile
and chemical industry workers.
154
4.10.10. References:
1. Global Initiative for Asthma. Definition. National Institutes of Health, National Heart,
Lung, and Blood Institute 2004; 1:1-7.
2. Gjorcev A. Makedonski nacionalen plan i programa za dijagnoza i lekuvanje na
bronhijalna astma-realnost ili vizija [Macedonian National Plan for Diagnosis and
Management of Bronchial Asthma -–Reality or Vision, in Macedonian]. Skopje:
Biro “M & M”, 1996, 60-65.
3. Janson C, Anto P, Burney P et al. The European Community Respiratory Health
Survey: what are the main results so far? Eur Respir J 2001; 18:598-611.
4. Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova N.
Alergiski bolesti-Lekuvanje [Allergic Diseases – Management, in Macedonian].
Skopje: Medis-informatika, 1998, 81-82.
5. Karadzinska-Bislimovska J, Cvetanov V, Petrovska J et al. Respiratory symptoms
and positive skin prick test in a prospective asthma study in Republic of Macedonia
(initial results). Eur Respir J 1999; 14 (30): 78.
6. Karadzinska-Bislimovska J. Vlijanieto na brasnenata prasina vrz pojavata i
prevalencijata na opstruktivna belodrobna bolest [Influence of the exposure to
flour dust on the occurrence and prevalence of obstructive lung disease, in
Macedonian]. Master thesis. Medical Faculty, University “Kiril i Metodij” Skopje,
1985.
7. Karadzinska-Bislimovska J. Definiranje stepenot na alergiskata preosetlivost i pojavata
na belodrobni zaboluvanja so alergiska etiologija kaj rabotnici vo prerabotkata na
oriz [Defining of the level of allergic sensitization and prevalence of allergic
lung diseases in the rice workers, in Macedonian]. Doctoral dissertation. Medical
Faculty, University “Kiril i Metodij” Skopje, 1990.
8. Jordanova R. Profesionalna bronhijalna astma kaj rabotnici vo kozarska industrija.
[Occupational bronchial asthma in tannery, in Macedonian]. Master thesis.
Medical Faculty, University “Sv. Kiril i Metodij” Skopje, 2005.
9. Trandafilovski P, Maceska-Badzakova G. Astmata i vaseto dete [Asthma and your
child, in Macedonian]. Bitola: Kiro Dandarot, 2002; 5-6.
10.Trandafilovski P, Jacovski Lj, Maneva M, et al. Prevalence of asthma among school
children in the territory of Skopje. Allergy & Clin Immunol News 1994; 2: 609.
11.Vlaski E, Stavric K, Seckova L, et al. Prevalencija i tezina na astma, alergiski rinitis
i egzema kaj skolski deca vo Skopje (Internacionalna studija za astma i alergii vo
detstvoto-faza 3) [Prevalence and severity of asthma, allergic rhinitis and eczema
among school children in Skopje (International Study of Asthma and Allergies in
Childhood – phase 30, in Macedonian]. Mak spi med 2005; 51 (1-2): 12-23.
12.Viegi G, Annesi I, Matteelli G. Epidemiology of asthma. Eur Respir Mon 2003; 8
(23): 1-19.
13.Burney P. Asthma. Eur Respir Mon 2000; 5 (15): 48-65.
14.Holloway JW, Jongepier H, Beghe B et al. The genetics of asthma. Eur Respir Mon
2003; 8 (23): 26-48.
15.Sandström T, Helleday R, Blomberg A. Air pollution and asthma: experimental
studies. Eur Respir Mon 2002; 7 (21): 52-64.
155
16.Parnia S, Brown JL, Frew AJ. The role of pollutants in allergic sensitization and the
development of asthma. Allergy 2002; 57 (12): 1111-1117.
17.Barnes PJ. Patophysiology of asthma. Eur Respir Mon 2003; 8 (23):84-104.
18.Global Initiative for Asthma. Mechanisms of asthma. National Institutes of Health,
Heart, Lung, and Blood Institute 2004; 4:49-54.
19.Asthma. Available at www.nlm.nih.gov/medlineplus/.
20.Bjornsdottir US, Cypcar DM. Asthma: an inflammatory mediator soup. Allergy 1999;
54 (49): 55-61.
21.Mast cell degranulation. Available at: en.wikipedia.org/wiki/.
22.Humbert M, Kay AB. Chronic inflammation in asthma. Eur Respir Mon 2003; 8(23):
126-134.
23.Karadzinska-Bislimovska J. Imunoalergijski aspekti profesionalnih alergiskih bolesti.
Vo: Ljaljevic J, ur. Klinicka imunologija [Immunoallergic aspects of professional
allergic disorders. In: Ljaljevic J, ed. Clinical Immunology, in Serbian]. Beograd:
European Center of Peace and Development, 2002: 709-733.
24.Tanurdzic S. Bronhijalna astma [Bronchial asthma, in Serbian]. Beograd:
S.
Tanurdzic 2004, 33-38.
25.Bel EH, Chanez P. Diagnosis and assessment of asthma. Eur Respir Mon 2003; 8
(23): 180-189.
26.Gjorcev A, Stefanovski T, Dimitrovski M, Cvetanov V, Trandafilovski P, Nikolovski
Lj, Dokic D. Makedonski nacionalen konsenzus za dijagnoza i lekuvanje na astma
i hronicna obstruktivna belodrobna bolest [Macedonian National Consensus for
Diagnosis and Management of Asthma and Chronic Obstructive Lung Disease,
in Macedonian]. Skopje: Mitkovski M & M, 1999, 7-15.
27.Global Initiative for Asthma. Management of asthma. National Institutes of Health,
National Heart, Lung, and Blood Institute 2004; 1:1-7.
28.National Institutes of Health, National Heart, Lung, and Blood Institute. Expert Panel
Report 2: Guidelines for the Diagnosis and Management of Asthma. 1997, 41-51.
29.Chung KF, O’Byrne PM. Pharmacological agents used to treat asthma. Eur Respir
Mon 2003; 8 (23): 339-363.
30.Mileva Z. Bronhialna astma. Vo: Nasev G, Mileva Z. Narcnik na obstopraktikuvastija
lekar [Bronchial Asthma. In: Nasev G, Mileva Z. Manual of the general
practitioner, in Bulgarian]. Sofija: Znanie EOOD 2003, 468-470.
31.Pekkanen J, Pearce N. Defining asthma in epidemiological studies. Eur Resp J 1999;
14: 951-957.
32.European Community Respiratory Health Survey. Variations in the prevalence of
respiratory symptoms, self-reported asthma attacks, and use of asthma medications in
the European Community Respiraory Health Survey (ECRHS). Eur Respir J 1996; 9:
687-695.
33.Keil T, Kulig M, Simpson A, et al. European birth cohort studies on asthma and atopic
diseases: II. Comparison of outcomes and exposures – a GA2LEN initiative. Allergy
2006; 61: 1104-1111.
34.Cerveri I, Locatelli F, Zoia MC et al. International variations in asthma treatment
compliance: the results of the European Community Respiratory Health Survey
(ECRHS). Eur Respir J 1999; 14: 288-294.
156
35.Paoletti P, Carrozzi L, Viegi G et al. Distribution of bronchial responsiveness in a
general population: effect of sex, age, smoking, and level of pulmonary function. Am
J Respir Crit Care Med 1995; 151: 1770-1777.
36.Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemioloski karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseases in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
37.Chinn, Burney P, Jarvis D, Luczynska C. Variation in bronchial responsiveness in
the European Community Respiratory Health Survey. Eur Respir J 1997; 10: 24952501.
38.National Hearth, Lung, and Blood Institute. Morbidity and Mortality: 1996 Chartbook
on Cardiovascular, Lung and Blood Diseases. National Institute of Health, Bethesda,
MD, 1996.
39.Minov J, Cvetanov V, Karadzinska-Bislimovska J, et al. Epidemioloski karakteristiki
na bronhijalnata astma vo R. Makedonija [Epidemiological characteristics of
bronchial asthma in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56:
156.
40.Peat JK, Haby M, Spijker J et al. Prevalence of asthma in adults in Busselton, Western
Australia. BMJ 1992; 305: 1326-1329.
41.Cvetanov V, Caev V, Gjorcev A, Dokic D, Nikolovski Lj, Ezova N, Risteska-Kuc S,
Milkovska S. Makedonski nacionalen konsenzus za alergiski rinitis [Macedonian
National Consensus for Allergic Rhinitis, in Macedonian]. Skopje: Macedonian
Society for Basic and Clinical Immunology and Allergology, 1999, 20-22.
42.Minov J, Cvetanov V, Karadzinska-Bislimovska J, et al. Povrzanost na alergiskiot rinitis
so respiratornite simptomi kaj adultnata populacija vo R. Makedonija [Association
between allergic rhinitis and respiratory symptoms in adults in R. Macedonia, in
Macedonian]. Mak Med Pregled 2003; 56: 143-144.
43.Dokic D. The upper airways: The guardian of the lower airways. Summer School
Sofia 2002.
44.Minov J, Karadzinska-Bislimovska J, Vasilevska K, et al. Astma i bolesti na gornite
disni patista [Asthma and the upper airways diseases, in Macedonian]. Mak Med
Pregled 2002; 5-6: 248-252.
45.Ezova N, Cvetanov V, Milkovska S, et al. Karakteristiki na alergiskiot rinitis vo R.
Makedonija [Characteristics of allergic rhinitis in R. Macedonia, in Macedonian].
Mak Med Pregled 2003; 56: 142-143.
46.Bousquet J, Vignola AM, Demoly P. Allergic inflammation of the upper and lower
airways: a continuum of disease? Eur Respir Mon 2003; 8 (23): 211-220.
47.Plavec D. ARIA – jedinstvena alergijska bolest disnog sustava: sto povezuje nasa
dosadasnja istrazivanja s koncepcijom? [ARIA – one airway, one disease: What
links our research to the concept?, in Croatian]. Arh Hig Rada Toksikol 2004; 55:
135-140.
48.Canonica GW. Special presentation. Eur Respir Mon 2001; 6 (18): b-d.
49.Cacciola RR, Sarva M, Polosa R. Adverse respiratory effects and allergic suspectibility
in relation to particulate air pollution: flirting with disaster. Allergy 2002; 57 (4): 281285.
50.Fishwick D, Pearce N, D’Souza W et al. Occupational asthma in New Zealenders: a
population based study. Occup Environ Med 1997; 54: 301-306.
157
51.Kogevinas M, Anto JM, Sunyer J et al. Occupational asthma in Europe and other
industrialised areas: a population-based study. Lancet 1999; 353: 1750-1754.
52.Godisen izvestaj za realizacija na programata za preventivna zdravstvena zastita
[Annual report for realisation of the preventive medical protection, in
Macedonian]. Republic Institute of Health Protection Skopje, 2004.
53.52. Minov J. Vlijanie na specificnata profesionalna ekspozicija vrz nastanokot
na bronhijalnata astma kaj rabotnicite od farmacevtskata industrija [Influence
of the specific occupational exposure on bronchial asthma development in
pharmaceutical industry workers, in Macedonian]. Doctoral dissertation. Medical
faculty, University “Sv. Kiril i Metodij” Skopje, 2006.
158
5.0. Atopic dermatitis - ICD 10; L 20.8-L20.9
5.1.
Definition
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by dry skin,
recurrent intense pruritus and a typically age-related distribution and skin morphology.
AD, allergic rhinoconjunctivitis, and asthma are referred to as atopic diseases.
According to the revised nomenclature of the allergic disease 2001, the current term for
eczematous hypersensitivity reactions in the skin is atopic eczema/dermatitis syndrome
(AEDS). Other synonyms, such as exudative eczematoid, endogenous eczema, eczema
flexurarum, diathetic prurigo, prurigo Besnier, neurodermatitis, asthma-eczema, hay
fever-eczema, and many others that reflect insufficient knowledge about the disease
pathogenesis were considered as not suitable for international use. However, during a
transition period, it may be useful to highlight the well-accepted view that AD is not one,
single disease but rather a group of several diseases with certain clinical characteristics
in common.
5.2.
Pathogenesis
AD is a genetic predisposed disease caused by immunological mechanisms in which
many other factors play a role with intensity that varies in certain individuals, as well
as in the same individual in different periods of life. However, the importance of the
immunological mechanisms in AD pathogenesis remains still unclear.
Allergic AD (AEDS) is a form of AD caused by immunological mechanisms that can be
demonstrated. IgE-associated AD is the only immunologically well-defined subgroup of
allergic AD, in which the clinical selection is based on Hanifin & Rajka criterion, “family
history of or simultaneous occurrence of symptoms of atopy”. Since less is known about
the precise role of IgE antibodies initiating the disease in comparison with other allergic
disease, the term associated is used instead of the term mediated. Another subgroup
of allergic AD, named T-cell-associated AD, seems to include cell-mediated forms.
This form is characterized by positive atopy patch test to aero- and food allergens or
allergen-specific T cells in the peripheral blood or in skin biopsies, but in absence of IgE
sensitization.
The form of AD in which immunological mechanisms can not be demonstrated is referred
to as nonallergic AD. This term should replace the term intrinsic/cryptogenic AD.
Genetic predisposition seems to be the main individual risk factor for AD development.
Results from the studies indicate significantly higher risk (OD varies from 3.0 to 6.0)
for AD in children with positive parental history of AD. Exposure to aero- and food
allergens, bacterial and viral superinfections, climate factors (fall-winter season, pollen
season), and emotional factors are considered as environmental factors that could play a
role in AD development and severity.
159
The role of AD as the first step of the allergic march, i.e. its role as a predictor of development
of the other allergic diseases such as allergic rhinoconjunctivitis and asthma, has a special
importance. Results of the studies that investigated the efficacy of the treatment of AD in
the prevention of the other allergic diseases are controversial.
5.3.
Clinical manifestations
Atopic dermatitis usually occurs in the early childhood. In about 60% of the cases it
occurs in infancy, and in about 85% in the first five years. In about 70% of the children
with AD symptoms of the disease improve at the age of puberty.
The disease is characterized by chronic course with exacerbations of variable severity. A
key feature of AD is severe dryness of the skin typically accompanied by intense pruritus
and inflammation that is triggered by a number of factors and conditions.
The morphology of the skin lesions and its distribution is variable in different periods
of the life. In infancy predominate exudative eczematous lesions localized on the face,
gluteal region, and on the extremities. (Figure 134).
Figure 134. AD in an infant – exudative eczematous lesions with typical distribution
Adapted from: Eczema (Atopic dermatitis). Available at: http://health.allrefer.com/
health/eczema-atopic-dermatitis-pictures-images.html
Lichenified papules usually localized on the antecubital and popliteal fossae, accompanied
by severe pruritus, are typical skin lesions in the period of childhood. Dominant skin
lesion in adults is a prurigo-papule with similar distribution (Figure 135).
160
Figure 135. AD in adult – prurigo-papules on the popliteal fossae
Adapted from: Betetto M, Fettich J. Mala dermatovenerologija [Manual of
dermatovenerology, in Croatian]. Ljubljana: Partizanska knjiga,1977.
5.4. Diagnosis
As there is a lack of the specific clinical or laboratory markers of the disease, the diagnosis
of AD is based on a combination of clinical features. Rajka & Hanifin determined major
and minor features for the diagnosis of AD. The diagnosis of AD is confirmed in cases
where at least positive three major and three minor features exist.
The major features of AD include:
-
-
-
-
intense itching,
characteristic skin rash in locations typical for the disease,
chronic or repeatedly occuring symptoms,
personal or family history of atopic disorders (eczema, hay fever, asthma).
The minor diagnostic features of AD include: early age of onset, dry skin that may also
have patchy scales or rough bumps, positive skin prick tests to aero- and food allergens,
increased total IgE, hand or foot involvement, inflammation around the lips, nipple
eczema, and susceptibility to skin infections.
The diagnostic work-up includes assessment of the disease severity and investigation
of exacerbating factors. On the basis of severity, AD is subdivided into mild, moderate
and severe. The investigation of exacerbating factors involves specific skin and blood
tests, and challenge tests. Both SPT and measurement of specific IgE can be used for
sensitization to a food. However, standardized food challenges provide the most accurate
diagnostic tool. Sensitization to inhalant allergens can be detected by means of SPT
(if the skin is free from eczema) or by measurement of specific IgE. Skin biopsies are
not essential for the diagnosis of AD but might be needed to exclude other diagnoses,
particularly in adults.
161
Atopy patch test (APT), an epicutaneous patch test with type 1 allergens known to elicit
IgE-mediated reactions and the evaluation of eczematous skin lesions after 24-72 h can be
used as a diagnostic tool in characterizing patients with aeroallergen- and food-triggered
AD. Allergen specific T cells cloned from the APT biopsies showed a characteristic Th
2 secretion pattern initially, whereas after 48 h a Th 1 pattern was predominant. The
same pattern is also found in the chronic lesions of AD. It has also been shown that APT
reactions to aeroallergens are associated with specific T-cell responses to the corresponding
allergen in the circulation. In the EAACI/GA2LEN Position paper 2006 entitled “Present
status of the atopy patch test”, indications for testing with APT, choice of allergens, test
material and technique, and present knowledge on sensitivity and specificity are reviewed
on the basis of available literature.
5.5. Management
The atopic dermatitis management includes non-pharmacological measures and
medications use.
5.5.1. Non-pharmacological treatment
Non-pharmacological treatment should comprise optimal skin care, addressing the skin
barrier defect with regular use of emollients and skin hydration, along with identification
and avoidance of specific and nonspecific trigger factors. The main nonspecific triggers
include contacts, such as clothing made from occluding or irritating synthetic or wool
material, as well as inadequate soaps and hot water temperature during showering and
bathing.
There is no universally recommended diet for patients with AD. Dietary restrictions should
be recommended in cases of established diagnosis of food hypersensitivity. The positive
effect of avoidance measures regarding inhalant allergens (dust mite, animal dander, and
pollens) has been shown in various studies.
For optimal disease management, education of the patient and appropriate psychosocial
support is needed. Orientation to occupations with lower exposure to allergens and
irritants is also recommended.
5.5.2. Pharmacological treatment
Pharmacological treatment includes use of topical and systemic medications. Topical
corticosteroids (TCS), topical calcineurin inhibitors (TCI), and topical antimicrobial
therapy are the basis of the local AD treatment. Systemic treatment includes use of
antihistamines, systemic corticosteroids, systemic antibiotics, cyclosporine A (CyA),
azathioprine, and phototherapy (UV therapy). Until today, immunotherapy is not an
established instrument for the treatment of AD.
162
The pharmacological AD treatment, on the basis of disease severity, includes multiple
therapeutic agents in a step-wise fashion. According to the actual guidelines, mild to
moderate AD should be treated with low-mid potency TCS and/or TCI, whereas the use of
mid-high potency TCS and/or TCI is recommended in the treatment of moderate to severe
AD. In cases of severe AD that cannot be controlled with topical treatment, systemic
treatment options should be considered (i.e. CyA or UV therapy).
5.6. Epidemiological studies of atopic dermatitis
As there is no single marker of the disease, it is difficult to carry out epidemiological
survey of AD. According to Schäfer “opinion of the experienced dermatologist is a gold
standard in AD diagnosis”. Usually, children or children of certain age group are the
target population of epidemiological observations of AD. The studies commonly are
based on questionnaire that includes items about type and distribution of the skin lesions
and duration and course of the disease, as well as about personal and family history of
allergic diseases. A few studies are based on questionnaire with additional allergologic
evaluation or reports of dermatologists.
The prevalence of AD in children, reported by epidemiological observations carried out
in the 1990s, varies from 0.7% in Tanzania, 4% in Turkey, 5.8% in Italy, 3.9-6.3% in
Czech Republic, 2.5-8.3% in Germany, up to 7% in Denmark, 9% in the USA, 10.4% in
Australia and 20.2% in the UK. The studies carried out in the USA, the UK, Sweden and
Swiss indicate increasing prevalence of AD in the last decades. The AD prevalence in
children in the UK increased from 4.1% in 1964 to 10.2% in 1989.
Epidemiological studies emphasize higher AD prevalence in girls, in children from the
urban areas with higher socioeconomic status, as well as the association between AD
and family history of AD and other allergic diseases (allergic rhinoconjunctivitis and
asthma).
Seasonal variations of the disease (worsening of the symptoms in the pollen season and in
the fall-winter period) are also reported by many epidemiological studies of AD. Results
of the studies that investigate association between AD and exposure to outdoor and
indoor pollutants are controversial. Some studies indicate higher risk of AD in children
with maternal smoking during pregnancy and exposure to environmental tobacco smoke
(ETS) in childhood.
5.6.1. Results of our epidemiological study of AD in R. Macedonia
Epidemiological observation of AD in R. Macedonia was not conducted previously. The
study we carried out included children aged 0 to 15 years. A questionnaire designed
similar to the model of questionnaires used in the studies of AD performed in the West
European countries.
163
The prevalence of AD among examined children was 3.8% (Figure 136). Similar prevalence
of AD was detected in Mediterranean (Turkey, Italy) and Central European countries
(Czech Republic, Germany). Higher prevalence of AD is registered in Scandinavian and
English speaking countries that could be due to the interaction of genetic and environmental
factors (lifestyle, diet, high proportion of childhood immunizations, low proportion of
children with intestinal infections and infestations, and effects of the outdoor and indoor
air pollutants in the urban areas).
Figure 136. Prevalence of AD in examined children
The prevalence of AD was nonsignificantly higher in girls (Figure 137) that is in compliance
with the results of many epidemiological studies of AD. Schäfer has indicated that female
sex is an independent risk factor for AD.
Figure 137. Sex distribution of AD in examined children
Results from many studies of AD reported that in about 70% of the cases the disease
occurred in the first year of life. Our results showed higher prevalence of AD in the
children aged less than 7 years (Figure 138).
164
Figure 138. Age distribution of AD in examined children
5.6.2. Prevalence of AD in certain centers
The prevalence of AD among examined children varied from 1.8% in Dojran, 2.4%
in Pehchevo, 2.9% in Debar, 3.1% in Ohrid, 3.3% in Skopje to 6.2% in Prilep (Figure
139).
Figure 139. Prevalence of AD among examined children in certain centers
5.6.3. Association between atopic dermatitis and other allergic entities
Seasonal worsening of the symptoms was reported by 60.0% of the children with AD
(Figure 140).
165
Figure 140. Prevalence of AD in examined children with seasonal variations of the disease
We registered significant association between AD and allergic rhinitis (P < 0,01) (Figure
124). Allergic rhinitis was present in 53.3% of the cases with AD. Association with other
allergic entities was statistically nonsignificant.
Figure 141. Association between AD and allergic rhinitis
Results of our study confirm the role of heredity in AD development. Positive family
history of allergic diseases was reported by 73.0% of the cases with AD (P < 0,001)
(Figure 142).
Figure 142. Association between AD and family history of allergic diseases
166
5.6.4. Association between AD and lifestyle
Results of the actual study indicated significantly higher prevalence of AD among
children from urban in respect to children from rural areas (P < 0,05) (Figure 143) that
is complementary to the results from many studies carried out in the West European
countries and in the USA.
Figure 143. Association between AD and living in urban area
Statistical analyses showed no statistically significant association between AD and birth
weight and type of feeding in infancy. However, AD is more frequent among children
with birth weight less than 3000 g and bottle fed children (Figure 144).
Figure 144. Presence of AD among children with low birth weight, complementary feeding
in the period of infancy, and breast-feeding shorter than 6 months
5.6.5. Association with air pollution
Results from a several studies indicated significant association between AD and maternal
smoking during pregnancy and exposure to ETS during childhood. Such associations
were not confirmed in our study (Figure 145).
167
Figure 145. Prevalence of AD among children with maternal smoking during
pregnancy and in children exposed to ETS
5.7. Conclusions
1. Prevalence of AD among examined children was 3.8%. AD was detected more
frequently among examined girls (4.1%) than among examined boys (3.4%). The
highest prevalence was detected in Prilep and the lowest one in Dojran.
2. Seasonal worsening of the disease was registered in 60.0% of the children with AD.
3. AD was significantly associated with family history of allergic diseases. In over half
of the cases with AD, the disease was accompanied by allergic rhinitis.
4. Association between AD and hypersensitivity to drug and food hypersensitivity and
insect sting allergy was not statistically significant.
5. Prevalence of AD was significantly higher in the children with urban residence than
in the children from rural areas.
6. AD was not significantly associated with low birth weight and type of feeding in
infancy. AD was also nonsignificantly associated with maternal smoking during
pregnancy and exposure to ETS.
5.8. References:
1. Johansson SGO, Hourihane JO’B, Bousquet J et al. A revised nomenclature for allergy.
Allergy 2001; 56 (9): 813-824.
2. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in
children and adults: European Academy of Allergology and Clinical Immunology /
American Academy of Allergy, Asthma and Immunology / PRACTALL Consensus
Report. Allergy 2006; 61: 969-987.
3. Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova N.
Alergiski bolesti-Lekuvanje [Allergic diseases – Management, in Macedonian].
Skopje: Medis-informatika 1998; 131-135.
4. Wollenberg A, Bieber T. Atopic dermatitis: from the genes to skin lesions. Allergy
2000; 53: 731-739.
5. Hanifin JM. Clinical and basic aspects of atopic dermatitis. Semin Dermatol 1983; 2:
5-19.
168
6. Eczema (Atopic dermatitis). Available at: http://health.allrefer.com/health/eczemaatopic-dermatitis-pictures-images.html.
7. Betetto M, Fettich J. Mala dermatovenerologija. Ljubljana: Partizanska knjiga,1977.
8. Schäfer T, Ring J. Epidemiology of allergic diseases. Allergy 1997; 52 (38): 14-22.
9. Wüthrich B. Clinical aspects, epidemiology and prognosis of atopic dermatitis. Ann
Allergy Asthma Imminol 1999; 83: 464-470.
10.Novak N, Bieber T. The skin as a target for allergic diseases. Allergy 2000; 55: 103107.
11.Bousquet J. Allergy as a global problem: “Think globally, act globally”. Allergy 2002;
57: 661-662.
12.Vlckova-Laskoska M, Starova A. Klinicka dermatologija [Clinical Dermatology, in
Macedonian]. Skopje: HIB DRESKO 1998; 291-294.
13.Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemiolosi karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseases in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
14.Mileva Z, ed. Svremenno lecenie na alergicnite bolesti [Current management of
allergic diseases, in Bulgarian]. St. Zagora: Znanie EOOD; 160-164.
15.Betetto M, Fettich J. Mala dermatovenerologija [Manual of dermatovenerology, in
Croatian]. Ljubljana: Partizanska knjiga,1977.
16.Schmid P et al. Epidemiology, clinical features, and immunology of the “intrinsic”
(non IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001;
56 (9): 841-848.
17.Turjanmaa K, Darsow U, Niggemann B, et al. EAACI/GA2LEN Position paper: Present
status of the atopy patch test. Allergy 2006; 61: 1377-1384.Girolomoni G, Abeni
D, Masini C et al. The epidemiology of atopic dermatitis in Italian schoolchildren.
Allergy 2003; 58 950: 420-425.
18.Kalyoncu AF et al. Prevalence of childhood asthma and allergic diseases in Ankara,
Turkey. Allergy 1994; 49: 485-488.
19.Cankov N, Nikolova K, Kazandzieva Z. Atopicen dermatit. Vo: Nasev G, Mileva Z.
Narcnik na obstopraktikuvastija lekar [Atopic dermatitis. In: Nasev G, Mileva Z.
Manual for the general practitioner, in Bulgarian]. Sofija: Znanie EOOD 2003,
449-450.
20.Varjonen E, Kalimo K, Lammintaausta K. Prevalence of atopic disorders among
adolescents in Turku, Finland. Allergy 2002; 47: 243-248.
21.Ninan T, Russell G. Respiratory symptoms and atopy in Aberdeen schoolchildren:
evidence from two surveys 25 years apart. Br Med J 1992; 304: 873-875.
22.American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy
Report: Science Based Findings on the Diagnosis and Treatment of Allergic Disorders
1996-2001.
169
6.0. Drug hypersensitivity - ICD - 10; T 88.7
6.1. Definition
Drug hypersensitivity is defined as an occurrence of objective and reproducible symptoms
and/or signs initiated by exposure to a drug at dose tolerated by other subjects (T 88.7).
When immunological mechanisms are shown, either antibody or cell mediated, the
adverse reaction to drug should be referred to as drug allergy. By adding the adjective
immediate, late or delayed, we can both describe the onset of symptoms and indicate
probable mediating mechanisms. If we wish to highlight the role of IgE antibody in the
drug allergy, it may be called IgE-mediated drug allergy. All other reactions to drugs,
caused by identifiable or unknown mechanisms, should be referred to as nonallergic drug
hypersensitivity.
6.2. Pathogenesis
The underlying immunological mechanisms that cause drug allergy include all four
types described by Gell and Coombs (Table 17). Some allergic reactions to drugs may
include mechanisms of two types (e.g. β lactames, sulphonamides). On the other hand,
the same drug in certain subjects may cause immunological reactions of different types
(e.g. benzylpenicillin may cause reaction type I, II, and IV) or may cause immunological
and non-immunological reactions (e.g. angiotensin-converting enzyme inhibitors).
Type
I
II
III
IV
Effector mechanism
IgE, mast cells and basophils
Clinical manifestations
Anaphylactic shock
Urticaria/angioedema
Bronchospasm
IgG, IgM, Complement and/or
phagocytosis
Cytopenia
Glomerulonephritis
Precipitins, IgG, IgM and
Complement
Serum sickness
Glomerulonephritis
Vasculitis
T-lymphocytes
Contact dermatitis
Maculopapular rash
Table 17. Immunological reactions according to Gell and Coombs
Nonallergic hypersensitive reactions mimic allergic symptoms but they do not have an
immunological mechanism. The etiologies of these reactions include different mechanisms
(Table 18).
170
Mechanism
Drug
Nonspecific histamine release
Opiates, Radiocontrast media, Vancomycin
Bradykinin accumulation
Angiotensin-converting enzyme (ACE)
inhibitors
Complement activation
Radiocontrast media, Protamine
Induction of leukotriene synthesis
Aspirin and other nonsteroidal antiinflammatory drugs (NSAIDs)
Bronchospasm
Sulfur dioxide released by
drugs containing sulfites
Table 18. Mechanisms of nonallergic drug hypersensitivity
6.3. Clinical manifestations
Drug hypersensitivity is a common and complicated problem in clinical practice. The
clinical picture of drug hypersensitivity is very heterogeneous, encompassing such
distinct diseases as morbilliform or bullous exanthema, urticaria, anaphylaxis, blood
cell dyscrasia, fever, interstitial lung disease, hepatitis, nephritis, and various forms of
autoimmune diseases.
6.4. Diagnosis
Diagnosis of the drug allergy is based on history, clinical manifestations, in vivo and
in vitro allergological evaluation, and provocation tests. The available clinical and
laboratory tools at our disposal are few and have not all been fully evaluated.
Under the aegis of the European Academy of Allergy and Clinical Immunology (EAACI),
the European Network of Drug Allergy (ENDA) is working for the establishment
of pragmatic and standardized clinical tools for daily practice. Members of ENDA
have developed a questionnaire that enables a uniform format for data collection and
harmonization of the drug hypersensitivity diagnostic procedures. It also includes some
procedures such as skin tests, provocation tests, and biological tests.
6.4.1 Clinical history
Clinical history includes symptomatology, chronology of the symptoms (previous
exposure, delay between the last dose and onset of the symptoms, effect of stopping
treatment), use of other medications (at the time of reaction and other affiliated drugs
171
used since), as well as the medical background of the subject (information about previous
allergies associated with medications or not).
6.4.2. Skin prick tests and intradermal tests
Skin prick tests and intradermal tests are particularly important in order to demonstrate an
IgE-mediated reactions. The diagnostic value of skin tests is not fully evaluated. In general,
there are no reliable skin tests procedures for the diagnosis of drug hypersensitivity and
test concentrations are poorly validated for most drugs.
Skin tests should be performed 4-6 weeks after the reaction. The sensitivity of skin tests
varies depending on the drug - from excellent (penicillins, myorelaxants, heterologous
sera, and enzymes), through satisfactory (vaccines, hormones, protamine, and opiates)
to poor or unknown (local anesthetics, paracetamol, sulfonamides, iodine radiocontrast
media, aspirin and other nonsteroidal anti-inflammatory drugs - NSAIDs, etc).
6.4.3. Dose-provocation tests (DPT)
Dose-provocation tests (DPT) have the highest sensitivity, but can only be performed
under the most rigorous conditions and therefore are restricted to certain specialist centers.
These tests are particularly needed for aspirin and other NSAIDs, local anesthetics,
antibiotics other than penicillins or penicillins when skin tests are negative.
6.4.4. In vitro tests
Laboratory tests are useful in the diagnosis of drug hypersensitivity but, similar to skin
tests, these tests are not fully validated.
The demonstration of drug-specific IgE (by UniCap or RAST method) to penicillins,
myorelaxants or tetanus toxoid, in conjunction with positive anamnesis suggests the IgEmediated reaction.
Increased concentration of histamine in the blood while receiving certain drug correlates
with skin tests and specific IgE for myorelaxants.
The test of basophil degranulation in the presence of incriminated drug is not recommended
due to the low sensitivity.
For drug-induced type II and III reactions, a Coomb’s test, in vitro hemolysis test,
determination of complement factors and circulating immune complexes can be
performed.
172
6.5. Prevention
6.5.1. Primary prevention
Measures of primary prevention include identification of the risk factors for development
of drug hypersensitivity, such as presence of other allergic diseases, liver disorders, and
chronic disease that requires use of several drugs. Primary prevention also includes
knowledge about adverse effects of the administered drug/drugs and avoidance of
polipragmasy.
6.5.2. Secondary prevention
Secondary prevention includes measures in the subjects with registered drug
hypersensitivity, such as discontinuation of drug, as well as avoidance of the administration
of medications with known cross-reactivity with incriminated drug. Registration of the
hypersensitive reaction to certain drug is recommended in all subjects in which drug
hypersensitivity has occured.
6.6. Epidemiological studies of drug hypersensitivity
A number of studies of drug hypersensitivity in the USA and the West European countries
in the last decades has been conducted. The majority of these studies has been based on
a questionnaire that included items about hypersensitive reaction to certain drug and its
clinical manifestations. Only in a few studies allergological evaluation has been added to
the completion of the questionnaire.
It is estimated that adverse reactions to drugs occur in about 25% of the treated subjects.
The prevalence of drug allergy is estimated to 5-10% and skin changes are the most
frequent clinical manifestations (70-80%). The prevalence of drug hypersensitivity in
hospitalized patients in the USA and France was found to be 5% and 2-3%, respectively.
The prevalence of self-reported drug hypersensitivity that is not confirmed by allergological
testing is about 15%, being more frequent among women.
6.6.1. Penicillins
Hypersensitivity to penicillins is the most frequent type of drug hypersensitivity. It occurs
in about 2.5% of the hospitalized patients in the USA. Hypersensitivity to penicillins is
responsible for 400 deaths from anaphylactic shock per year in the USA. The studies
carried out in the USA reported that in only 10-20% of the subjects with history for
penicillins hypersensitivity it was demonstrated by in vivo or in vitro tests.
173
6.6.2. Antibiotics other than penicillins and sulphonamides
Prevalence of the reactions of hypersensitivity to other antibiotics is much lower in respect
to penicillins. Hipersensitivity to sulphonamides occurs in 3-6%, to tetracyclines in 0.1
- 0.5%, to macrolydes in 0.5%, and to gentamicin in 0.1 - 2% of the treated subjects.
Different immunological and nonimmunological mechanisms could be involved in the
pathogenesis of hypersensitive reactions to these medications.
6.6.3. Aspirin and other NSAIDs
Aspirin causes hypersensitive reactions, commonly manifested by skin rash, angioedema
and/or bronchospasm, in 0.3 -0.5% of the general population, in 1.4% of the subjects with
allergic rhinitis, in about 4% of the subjects with asthma, in 10-15% of the subjects with
sinonasal polyposis, as well as in about 20% of the subjects with chronic urticaria. Similar
reactions could occur in the course of use of other NSAIDs affecting usually middle
aged women. The mechanism of aspirin-induced hypersensitivity is non-immunological
and may involve increased leukotriene synthesis, higher sensitivity of the leukotriene
receptors, disturbances in synthesis of the platelet mediators, etc.
In some subjects that have used aspirin, antibodies to aspirin may be detected in the blood,
but their appearance and titre do not correlate with clinical manifestations of aspirininduced hypersensitivity.
6.6.4. Myorelaxants
Myorelaxans may cause IgE-mediated reaction that usually occurs in women. The
prevalence of allergic reactions to myorelaxants is about 1/4,500 general anesthesias.
Fatal reactions occur in about 6% of the subjects with myorelaxants-induced allergy.
6.6.5. Local anesthetics
Local anesthetics may cause hypersensitive reactions, usually manifested by dizziness
or collapse, in 2 - 3% of the subjects in which they are administered. The mechanism of
these reactions is unknown.
6.6.6. ACE inhibitors
ACE inhibitors (usually enalapril) cause nonproductive cough (enalaprile-induced cough)
in about 10% of the treated subjects by bradykinin accumulation as underlying mechanism.
ACE inhibitors may also cause IgE-mediated reaction manifested by angioedema.
174
6.7. Results of the actual study of drug
hypersensitivity in R. Macedonia
The actual study is the first epidemiological observation of drug hypersensitivity in R.
Macedonia. The study was based on a questionnaire designed according to the ENDA
recommendations.
6.7.1. Prevalence of drug hypersensitivity
Prevalence of drug hypersensitivity in all examined subjects (both adults and children) was
10.5%, that is within range of the published data for self-reported drug hypersensitivity
(Figure 146).
Figure 146. Drug hypersensitivity in all examined subjects
Similarly to the other allergic entities, the prevalence of drug hypersensitivity was not
significantly higher in females (12.4% vs. 8.9%) (Figure 147).
Figure 147. Sex distribution of drug hypersensitivity in all examined subjects
175
6.7.2. Prevalence among examined subjects in certain centers
The highest prevalence of drug hypersensitivity was registered in Skopje (17.8%) and the
lowest one in Dojran (3.1%). The prevalence of drug hypersensitivity in Prilep, Debar,
Ohrid, and Pehchevo was 13.7%, 9.6%, 4.9%, and 4.2%, respectively (Figure 148).
Figure 148. Prevalence of drug hypersensitivity among examined subjects in certain centers
6.7.3. Age distribution
6.7.3.1. Prevalence of drug hypersensitivity in adults
Prevalence of drug hypersensitivity in adults was 11.2%. It was higher in women than in
men (13.4% vs. 7.8%), but there was no statistical significance (Figure 149).
Figure 149. Sex distribution of drug hypersensitivity in examined adults
The highest prevalence of drug hypersensitivity in examined adults was registered in
the age group 51-60 (14.7%), and the lowest one in the age group 21-30 (9.3%) (Figure
150).
176
Figure 150. Age distribution of drug hypersensitivity in examined adults
6.7.3.1.1. Prevalence among examined adults in certain centers
The highest prevalence of drug hypersensitivity in adults was registered in Prilep (16.9%),
and the lowest one in Dojran (4.3%). The prevalence of drug hypersensitivity in adults in
Skopje was 8.0% (Figure 151).
Figure 151. Prevalence of drug hypersensitivity among examined adults in certain centers
6.7.3.1.2. Prevalence of hypersensitivity to certain drugs
Hypersensitivity to antibiotics was the most common type of drug hypersensitivity in the
examined adults (73.9% of the adults with self-reported drug hypersensitivity). It was
followed by hypersensitivity to NSAIDs (17.4%), to anesthetics (4.3%), and to other
drugs (4.3%) (Figure 152).
177
Figure 152. Hypersensitivity to certain drugs in examined adults
Hypersensitivity to natural and synthetic penicillins was the most frequent type of drug
hypersensitivity in the examined adults (6.8%). Literature data indicate prevalence of the
self-reported hypersensitivity to penicillins of approximately 10%, but allergic background
was demonstrated in only 10-20% of these subjects. Hypersensitivity to aspirin and
affiliated drugs was reported by 0.6% of the examined adults (Figure 153). Consulted
studies indicate prevalence of hypersensitivity to aspirin in the general population of
0.3–0.5%.
Figure 153. Prevalence of hypersensitivity to penicillins and aspirin
in the adults with drug hypersensitivity
6.7.3.1.3. Clinical manifestations in the adults with drug hypersensitivity
As many studies have indicated, skin changes are the most common clinical manifestations
of drug hypersensitivity. Our data also showed skin manifestations as the most common
type of drug hypersensitivity in adults (skin rash was reported by 41.0% and angioedema
by 23.0% of the adults with self-reported drug hypersensitivity), followed by dyspnea
(18.7%) and collapse (15.6%) (Figure 154).
178
Figure 154. The most frequent clinical manifestations in the adults with drug hypersensitivity
6.7.3.2. Prevalence of drug hypersensitivity in children
The prevalence of drug hypersensitivity in children was 9.8%. It was slightly higher in
boys (10.7%) than in girls (8.9%) (Figure 155).
Figure 155. Prevalence and sex distribution of drug hypersensitivity in examined children
Similarly to the food hypersensitivity, prevalence of drug hypersensitivity in examined
children was higher in the age group 0-6 than in the age group 7-15 years (11.6% vs.
6.7%) (Figure 156).
179
Figure 156. Age distribution of drug hypersensitivity in examined children
6.7.3.2.1. Prevalence among examined children in certain centers
The highest prevalence of drug hypersensitivity in the examined children was registered
in Skopje (23.5%). Drug hypersensitivity was not registered in the examined children in
Pehchevo (Figure 157).
Figure 157. Drug hypersensitivity among examined children in certain centers
6.7.3.2.2. Hypersensitivity to certain drugs
The most common type of drug hypersensitivity in the examined children was
hypersensitivity to antibiotics. Hypersensitivity to natural penicillins was reported by
48.2%, semisynthetic penicillins by 37.9%, and sulphonamides by 13.7% of the children
with drug hypersensitivity (Figure 158). Prevalence of hypersensitivity to penicillins in
the examined children was 8.4%.
180
Figure 158. Hypersensitivity to certain drugs in the children with drug hypersensitivity
6.7.3.2.3. Most common clinical manifestations
The most common clinical manifestations in the children with drug hypersensitivity
were skin manifestations (70%), followed by diarrhea (18.3%) and other manifestations
(11.7%) (Figure 159).
Figure 159. The most common clinical manifestations in the
examined children with drug hypersensitivity
6.7.3.2.4. Association of drug hypersensitivity with other allergic diseases
Drug hypersensitivity in the examined adults was closely related to food hypersensitivity
(P < 0.05). Drug hypersensitivity was reported by 11.1% of the examined adults with food
hypersensitivity, whereas it was present in 4.1% of the examined adults that did not report
food hypersensitivity (Figure 160). Association between drug hypersensitivity with other
allergic entities was nonsignificant. Nonsignificant association was also detected between
drug hypersensitivity and other endogenous and exogenous factors of interest.
181
Figure 160. Prevalence of drug hypersensitivity in the examined adults
with and without food hypersensitivity (FH)
Drug hypersensitivity in the examined children was significantly associated with allergic
rhinitis (P < 0,05) and family history of allergic diseases (P < 0,05) (Figure 161). There
was no significant association between drug hypersensitivity in the examined children
and other endogenous and exogenous factors.
Figure 161. Prevalence of drug hypersensitivity in the examined children with
allergic rhinitis and positive family history of allergic diseases
6.8. Conclusions
1. Drug hypersensitivity was reported by 10.5% of all examined subjects that suggested
that more than 200,000 subjects in R. Macedonia had history of hypersensitivity to
one or more medications. The prevalence of drug hypersensitivity was higher in the
examined adults (11.2%) than in the examined children (9.8%), as well as in the
females (12.4%) than in the males (8.9%).
2. Drug hypersensitivity in the examined adults was commonly caused by penicillins
and NSAID and in the examined children by penicillins and sulphonamides.
3. Hypersensitivity to penicillins was the most frequent type of drug hypersensitivity. It
was reported by 6.8% of the examined adults and 8.4% of the examined children.
182
4. Hypersensitivity to aspirin and affiliated drugs was reported by 0.6% of the examined
adults.
5. Skin manifestations was the most frequent clinical manifestation of drug
hypersensitivity in both adults and children.
6. Drug hypersensitivity in the examined adults was closely related to food hypersensitivity.
In the examined children significant association of drug hypersensitivity with allergic
rhinitis and family history of allergic diseases was registered.
6.9. References:
1. Johanson SOG, Hourihane JO’B, Bousquet J et al. A revised nomenclature for allergy.
Allergy 2001; 56 (9): 813-822.
2. Sanchez E, Torres MJ, Mayorga C et al. Adverse drug reactions with an immunological
basis: from clinical practice to basis research. Allergy 2002; 57 (72): 41-44.
3. Blanca M, Canto G, Lopez C et al. The connection between basic research and clinical
practice. Clin Exp Allergy 1998; 28 (4): 87-91.
4. Pichler WJ. Deciphering the immune pathomechanism of cutaneous drug reactions.
Allergy 2002; 57 (72): 34-36.
5. Gruchalla R. Understanding drug allergies. J Allergy Clin Immunol 2000; 105: 637644.
6. Demoly P, Bousquet J. Drug allergy diagnosis work up. Allergy 2002; 57 (72): 3740.
7. Demoly P, Kropf R. Bircher A. Pichler WJ. Drug hypersensitivity questionnaire.
Allergy 1999; 54: 999-1003.
8. Ring J, Brockow K. Adverse drug reactions: Mechanisms and assessment. Eur Surg
Res 2002; 34: 170-175.
9. Brockow K, Romano A, Blanca M et al. General considerations for skin test procedures
in the diagnosis of drug hypersensitivity. Allergy 2002; 57: 45-51.
10.Aberer W, Bircher A, Romano A et al. Drug provocation testing in the diagnosis of
drug hypersensitivity reactions: general considerations. Position paper. Allergy 2003;
58 (9): 854-861.
11.Vlckova-Laskoska M, Starova A. Medikamentozni egzantemi. Vo: Vlckova-Laskoska
M, Starova A. Klinicka dermatologija [Drug-induced exanthemas. In: VlckovaLaskoska M, Starova A. Clinical Dermatology, in Macedonian]. Skopje: HIB
DRESCO 1998; 297-302.
12.Balabanova-Stefanova M. Hipersenzitivni kutani reakcii na betalaktamski antibiotici
[Hypersensitive skin reactions to β lactams, in Macedonian]. Doctoral dissertation.
University “Sv. Kiril i metodij” Skopje, 1996.
13.Mileva Z. Medikamentozna alergija. Vo: Narcnik na obstopraktikuvastija lekar [Drug
allergy. In: Nasev G, Mileva Z: Manual for the general practitioner, in Bulgarian].
Sofja: Znanie EOOD 2003; 477-480.
14.Li Wan Po A, Kendall MJ. Causality assessment of adverse effects. When is rechallenge acceptable? Drug Safety 2001; 24: 793-799.
15.Gruchalla RS. Clinical assessment of drug-induced disease. Lancet 2000; 28: 15051511.
183
16.Demoly P, Bousquet J. Epidemiology of drug allergy. Curr Opinion Allergy Clin
Immunol 2001; 1: 305-310.
17.Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemioloski karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseases in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
18.Marsenic M, Cvetanov V, Karadzinska-Bislimovska J, et al. Referirana preosetlivost
na lekovi vo R. Makedonija [Self-reported drug hypersensitivity in R. Macedonia,
in Macedonian]. Mak Med Pregled 2003; 56: 144-145.
19.Lazaru J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized
patients. JAMA 1998; 279: 1200-1205.
20.Vervloet D, Pradal M. Drug Allergy. Sundbyberg Sweden, 1992.
21.Gleckman RA, Borrego F. Adverse reactions to antibiotics. Postgrad Med 1997; 101:
97-108.
22.Shepherd GM. Penicillin allergy. Allergy & Asthma Advocate Spring 2000.
23.Salkind AR, Cuddy PG, Foxworth JW. Is this patient allergic to Penicillin? JAMA
2001; 285 (19).
24.American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy
Report: Science Based Findings on the Diagnosis & Treatment of Allergic Disorders
1996-2001.
25.AAAAI Board of Directors. Anaphylaxis in schools and other childcare settings.
Journal of Allergy and Clinical Immunology 1998; 102 (2): 173-176.
26.Kowalski ML, Pawliczak R, Wozniak J et al. Differential metabolism of arachidonic
acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-intolerant
patients. Am J Resp Crit Care Med 2000; 161: 391-398.
27.Gadde J. Clinical experience with penicillin skin testing in a large inner-city STD
clinic. Journal of the American Medical Association 1993; 270: 2456-2463.
28.CDC National Center for Health Statistics. Vital and Health Statistics Series 1996. 13
(134).
29.Neugut AL, Ghatak AT, Miller RL. Anaphylaxis in the United States: An investigation
into its epidemiology. Arch of Inter Med 2001; 61 (1): 15-21.
184
7.0. Food hypersensitivity - ICD 10; L 23.6; L 25.4; L 27.2; T 78.0
7.1.
Definition
Similar to drug hypersensitivity, food hypersensitivity is defined as an occurrence of
objective and reproducible symptoms and/or signs initiated by exposure to food tolerated
by other subjects. When immunologic mechanisms are demonstrated, the appropriate
term is food allergy. Food allergy, depending upon underlying mechanism, may be IgEmediated and Non-IgE-mediated. All other reactions, previously sometimes referred to as
“food intolerance”, should be referred to as nonallergic food hypersensitivity.
7.2.
Pathogenesis
Everyday consumed food includes a number of allergens which may cause allergic
reactions in sensitized subjects. The allergenicity of the consumed food may change in the
process of its preparing, as well as in the process of its digestion in the GI tract. Allergic
reactions in sensitized subjects may occur following the consumption of certain food; in
some cases as little as one five-thousandth of a teaspoon of an allergenic food can cause
death. Reactions can also occur simply by touching or inhaling a food allergen. The most
important products that may cause allergic reaction in sensitized subjects include cow
milk, egg, soy, fish, shellfish, wheat, peanut, and tree nut.
Everyday consumed food also includes numerous substances which may cause nonallergic
hypersensitive reactions in some individuals. These reactions may be caused by high
histamine content of certain food or by nonspecific histamine release (e.g. tuna, mackerel,
strawberry, and citrus). The other mechanism of nonallergic reactions to food is an enzyme
deficit, such as hypersensitivity to cow milk in the subjects with lactase deficit. Reactions
of hypersensitivity to food may also be caused by a number of food additives, such as
benzoate, glutamates, sulfites, tartrazine, etc.
The underlying mechanisms of the allergic and nonallergic reactions to food are shown
in Table 19.
Allergic reactions
Clinical manifestations
IgE-mediated
IgG/IgM-mediated
IgA-mediated
Cell mediated
Anaphylactic shock, urticaria/angioedema,
atopic dermatitis, asthma, dyspepsia, diarrhea
Serum sickness, vasculitis
Gluten enteropathy
Contact dermatitis
Nonallergic reactions
Mediators release
Clinical manifestations
Anaphylactic shock,
urticaria/angioedema
Diarrhea,
syndrome of malabsorption
Enzyme deficits (lactase, galactocinase,
uridyl transferase)
Table 19. Mechanisms of food hypersensitivity
185
7.3. Clinical manifestations
Skin manifestations are the most frequent reactions of food hypersensitivity (about half
of the cases), followed by respiratory and gastrointestinal manifestations (about 20%)
and cardiovascular disturbances (10-15%).The skin reactions involve a maculopapular
exanthema, urticaria, angioedema, atopic dermatitis, and contact dermatitis. The respiratory
manifestations include rhinitis symptoms and asthma attacks, whereas the GI affection
may be manifested by dyspepsia and/or diarrhea. The life-threatening anaphylactic shock
is the most serious manifestation of food allergy. A case of anaphylactic shock in a school
child following the consumption of sesame was published in our literature, as well. The
risk of anaphylactic shock in the subjects with food allergy, if they consume the food
to which they are sensitized, is estimated to 40-50%. Every food allergy reaction has
the possibility of developing into a life-threatening and potentially fatal anaphylactic
reaction. This can occur within minutes of exposure to an allergen.
Special consideration is the cross-reactivity between food and air allergens (i.e. pollenfood syndromes). Subjects suffering from pollinosis often display adverse reactions after
ingestion of a wide variety of plant-derived foods as a consequence of IgE cross-reactive
structures shared by pollen and food allergen sources. There are a number of documented
pollen-food syndromes, such as birch-apple syndrome, birch-carrot syndrome, mugwortpeach association, goosefoot-fruit association, plantain – melon association, ragweedmelon-banana association, etc.
The natural course of food allergy is of special importance since its frequency is higher
in children than in adults. The outcome of food allergy in childhood is variable. Egg and
cow’s milk allergy usually resolve early in life, while peanut and tree nut, along with fish
and shellfish, are often considered to be lifelong allergies.
7.4. Diagnosis
The diagnostic modalities currently available to clinicians for the diagnosis of food
allergy include clinical history, physical examination, SPT, specific IgE assays, and oral
food challenge (OFC).
7.4.1. Clinical history
Clinical history includes symptomatology, chronology of the symptoms (previous
consumption, delay between the last consumption and onset of the symptoms, effect of
stopping consumption), and allergic background of the affected subject (personal and
family history of food allergy or other allergic diseases).
7.4.2. Oral food challenge (OFC)
At present, the double-blind placebo-controlled food challenge (DBPCFC) represents
the only way to establish or rule out an allergy to food in older children and adults,
186
whereas an open challenge controlled by trained personnel is sufficient in infants and
young children.
The clinical history is important when making the diagnosis of food allergy, but its
relation to OFC may not be optimal. In general, studies that make use of the OFC to
establish a diagnosis of food allergy reveal that a comprehensive clinical history may only
be validated in less than 50% of patients. The reasons for negative OFC in the face of a
suggestive history include confusing histories, misidentification of food in the history,
and non-allergic causes of symptoms.
On the other hand, the challenge procedure is not fully developed and no standardized
procedure has so far been agreed upon.
7.4.3. Skin prick tests
Results of the skin prick tests are of limited value in the diagnosis of food allergy due to
the high prevalence of false positive and negative results. There is a general consensus
that negative SPT or negative specific IgE to some foods (egg, milk, and peanut), in the
presence of negative history, have a high negative predictive value. However, no negative
predicted value is sufficiently high if it does not reach 100%, and any discrepancy between
a positive history and negative SPT or specific IgE must be adjudicated by an OFC.
7.4.4. Laboratory tests
In vitro tests, such as measurement of specific IgE, circulating immune complexes and
complement, are not sufficient in the diagnosis of food allergy due to reasons mentioned
above.
7.5.
Prevention
The primary prevention measures in infancy include exclusively breast-feeding in the
first 4-6 months and avoidance of the potent food allergens, such as egg or fish, in the first
year.
Secondary prevention includes avoidance of the known food the subject is sensitized
to. Use of oral disodium cromoglycate is indicated as sufficient preventive measure by
some authors. Some authors indicated that treatment with humanized anti-IgE antibodies
may protect at least a subset of patients by increasing their threshold dose for allergenic
responses. Consumption of hypoallergenic foods (e.g. hypoallergenic milk) may also
help in the prevention of allergic reactions to food.
A couple of case reports and a few studies on a limited number of patients suggested
that specific oral tolerance can be induced by oral administration of the offending food,
starting with very low dosages, gradually increasing the daily dosage up to an amount
187
equivalent to a usually relevant dose for daily intake. However, the body of scientific
evidence concerning specific oral tolerance induction (SOTI) is still rather poor and
SOTI is not recommended for daily practice. The efficacy of anti-IgE antibodies or pollen
immunotherapy as preventive measures for food allergy is still unknown.
Treatment of the allergic reaction to food is based on the principles of the treatment of
the certain type of reaction (urticaria, bronchospasm, anaphylactic shock) in the event of
accidental ingestion.
7.6.
Epidemiological studies of food hypersensitivity
Results from the published studies indicate the food allergy as a cause of considerable
morbidity and mortality in the USA and in the West European countries.
It is estimated that approximately 2.5% of the US population have food allergies, which
translates to approximately 6 to 7 million Americans, the majority being children. Food
allergy prevalence in the USA has increased 55% in the last five years. Anaphylaxis
is estimated to cause about 2,500 emergency room visits annually and believed to be
responsible for up to 125 deaths each year. Eight foods (peanut, tree nut, milk, egg, soy,
wheat flour, fish and shellfish) account for 90% of total food allergies in the USA, although
any food has the potential to cause an allergic reaction. Peanut and tree nuts account for
92% of severe and fatal reactions.
The prevalence of food allergy in the French general population is estimated to 3.5%,
being more frequent among children. Fish, egg, soy, and cow milk are most important
in the allergic adults, whereas the reactions to cow milk, peanut, egg, and fish are most
frequent in the allergic children.
The German study indicated prevalence of food allergy in Berlin general population
sample of 3.6%, being more frequent in females (60.6%) than in males (39.4%). The
prevalence of IgE-mediated and non-IgE-mediated food allergy was found to be 2.5%
and 1.1%, respectively.
The prevalence of food allergy in the UK and Scandinavian countries is estimated to
approximately 5% in children and 2% in adults.
Anaphylaxis due to food allergy is estimated to cause about 200 deaths each year in the
West European countries.
7.7.
Results of our study of food hypersensitivity in R. Macedonia
The present study represents the first epidemiologic observation of food hypersensitivity
in R. Macedonia. Evaluation of examined adults and children included completion of a
questionnaire.
Food hypersensitivity was reported by 4.2% of all examined subjects (Figure 162).
188
Figure 162. Prevalence of food hypersensitivity in all examined subjects
The prevalence of food hypersensitivity in all examined subjects was significantly higher
in females than in males (5.1% vs. 2.3%, P < 0.05) that is comparable to data from the
published studies (Figure 163).
Figure 163. Sex distribution of food hypersensitivity in all examined subjects
7.7.1. Prevalence of food hypersensitivity in certain centers
The highest prevalence of food hypersensitivity was reported by examined subjects in
Dojran (8.9%). There was no reported any case of food hypersensitivity by examined
subjects in Ohrid (Figure 164).
189
Figure 164. Prevalence of food hypersensitivity among examined subjects in certain centers
7.7.2. Prevalence of food hypersensitivity in adults
Prevalence of food hypersensitivity in adults was 3.3%. The difference in the food
hypersensitivity prevalence between males and females was statistically significant (1.8%
vs. 4.3%, P < 0.05) (Figure 165).
Figure 165. Prevalence of food hypersensitivity in examined adults
The highest prevalence of food hypersensitivity in examined adults was registered in the
age group 21-30, and the lowest one was reported by the subjects aged over 60 (Figure
166).
190
Figure 166. Age distribution of food hypersensitivity in examined adults
The highest prevalence of food hypersensitivity was registered among examined adults
in Prilep (7.6%). There was no reported food hypersensitivity among examined adults in
Ohrid (Figure 167).
Figure 167. Prevalence of food hypersensitivity among examined adults in certain centers
7.7.3. Prevalence of food hypersensitivity in children
Prevalence of food hypersensitivity in examined children was 5.0%. As in the examined
adults, the difference in its prevalence between boys and girls was significant (6.8% vs.
3.1%, P < 0.05) (Figure 168).
191
Figure 168. Prevalence of food hypersensitivity in examined children
The prevalence of food hypersensitivity was significantly higher in the examined children
aged less than 7 years than in the examined children aged over 7 years (9.0% vs. 4.4%,
P < 0.05) (Figure 169).
Figure 169. Age distribution of food hypersensitivity in examined children
The highest prevalence of food hypersensitivity among examined children was registered
in Dojran (11.5%). There was no reported food hypersensitivity among examined children
in Ohrid (Figure 170).
192
Figure 170. Prevalence of food hypersensitivity among examined children in certain centers
7.7.4. Most frequent clinical manifestations
The most frequent clinical manifestations of food hypersensitivity in both adults and
children were skin changes. The skin manifestations following consumption of certain
food were reported by approximately 50% of the subjects with food hypersensitivity
(Figure 171).
Figure 171. Skin manifestations of food hypersensitivity in adults and children
There was a significant association between food and drug hypersensitivity in the
examined adults. History of drug hypersensitivity was reported by 56.3% of the adults
who experienced reaction of food hypersensitivity (Figure 172).
193
Figure 172. Prevalence of adults with food hypersensitivity
accompanied by drug hypersensitivity
There was no positive association between food hypersensitivity in the examined adults
and any other endogenous and exogenous factor.
Significant relation of food hypersensitivity in the examined children was registered with
positive family history of allergic diseases. Food hypersensitivity was reported by 20.0%
of children with positive family history of allergic diseases and by only 3.1% of children
with no allergic diseases in their blood relatives (P < 0.001) (Figure 173).
Figure 173. Prevalence of food hypersensitivity in children with positive
and negative history of allergic diseases
There was no positive association between food hypersensitivity in the examined adults
and any other endogenous and exogenous factor.
194
7.8. Conclusions
1. Prevalence of reported food hypersensitivity in examined subjects was 4.2% which
meant over 80,000 subjects in R. Macedonia that experienced an adverse reaction to
food. As in the other allergic diseases, the higher prevalence of food hypersensitivity
was registered in females than in males.
2. Prevalence of food hypersensitivity was higher among children than among adults.
The higher prevalence was registered in the age group 0-7 years and the lowest
prevalence of food hypersensitivity was reported by subjects aged over 60 years.
3. The highest prevalence of food hypersensitivity was registered among examined
adults in Prilep and among examined children in Dojran.
4. Skin manifestations were the most frequent clinical manifestations in both adults
and children, occuring in approximately half of the subjects with reported food
hypersensitivity.
5. Food hypersensitivity was closely related to the allergic background of examined
subjects, being significantly associated with drug hypersensitivity in examined adults
and with positive family history of allergic diseases in examined children.
7.9.
References:
1. Johanson SGO, Hourihane JO’B, Bousquet J, et al. A revised nomenclature for allergy.
Allergy 2001; 56 (9): 813-824.
2. Sampson HA. Food allergy. J Allergy Clin Immunol 2003; 111: 540-547.
3. Sampson HA. Clinical manifestations of adverse food reactions. Pediatr Allergy
Immunol 1995; 6 (8): 29-37.
4. The UCB Institute of Allergy. Allergies. c/o UCB Center 1999; 40-45.
5. Crespo JF, Rodriquez J. Food allergy in adulthood. Allergy 2003; 58(2): 114-120.
6. Eigenmann PA. Future therapeutic options in food allergy. Allergy 2003; 58 (12):
1217-1221.
7. Kagan RS. Food allergy: an overview. Environ Health Perspect 2003; 111: 223-226.
8. Host A. Adverse reactions to foods: Epidemiology and risk factors. Pediatr Allergy
Immunol 1995; 6 (8): 20-28.
9. Host A, Andrae S, Charkin S, et al. Allergy testing in children: why, who, when and
how? Allergy 2003; 58(7): 559-569.
10.Mills ENC, Valovirta E, Madsen C, et al. Information provision for allergic consumers
– where are we going with food allergy labelling? Allergy 2004; 59: 1262-1267.
11.Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova N.
Alergiski bolesti – lekuvanje [Allergic diseases – Management, in Macedonian].
Skopje: MEDIS-informatika 1998; 145-150.
195
12.Mileva Z, ur. Svremenno lecenie na alergicnite bolesti [Current management of
allergic diseases, in Bulgarian]. St. Zagora: Znanie EOOD 1999; 132-136.
13.Hourihane JO’B. Prevalence and severity of food allergy – need to control. Allergy
1998; 53: 84-88.
14.Mileva Z. Hranitelna alergija. Vo: Nasev G, Mileva Z. Narcnik na obstopraktikuvastija
lekar [Food allergy. In: Nasev G, Mileva Z. Manual for the general practitioner,
in Bulgarian]. Sofija: Znanie EOOD 2003; 481-483.
15.Food Allergy Guideline. Available from: http://www.windhamsd.org/allergy.htm.
16.Niggemann B, Staden U, Rolinck-Werninghaus C, Beyer K. Specific oral tolerance
induction in food allergy. Allergy 2006; 61: 808-811.
17.American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy
Report: Science Based Findings on the Diagnosis and Treatment of Allergic Disorders
1996-2001.
18.Neugut AL, Ghatak AT, Miller RL. Anaphylaxis in the United States: An investigation
into its epidemiology. Archives of Internal Medicine 2001; 61 (1): 15-21.
19.Sicherer SH, Munoz-Furlong A, Burks AW, et al. Prevalence of peanut and tree nut
allergy in the US determined by a random digit dial telephone survey. J Allergy Clin
Immunol 1999; 103: 559-562.
20.Schäfer T, Böhler E, Ruhdorfer S, et al. Epidemiology of food allergy/food intolerance
in adults: associations with other manifestations of atopy. Allergy 2001; 56: 11721179.
21.Staevska M. New perspectives in treating food allergy. EAACI Newsletter 2004; 4:
12-15.
22.Young E, Stoneham MD, Petruckevitch A, et al.: A population study of food intolerance.
Lancet 1994; 343: 1127-1130.
23.Niestijl Jansen JJ, Kardinaal AFM, Huijbers GH, et al.: Prevalence of food allergy
and intolerance in the adult Dutch population, J Allergy Clin Immunol 1994; 93: 446456.
24.Kanny G, Moneret-Vautrin DA, Flabbee J, et al.: Population study of food allergy in
France. J Allergy Clin Immunol 2001; 108: 133-140.
25.Zuberbier T, Edenharter G, Worm M, et al. Prevalence of adverse reactions to food in
Germany – a population study. Allergy 2004; 59: 338-345.
26.Badzakova G: Anafilakticna reakcija na hrana - prikaz na slucaj [Anaphylactic
reaction to food – a case report, in Macedonian]. Mak Med Pregled 1996; 50: 9699.
27.Wütrich B. Highlights in food allergy. Monogr Allergy. Basel: Karger, 1996: 1-254.
196
8.0.
Insect sting allergy - ICD 10 (T 63.4 X 23)
8.1.
Definition and classification
Insect allergy can be categorized into the following main subtypes: stinging and
biting insect allergy (Hymenoptera, fleas, horseflies, etc.) and inhalant insect allergy
(cockroaches). Mosquitoes fit into both categories. Not only allergic reactions can be
expected with insect stings or bites, but toxic reactions are quite common too and many
infectious diseases are transmitted by insects as well.
Allergic reactions caused by Hymenoptera sting are the most important subtype of the
insect stinging allergy due to their frequency and severity. Biting insect allergy, i.e.
allergic reactions which occur in the subjects sensitized to salivary proteins of the insects
that bit, such as fleas, horseflies, and mosquitoes, are characterized by lower frequency
(commonly occur in children) and severity (commonly limited to skin reactions).
Respiratory allergies may occur in individuals sensitized to inhalant particles of
cockroaches (inhalant insect allergy). The prevalence of sensitization to cockroach in the
subjects with asthma in the USA is estimated to approximately 40%. The results of the
actual study indicated the prevalence of cockroach sensitization in 10% of the subjects
with asthma.
8.2. Insects from Hymenoptera order and allergens from
Hymenoptera venoms.
The order Hymenoptera includes the Apids, or bees, and the Vespids, represented by
wasps and hornets. The most important species in R. Macedonia include the Honeybee
(Apis mellifera), the Common wasp (Vespula spp.), the Paper wasp (Polites spp.), and the
Hornet (Vespa spp.) (Figure 174).
A.
B.
C.
Figure 174.
A. Honeybee (Apis mellifera), B. Wasp (Vespula spp.), and C. Hornet (Vespa spp.)
Adapted from: Insect Venom Allergy. Available at: www.intelihealth.com
197
Honeybees, the most common of these stinging insects, are not aggressive unless
provoked. They can be easily recognized by their hairy bodies and bright yellow or black
markings. The honeybees are typically found around flowers or clover. Once they sting,
they die. They often leave their stinger behind. Wasps are hairless with narrow “waists”
that separate their chests from their long, slim, lower bodies. They can be black, brown or
red. Wasps build nests in the caves of buildings and under rafters. They sting repeatedly.
Hornets have short black bodies with yellow or white markings. They nest in trees or
bushes and sting repeatedly.
Venoms from these insects contain several vasoactive substances, which are hemolytic
and neurotoxic. They are also highly potent sensitizing agents which may cause mild to
life-threatening allergic reactions in the sensitized subjects. Hymenoptera venoms were
defined in the late 1980s. Honeybee and wasp venom are different, while wasp and hornet
venom are similar by their allergens content. The honeybee venom includes melitine and
fosfolipase 2, and the antigen 5 is the major wasp venom allergen (Figure 175). Wasp
venom may cross-react with hornet venom, while the cross-reactivity between honeybee
and wasp venom is quite weak.
Figure 175. Tertiary structure of the wasp venom antigen 5
Adapted from Brusic V, Petrovsky N, Gendel SM, et al. Computational tools
for the study of allergens. Allergy 2003; 58: 1083-1092.
The subjects stung by a Hymenoptera insect are exposed to large quantities (i.e.
several micrograms) of the major allergens per sting, an amount similar to the
annual dose of inhaled pollen allergen. This is probably the reason for almost the same
prevalence of atopy among patients with IgE sensitization to Hymenoptera venoms as in
the normal population. There is a different multisystem response pattern when a subject
is exposed to very high allergen dosage via mucosal membrane , as by food and drugs,
or by inoculation, as by Hymenoptera venoms and drugs. Moreover, subjects with a less
obvious tendency to mount an IgE antibody response will do this after a large dose of
allergen stimulation.
198
8.3. Clinical manifestations
Manifestations in the stung individual include a local reaction with pain, swelling (up to
1 cm diameter), and redness confined at the sting site that usually resolves in a few hours.
The clinical reaction in the allergic individual covers a wide range of symptoms, often
starting locally and sometimes developing into a general reaction.
8.3.1. Local allergic reactions
Local allergic reactions include intense redness, swelling spanning two joints, itching and
pain; these reactions occur within minutes and last for more than 24 hours (Figure 176).
Figure 176. Local reactions due to wasp sting
Adapted from: Ewan PW. Venom allergy.
Available at: http://bmj.bmjjournals.com/cgi/
8.3.2. Systemic allergic reactions
Such a reaction is characterized by hives, itching, and swelling in areas other than the
sting site, difficulty in breathing, dizziness or a sharp drop in blood pressure, nausea,
cramps or diarrhea, unconsciousness and cardiac arrest.
According to Müller the severe allergic reactions to Hymenoptera venoms are classified
in four stadiums:
I.
II.
II.
Large local reaction at the sting site;
Large local reaction associated with generalized skin reaction;
Generalized skin reaction associated with affection of other systems (laryngeal edema, asthma attack and/or abdominal pain);
IV. Shock associated with loss of consciousness.
199
8.3.3. Course and prognosis
A substantial proportion of patients (20-80% in different studies) with a history of a
generalized reaction to a sting have no such reaction to a subsequent sting. Less or more
severe generalized reactions may also occur. However, the course can be variable, a series
of stings may result in a generalized reaction, no reaction, and then another generalized
reaction. Children do particularly well, one study showed that 95% of those with a
history of mild generalized reactions had no reaction to a re-sting. The next sting will
not necessarily cause a more severe reaction, but patients in accident and emergency
departments are often told that it will.
Reasons for the variable outcome are not well understood but include the interval from
the last sting (the longer the interval the lower the risk of another generalized reaction),
the patient’s immune response at the time of the sting (this will change with time), the
dose of venom injected, and the site of the sting.
8.4. Diagnosis
The diagnosis of insect sting allergy rests on the history, because positive test results can
occur in persons who do not react to insect stings. Positive in vivo and/or in vitro tests are
used to confirm the presence of allergy in a patient who has reacted to an insect sting and
to identify the specific insect to which the patient is allergic.
There is no correlation between the severity of the insect sting reaction and the level of
specific IgE. In fact, the strongest reactions on skin tests often occur in patients who have
had only large local reactions to insect stings and have a low risk of anaphylaxis, whereas
weak sensitivity on skin or laboratory test may be demonstrated in some patients who
have experienced life-threatening anaphylactic shock.
8.5. Prevention
Preventive measures regarding re-sting include:
•
•
•
•
•
•
•
•
•
To avoid wearing sandals or walking barefoot in the grass;
To avoid wearing bright-colored clothing;
To avoid sweet-smelling perfumes, hair sprays, colognes and deodorants;
Not to drink from open beverage cans since the stinging insects may crawl inside a
can attracted by the sweet beverage;
To keep food covered at all times when eating outdoors;
To avoid insects nests since the stinging insects are most dangerous in the vicinity
of their nests;
Yard work and gardening should be done with caution;
To keep doors and windows of the house and car shut as much as possible;
To keep prescribed medications handy at all times and to follow the attached
instructions in the case of re-sting. These medications are for immediate emergency
use while en route to a hospital emergency room for observation and further
treatment.
200
8.6.
Treatment
The treatment depends on the severity of the reaction. The local reaction should
subside uneventfully over 48 hours, but on occasion will require the application of ice
or a cold compress, elevation of affected arm or leg, antihistamines, and, rarely, oral
corticosteroids.
The mild and moderate systemic reactions should be treated by oral or parenteral
antihistamines and corticosteroids. Severe systemic reaction requires parenteral
administration of adrenaline (epinephrine), antihistamines, and corticosteroids. In
some cases, further therapy with intravenous fluids, oxygen and medications will be
necessary. With the potential for repeated reactions hovering menacingly overhead prevention
is paramount. Epinephrine kits are available by prescription for self-administering
epinephrine immediately after a second sting. Using this as directed will delay a reaction
that otherwise may have progressed. ASIT is the treatment of choice for children with a
history of anaphylaxis and adults with hives or anaphylaxis following a sting.
8.7.
Specific immunotherapy
ASIT towards insect sting allergy has been available since the pioneer works of Hunt
et al. 1978. These studies demonstrated an almost complete protection by treatment
with specific insect venom in contrast to earlier studies using whole body extract which
turned out to be equivalent to placebo. Since then many therapy modalities have been
developed.
In double-blind, placebo controlled clinical studies, venom immunotherapy has been
shown to be 97% effective in eliminating a reoccurrence of a systemic reaction to an
insect re-sting. Numerous other studies evaluating the frequency of anaphylaxis after resting in immunotherapy treated patients and in untreated patients confirm these results.
The venom immunotherapy is recommended in subjects with history of Müller III and
IV reaction associated with positive SPT or in vitro tests to venom allergens. Injections
of gradually increasing concentrations of venom are given on a weekly basis for 6-8
weeks to confer immunity. Maintenance injections of full-strength venom are then given
every 4-6 weeks. Clinical improvement (i.e. protection of the re-sting) occurs earlier than
serologic improvement. The prevalence of the systemic adverse effects is approximately
10%.
In the Appendices 10 and 11 the protocols for rush and conventional venom immunotherapy
according to Döring et al., by which over 600 subjects with systemic reaction was
201
successfully desensitized, are presented.
8.8.
Epidemiological studies of insect sting allergy
The published data indicate the prevalence of Hymenoptera venom allergy of 9%-13%.
As many as two million people in the USA are allergic to the venom of stinging insects.
Many of these individuals are at risk for life-threatening anaphylactic reactions, resulting
in curtailment of outdoor activities. More than 500,000 people enter hospital emergency
rooms every year suffering from insect stings. Mortality attributed to these stings is
estimated to 50 deaths per year. Data from the UK suggest an annual average of four
deaths from bee or wasp stings, but this is almost certainly an underestimate because
venom anaphylaxis is not always recognized as the cause of death.
Insect sting allergy can occur in persons of any age, especially after multiple stings. Systemic
reactions to insect stings are estimated to occur in 3% of adults, while approximately 1%
of children have a medical history of severe sting reactions. Large local reactions are
more common than systemic reactions and are mediated by IgE in up to 85% of cases. IgE
antibodies to Hymenoptera venom, measured by SPT or in vitro test, are present in 20 to
30% of normal adults who had an insect sting in the previous two to three years.
8.9. Results of our study of insect sting allergy in R. Macedonia
There has been no epidemiological observation of insect sting allergy in R. Macedonia
previous to this study. The diagnosis of insect sting allergy in adults and children was
questionnaire-based.
Insect sting allergy was reported by 3.1% of all examined subjects indicating over 60,000
subjects in R. Macedonia with reaction following the Hymenoptera insect sting (Figure
177).
Figure 177. Prevalence of insect sting allergy in all examined subjects
8.9.1. Prevalence of insect sting allergy in adults
202
Insect sting allergy was reported by 2.5% of examined adults. Its prevalence was
significantly higher in women than in men (3.8% vs. 1.1%, P < 0.05) (Figure 178).
Figure 178. Prevalence of insect sting allergy in examined adults
The highest prevalence of insect sting allergy was registered in the age group 41-50
(3.2%), and the lowest one in the age group over 60 years (1.7%) (Figure 179).
Figure 179. Age distribution of insect sting allergy in examined adults
8.9.1.1. Prevalence of insect sting allergy in certain centers
The highest prevalence of insect sting allergy was registered among examined adults in
Dojran (8.5%). No reaction after Hymenoptera insects sting was reported by examined
adults in Ohrid and Prilep (Figure 180).
203
Figure 180. Prevalence of insect sting allergy among examined adults in certain centers
8.9.2. Prevalence of insect sting allergy in children
Insect sting allergy was reported by 3.8% of examined children. Its prevalence was not
significantly higher in girls than in boys (4.4% vs. 3.1%) (Figure 181).
Figure 181. Prevalence of insect sting allergy in examined children
Non-significantly higher prevalence of insect sting allergy was registered in children
aged over 7 years (Figure 182).
Figure 182. Age distribution of insect sting allergy in examined children
204
8.9.2.1. Prevalence of insect sting allergy in certain centers
The highest prevalence of insect sting allergy was registered among children in Dojran
(9.1%), while among examined children in Ohrid insect sting allergy was not reported
(Figure 183).
Figure 183. Prevalence of insect sting allergy among children in certain centers
8.9.3. Clinical manifestations of insect sting allergy
Systemic allergic reactions following the insect sting were reported more frequently by
examined adults with insect sting allergy that can be compared with the published data.
The prevalence of skin and systemic reactions among allergic adults was 24.7% and
75.3%, respectively. In the allergic children local reactions following the insect sting
were reported by 45.5%, while the prevalence of systemic reactions was 54.5% (Figure
184).
Figure 184. Prevalence of skin and systemic reactions in the subjects with insect sting allergy
205
8.9.4. Association between insect sting allergy and other allergic diseases
Association between insect sting allergy and positive family history of insect sting
allergy was not significant in both adults and children with reported allergic reaction to
Hymenoptera venom.
In allergic adults significant association was registered between insect sting allergy
and food hypersensitivity. Insect sting allergy was reported by 22.2% of the adults who
experienced food hypersensitivity reaction and by only 2.2% of the adults who had no
such reaction (P < 0.05) (Figure 185). Association between insect sting allergy in examined
adults with family history of allergic diseases and atopy was statistically non-significant.
Figure 185. Prevalence of the subjects with insect sting allergy
with and without food hypersensitivity
On the contrary, insect sting allergy in examined children was significantly associated with
positive family history of allergic diseases (Figure 186). Association between insect sting
allergy and other allergic diseases in examined children was not statistically significant.
Figure 186. Prevalence of insect sting allergy in children with positive
and negative family history of allergic diseases
206
8.10.
Conclusions
1. The prevalence of insect sting allergy in all examined adults was 3.1%, being more
frequent in females (3.9%) than in males (1.9%).
2. The prevalence of insect sting allergy in examined adults was 2.5%, being significantly
higher in women (3.8%) than in men (1.1%).
3. The prevalence of insect sting allergy in examined children was 3.8%, being more
frequent in girls (4.4%) than in boys (3.1%).
4. The high prevalence of Hymenoptera insects sting allergy among examined subjects
in Dojran may be due to higher exposure to these insects in the area characterized
by warm climate. On the other hand, the prevalence of insect sting allergy may be
overreported or underreported (e.g. no reported insect sting allergy among examined
subjects in Ohrid) that can not be excluded in the questionnaire-based studies.
5. Systemic reactions following the Hymenoptera insect sting were more frequent in
allergic adults than in allergic children.
6. There was no positive association between insect sting allergy and positive family
history of insect sting allergy in both adults and children.
7. Insect sting allergy in examined adults was significantly related to food hypersensitivity.
Association with other endogenous and exogenous factors was not significant.
8. Insect sting allergy in examined children was closely related to positive family history
of allergic diseases. There was no positive association between insect sting allergy in
examined children and other endogenous and exogenous factors.
8.11. References:
1. Golden DB. Stinging Insect Allergy. Am Fam Physician 2003; 67: 2541-2546.
2. Insect Venom Allergy. Available at: www.intelihealth.com.
3. Johansson SGO, Hourihane JO’B, Bousquet J et al. A revised nomenclature for allergy.
Allergy 2001; 56 (9): 813-824.
4. Ewan PW. Venom allergy. Available at: http://bmj.bmjjournals.com/cgi/.
5. Müller UR. New development in the diagnosis and treatment of Hymenoptera venom
allergy. Int Arch Allergy Immunol 2001; 124: 447-453.
6. Brusic V., Petrovsky N., Gendej SM. et al. Computational tools for the study of allergy.
Allergy 2003; 58: 1083-1092.
7. Döring HF, Ilgner M, Tüttenberg HW. Insektengifthyposensibilisierung beim
niedergelassenen Dermatologen – Rückblick auf die Erfahrungen von vierzehn
Jahren. Der Deutsche Dermatologe 1994; 42 (9).
8. Cvetanov V, Trandafilovski P, Karadzinska-Bislimovska J, Balabanova M, Ezova N.
Alergiski bolesti-lekuvanje [Allergic diseases – Management, in Macedonian].
Skopje: MEDIS-informatika 1998; 163-173.
9. Mileva Z, ed. Svremenno lecenie na alergicnite bolesti [Current management of
allergic diseases, in Bulgarian]. St. Zagora: Znanie EOOD 1999; 142-148.
10.Gavrilovski M, Dokic D. Imunoterapija [Immunotherapy, in Macedonian]. Skopje:
EDIT 1992; 20-30.
207
11.Wenzel J, Meissner-Kraemer M, Bauer R et al. Safety of rush insect venom
immunotherapy. The results of a retrospective study in 178 patients. Allergy 2003; 58
(11): 1176-1180.
12.American Academy of Allergy, Asthma and Immunology (AAAAI). The Allergy
Report: Science Based Findings on the Diagnosis & Treatment of Allergic Disorders
1996-2001.
13.CDC. Fact Stats A-Z, Vital and Health Statistics, Series 10, No 13, 1999. Available
from: http://www.cdc.gov/nchs/fastats/allergies.htm.
14.Neugut AL, Ghatak AT, Miller RL. Anaphylaxis in the United States: An investigations
into its epidemiology. Arch Inter Med 2001; 61(1): 15-21.
15.AAAAI Board of Directors: Anaphylaxis in schools and other childcare settings. J
Allergy Clin Immunol 1998; 102 (2): 173-176.
16.Mileva Z. Alergija km insekti. Vo: Nasev G, Mileva Z. Narcnik na obstopraktikuvastija
lekar [Insect allergy. In: Nasev G, Mileva Z. Manual for the general practitioner,
in Bulgarian]. Sofija: Znanie EOOD 2003; 483-485.
17.Cvetanov V, Milkovska S, Risteska-Kuc S, et al. Epidemioloski karakteristiki na
alergiskite bolesti vo R. Makedonija [Epidemiological characteristics of allergic
diseases in R. Macedonia, in Macedonian]. Mak Med Pregled 2003; 56: 140-141.
208
Part IV
Economic burden of
certain allergic diseases
in R. Macedonia
210
1.0.
Economic burden of allergic rhinitis and asthma
At the turn of the new millenium, allergic diseases represent considerable cause of
morbidity and mortality and a further increase in morbidity is expected in the future.
Substantial limitations to the patients’ well being and quality of life, as well as the financial
impact of allergic diseases on the society are considered to be significant.
A number of studies were performed to quantify the cost attributed to allergic diseases.
The burden associated with allergic diseases include both direct and indirect costs. Direct
costs comprise the costs of hospitalization, rehabilitation and drugs, physician visits and
diagnostic tests. Indirect costs involve the adverse effect of allergic diseases at personal
and society level, i.e. the effect of the disease on life and work activities.
1.1.
Allergic rhinitis (AR)
AR is extremely common condition, affecting approximately 20% of the population.
While it is not a life-threatening condition, complication can occur and the disease can
significantly impair quality of life, which leads to a number of direct and indirect costs.
The total direct and indirect cost of AR in the USA was estimated to be $ 2.7 billion in
1995. It is estimated that in 1995 there was 10 millions lost work and school days and 28
million days with reduced work and school activities. This expenditure underestimated
the true economic burden associated with AR since the costs due to the accompanying
diseases, such as sinusitis and asthma, were not included. The total direct and indirect
costs attributed to AR were estimated to be $ 5.3 billion in 1996. According to the public
health experts the doubled cost was due to the increase of the indirect costs, especially to
the extensive use of systemic antihistamines which may seriously affect psychomotor and
cognitive functions. Due to this, some allergologists indicated the ASIT as a more eligible
AR treatment modality.
1.1.1. Seasonal allergic rhinitis in R. Macedonia
Although seasonal allergic rhinitis (SAR) is the most frequent allergic disease in R.
Macedonia there is no evidence about the economic burden attributed to this condition.
Table 20. and Table 21. show the direct costs associated with medical treatment of SAR
in adults and in children aged 4-12 years. The monthly costs were calculated taking into
account the costs of the medications registered in R. Macedonia following the treatment
modalities recommended by the Allergic Rhinitis and its Impact on Asthma guidelines.
211
SAR
Treatment modality
Monthly cost
Mild
Tablets Cetirizin
300,00 MKD (5 €)
Moderate / severe
Spay Fluticasone 50 mcg
+
Tablets Cetirizin
1.100,00 MKD (19 €)
Table 20. Monthly costs for treatment of SAR in adults
SAR
Treatment modality
Monthly cost
Mild
Syrup Cetirizin
200,00 MKD (3,5 €)
Moderate/severe
Spray Fluticasone 50 mcg
1.000,00 MKD (17 €)
Table 21. Monthly costs for treatment of SAR in children aged 4-12 years
Data obtained suggest that monthly cost for medical treatment of SAR in adults varied
from 5 to 19 euros depending on the severity of the disease. The monthly cost for medical
treatment of SAR in children aged 4-12 varied from 3.5 to 17 euros. The monthly amount
did not include the costs for medications required in the treatment of conjunctivitis which
was often associated with AR, as well as the costs for additional medications which may
be required in the SAR treatment (e.g. short-term course of oral corticosteroids).
1.1.2. Perennial allergic rhinitis in R. Macedonia
Table 22. and Table 23. present the direct costs associated with medical treatment of PAR
in adults and in children aged 4-12. As with SAR, the monthly costs were calculated
taking into account the costs of the medications registered in R. Macedonia following
the treatment modalities recommended by the Allergic Rhinitis and its Impact on Asthma
guidelines.
212
PAR
Treatment modality
Monthly cost
Mild
Tablets Cetirizin
or
Spray Fluticasone 50 mcg
300,00 MKD (5 €)
Moderate / severe
Spray Fluticasone 50 mcg
+
Tablets Cetirizin (1,5 sk)
780,00 MKD (13 €)
1.900,00 MKD (30 €)
Table 22. Monthly costs for treatment of PAR in adults
PAR
Treatment modality
Monthly cost
Mild
Syrup Cetirizin
or
Spray Fluticasone 50 mcg
200,00 MKD (3,5 €)
or
780,00 MKD (13 €)
Moderate / severe
Spray Fluticasone 50 mcg
+
Syrup Cetirizin
1.000,00 MKD (17 €)
Table 23. Monthly costs for treatment of PAR in children aged 4-12 years
Data obtained suggest that monthly cost for medical treatment of PAR in adults varied
from 5 to 30 euros depending on the severity of the disease. The monthly cost for medical
treatment of SAR in children aged 4-12 varied from 3.5 to 17 euros. The monthly amount
did not include the costs for medications required in the treatment of accompanied
conditions, such as allergic conjunctivitis, sinusitis, and sinonasal polyposis.
1.2. Asthma
Asthma is a common life-long chronic inflammatory disease that affects adults and
children of all ages placing a considerable burden on society. As there is an evidence of
increasing asthma prevalence in some European countries, such as France and Finland,
asthma has been officially recognized by their respective public health authorities as a
priority area for action.
According to data from the European Lung White Book the total cost of asthma in the
Europpean Union countries, Norway, and Switzerland in 2000 was 17.7 billion euros
(Table 24).
213
Table 24.
Type of costs
Amount (€)
Ambulatory care
Inpatient care
Drugs
3.765 millions
507 millions
3.641 millions
Lost work days
9.754 millions
Total cost
17.7 billions
Direct, indirect, and total costs attributed to asthma
in the European Union countries, Norway, and Switzerland in 2000
Adapted from European Lung White Book. European Respiratory Society Journals &
European Lung Foundation, Lausanne 2003, p. 9.
According to the WHO reports from 2000, the estimate of economic costs associated to
asthma exceeds the combination of those for tuberculosis and humman immunodeficiency
virus/acqured immune deficiency syndrome (HIV/AIDS).
Current costs attributed to asthma in the UK are estmated to approximately 1.8 billion
dollars for medical treatment and for sick leave due to the disaese. In Australia direct
and indirect costs associated with asthma are close to 460 million dollars. In the UK,
the data indicate that asthma is significant cause of absence from work, with 2.7 million
days of sickness benefit paid in 1991/1992. It seems that the lost work days attributed to
asthma exacerbations are markedly underreported as the patients present their disease as
respiratory infection afraid of the workplace loss.
The costs attributed to asthma in the USA in the late 1990s were estimated to 12.6 billion
dollars in total costs, 1.9 billion dollars in indirect morbidity costs, and 0.9 billion dollars
in indirect mortality costs. In these reports the costs of the adults and children with private
health insurance were not taken into account. Data from the USA indicate 10 million lost
school days, as well as limited physical activities in approximately 30% of the children
with asthma.
In both France and the UK, the number of prescriptions for asthma medications doubled
in the period from 1980 to 1990. In the UK the number of prescriptions for inhaled
corticosteroids was approximately 1.2 million in 1980, increasing to 7 million in 1992.
1.2.1. Asthma in R. Macedonia
As with AR, there is no evidence about economic burden of asthma in R. Macedonia.
Table 25. shows the direct costs associated with chronic treatment of asthma in adults
and children aged over 5 years. Table 26. shows the direct costs attributed to the chronic
214
treatment of asthma in children aged less than 5 years. The monthly costs were calculated
taking into account the costs of the medications registered in R. Macedonia following the
treatment modalities recommended by the GINA Updated 2004.
Asthma
Treatment modality
Monthly cost
Mild persistent
Spray Fluticasone 125 mcg
1.800,00 MKD (30 €)
Moderate persistent
Spray Fluticasone 125 mcg
+
Spray Salmeterol
5.200,00 MKD (85 €)
Severe persistent
Spray Fluticasone 125 mcg
+
Spray Salmeterol
7.000,00 MKD (110 €)
Table 25. Monthly cost for chronic treatment of asthma in adults and children aged over 5 years
Asthma
Treatment modality
Monthly cost
Mild persistent
Spray Fluticasone 50 mcg
950,00 MKD (15 €)
Moderate persistent
Spray Fluticasone 125 mcg
1800,00 MKD (30 €)
Severe persistent
Spray Fluticasone 125 mcg
+
Spray Salmeterol
5.200,00 MKD (85 €)
Table 26. Monthly cost for chronic treatment of asthma in children aged less than 5 years
Data obtained suggest that monthly cost for chronic treatment of asthma in adults and
children aged over 5 years varied from 30 to 110 euros depending on the severity of the
disease. The monthly cost for chronic treatment of asthma in children aged less than 4 years
varied from 15 to 85 euros. The monthly amount did not include the costs for medications
required in the treatment of acute exacerbations of asthma (antibiotics, bronchodialtors,
such as short-acting β2 agonists and theophyline, and systemic corticosteroids).
215
1.3.
Conclusions
1. Despite the need of estimated costs, there is no evidence of economic burden
attributable to allergic diseases in R. Macedonia.
2. The direct costs for medical treatment of SAR in adults varied from 5 to 19 euros per
month, depending on the disease severity. The direct costs for medical treatment of
SAR in children aged 4-12 varied from 3.5 to 17 euros per month.
3. The direct costs for medical treatment of PAR in adults varied from 5 to 30 euros per
month, depending on the disease severity. The direct costs for medical treatment of
PAR in children aged 4-12 varied from 3.5 to 17 euros per month.
4. The direct costs for chronic treatment of asthma in adults and children aged over 5
years varied from 30 to 110 euros per month, depending on the disease severity. The
direct costs for chronic treatment of asthma in children aged less than 5 years varied
from 15 to 85 euros per month.
Data obtained suggest considerable economic burden attributable to AR and asthma in
R. Macedonia.
1.4.
References:
1. Canonica GW. Expanding the Anti-Allergy Therapeutic Horizon. Allergy 2002; 75:
5-7.
2. Integrated care for asthma: a clinical, social, and economic evaluation. Grampian
Asthma Study of Integrated Care (GRASSIC). BMJ 1994; 308: 838-842.
3. Allergic Rhinitis and its Impact on Asthma. Allergic Rhinitis and its Impact on Asthma
Workshop Report 2001 in collaboration with the World Health Organisation.
4. International Consensus Report on the Diagnosis and Management of Rhinitis. Allergy
1994; 49 (Suppl 19) :5-34.
5. Ross RN. The costs of allergic rhinitis. Am J Managed Care 1996; 2: 285–290.
6. Cvetanov V. Bazicni principi za sproveduvanje na alergiskata specificna imunoterapija
[Basic principles for allergen-specific immunotherapy, in Macedonian].
Simposium Specific immunotherapy. Mak Med Pregled 2001; 55 (47): 15-17.
7. Schaedlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus
symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17:
37-52.
8. European Lung White Book. European Respiratory Society Journals & European
Lung Foundation, Lausanne 2003.
9. World Health Organization (WHO). Bronchial asthma. WHO Fact Sheet No 206.
http://www.who.int/inf-fs/en/fact206.html. Revised January 2000.
10.Viegi G, Annesi I, Matteelli G. Epidemiology of asthma. Eur Respir Mon 2003; 8
(23): 1-25.
11.Global Initiative for Asthma. Burden of Asthma. National Institutes of Health, National
Heart, Lung, and Blood Institute 2004; 2: 11-26.
216
12.Australian Bureau of Statistics. 1989/1990 National Health Survey: asthma and other
respiratory conditions. Australian Cat No 4373.0, 1991.
13.Action asthma: the occurrence and cost of asthma. West Sussex, United Kingdom:
Cambridge Medical Publications; 1990.
14.Action against asthma. A strategic plan for the Department of Health and Human
Services. Washington, DC: Department of Health and Human Services; 2000.
15.Karadzinska-Bislimovska J, Minov J, Risteska-Kuc S. Occupational Lung Diseases
as a Public Health Problem. In: Georgieva L, Burazeri G (ed): Health Determinants in
the Scope of New Public Health. Sofia, 2005.
16.Taylor WR, Newacheck PW. Impact of childhood asthma on health. Pediatrics 1992;
90: 657-662.
17.Fowler MG, Davenport MG, Grag R. School functioning of US children with asthma.
Pediatrics 1992; 90: 939-944.
18.Office of National Statistics. Key Health Statistics from General Practice 1996. Series
MB6, No 1. London, The Stationery Office, 1998.
19.Institute of Public Health. Common Data Set 1995. London, Dept of Health, 1996.
20.National Asthma Campaign. Where next in basic asthma research? A National Asthma
Campaign consultation on basic asthma strategy. London: Asthma Enterprises Ltd,
2001.
21.Neville RG, Pearson MG, Richards N, et al. A cost analysis on the pattern of asthma
prescribing in the UK. Eur Respir J 1999; 14: 605-609.
22.Global Initiative for Asthma. Asthma Management Program. National Institutes of
Health, National Heart, Lung, and Blood Institute 2004; 7: 93-133.
217
Part V
Appendices
219
220
Appendix 1:
Appearance and spread of some plants and their pollen grains
I. TREE POLLENS
SILVER BIRCH (Betula pendula)
Birch
Birch pollen grain
The birch is a deciduous tree of 25 - 30 m height.
It is widely spread in Europe as well as in our country. It is found along the south border
of R. Macedonia as well as in beech region.
Birch pollen grains were numerously present in the air of examined cities.
221
BEECH (Fagus sylvatica)
Beech
Beech pollen grain
The beech is a deciduous tree, up to 30 m high and a crown rich in leaves.
It is spread in Central and Western Europe. In the R. Macedonia it is present in all
mountains at the height of 800 to 2000 m above the sea level.
Beech pollen grains were registered in the air of all examined cities. These pollen grains
are characterized by their largeness (diameter 40 - 50 mcm).
222
COMMON OAK (Quercus petraea)
Oak-common
Oak pollen grain
The oak-common is a deciduous tree, 25 - 30 m high.
It is wide spread in Europe as well as in our country. It is found along the south border of
R. Macedonia as well as in beech region.
Oak pollen grains were numerously present in the air of examined cities.
223
BLACK PINE (Pinus nigra)
Pine black
Pine pollen grains
Pine black is an evergreen (periwinkle) tree, up to 40 m high. The crown in young stalk is
piramidal and later becomes egg-shaped, widely branched with a horizontal top.
It is spread in Southern Europe. In R. Macedonia it is present at the height of 1000 to 1800
m above the sea level.
Pine black pollen grains were numerously present in the air of examined cities. These
pollen grains are characterized by their air balloons.
224
JUNIPER (Juniperus sabinoides)
Juniper
Juniper pollen grain
Mountain juniper is an evergreen (periwinkle) bush or short tree, up to 6 m high.
It is particularly specific for the North America areas. It is found on limestones and rocks
in the western part of R. Macedonia.
Cypress-juniper pollen grains were numerously present in the air of examined cities.
225
II. WEED POLLENS
DOCK (SORREL) (Rumex sp.)
Dock - Sorrel
Dock pollen grain
Dock - Sorrel is one-year plant of 10 to 40 cm height.
It is widely spread plant both in the world and in our country. In R. Macedonia it is found
in all valleys.
Dock-Sorrel pollen grains were numerously present in the air of examined cities.
226
NETTLE (Urtica dioica)
Nettle
Nettle pollen grains
Nettle is many-years plant of 2 m height. It is widely spread plant both in the world and
in our country. In R. Macedonia it is present in all valleys.
Nettle pollen grains were numerously found in the air of examined cities. These pollen
grains are significantly smaller in size than others.
227
PIGWEED (Amarantus sp.)
Pigweed
Pigweed pollen grains
Pigweed is one-year plant of 30 to 130 cm height. It is widely spread plant both in the
world and in our country. In R. Macedonia it is present in all valleys.
Pigweed pollen grains were numerously found in the air of examined cities.
228
DANDELION (Taraxacum officinale)
Dandelion
Dandelion pollen grains
Dandelion is one-year plant of 10 to 40 cm height.
It is widely spread plant both in the world and in our country. It is found in all valleys in
R. Macedonia.
Dandelion pollen grains were present in the air of examined cities for a short period of
time.
229
III. GRASS POLLENS (fam. Poaceae)
Smooth-Stalked meadowgrass (Poa pratensis)
Timothy (Phleum pretense)
Poaceae pollen grain
Grasses (Fam. Poaceae) is a wide group of plants, comprising one-year and many-year
grasses.
230
Appendix 2.
Health Center Skopje
Institute of Occupational Health-WHO Collaborating
Center -Allergy Center-
No______________
Date______________
QUESTIONNAIRE FOR ALLERGIC AND RESPIRATORY SYMPTOMS IN ADULTS
Name___________________________________
Birth date_______________________________
Address:________________________________
Are you: 1. employed (where?____________)
Duration of the employment: _____________
Ethnicity:
1.
Residence
1. urban
2. rural
1. house
2. flat
2.
Heating conditions:
1. central heating
2. wood heating
3. electric heating
4. other_______
3.
Green plants:
a) indoors:
b) outdoors:
Sex:
1. male
2. female
Place of living____________________________
Tel: ___________ Education level:__________
____
2. unemployed
3. renter
Tel. (office):_____________________________
4.
Environmental air pollution:
if “no” go to question 6, if “yes”:
5.
Type of air pollutants:
1. manure 2. industrial air pollutants 3. traffic air pollutants 4. other______
6.
Pets ownership:
if “no” go to question 8, if “yes”:
7.
Which pet do you own?
1. dog
2. cat
3. parrot
8.
Do you smoke?
if you are unemployed go to question
9.
Actual workplace:________________________________________________
Duration of employment at the actual workplace:______________________
10.
Workplce hazards:
a) dust
b) high air humidity
1. no
1. no
2. yes
2. yes
1. no
2. yes
1. no
2. yes
4. other._____________
231
1. no
2. yes
1. no
1. no
2. yes
2. yes
c) high air temperature
d) other (chemical agents, ionisating radiation, etc):____________________
1. no
1. no
2. yes
2. yes
11.
Have you any nose symptom?
if “no” go to the item 22
1. no
2. yes
12.
Type of symptom:
a) nasal blockage
b) sneezing
c) itching
d) runny nose
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
1. no
2. yes
13.
At what age did nose symptoms occur __________________________________
14.
Are there seasonal occurrence of the nose symptoms (spring/summer)?
if “no” go to question 18, if “yes”:
15.
Season of the occurence of the nose symptoms (month): __________________
Duration: _________________________________________________________
16.
Do the symptoms occur year by year subsequently?
1. no
2. yes
17.
Is there worsening of the nose symptoms in the environment rich with:
a) trees
1. no
2. yes
b) grasses
1. no
2. yes
18.
Do the nose symptoms persist year-round?
1. no
2. yes
19.
Is there worsening of the symptoms by exposure to:
a) dust
1. no
2. yes
b) smoke
c) workplace air pollutants
d) other: _______________
1. no
1. no
1. no
2. yes
2. yes
2. yes
20.
Is there worsening of the symptoms by exposure to cold air?
1. no
2. yes
21.
Are the nose symptoms associated with:
a) respiratory problems
b) ocular symptoms
c) skin changes
1. no
1. no
1. no
2. yes
2. yes
2. yes
Have you any respiratory symptom?
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
22.
if “no” go to question 29, if “yes:
23.
Type of symptoms:
a) shortness of breath
b) wheezing or whistling
c) cough
d) phlegm
232
e) chest tightness
1. no
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
31.
At what age did the ocular symptoms occur?____________________________
32.
Is there seasonal occurrence (spring and/or summer) of the ocular symptoms? 1. no
2. yes
33.
Have you any skin changes?
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
24.
At what age did the respiratory symptoms occur?
25.
Have you any asthma attack?
if “no” go to question 28, if “yes”:
26.
Are the respiratory problems:
1. seasonal 2. persistent
27.
How frequent do the respiratory symptoms occur:
1. daily
2. weekly
3. monthly
4. rarely
28.
Triggers of the respiratory symptoms:
a) exercise
b) cold air
c) wind
d) other_________
29.
Have you any ocular symptom?
if “no” go to question 33, if “yes”:
30.
Type of the ocular symptoms:
a) tearing
b) redness
c) itching
d) eyelids swelling
______________________
if “no” go to question 38, if “yes”:
34.
Type of the skin changes:
a) rash
b) itching
c) angioedema
d) other_____________
35.
At what age did the skin changes occur? ________________________________
36.
Is there seasonal occurence of the skin changes?
1. no
2. yes
37.
Are the skin changes associated with:
a) food consumption:_____________
b) insect sting ___________________
1. no
1. no
2. yes
2. yes
c) workplace exposure____________
d) other________________________
1. no
1. no
2. yes
2. yes
38.
Have you any adverse reaction after drug intake, such as:
233
1. rash
2. angioedema
3. shortness of breath
4. diarrhea
5. colapse
6. other____________
by which drug the adverse reaction was caused?
39.
Do you actually use any medication?
which medication if “yes”:
40.
Have you positive family history of allergic diseases such as:
1. asthma
4. insect sting allergy
2. hay fever
5. drug allergy
1. no
3. skin changes
6. other_______
234
2. yes
Appendix 3.
Health center Skopje
Institute of Occupational health-WHO Collaborating Center
-Allergy Center -
No ____________
Date____________
QUESTIONNAIRE FOR ALLERGIC AND RESPIRATORY SYMPTOMS IN CHILDREN
Name___________________________________
Birth date_______________________________
Address:________________________________
Sex:
1. male
2. female
Place of living______________________________
Tel: ______________________________________
Education level:
Workplace:
Ethnicity:
1. mother___________ 2. father____________
1. mother___________ 2. father____________
1. mother___________ 2. father____________
1.
2.
During the pregnancy did the mother:
a) smoke
b) take medications
c) experience stress
d) have any kind of health problems
Was the child born:
1. at time 2. premature
Caesarea
1. normal
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
2. yes
2. yes
2. forceps 3. vacuum 4. Sectio
3.
Apgar index ____________________________________________________
4.
Birth weight _____________________birth length_____________________
5.
Has the child been breastfed during the first 4-6 months?
if “no” go to question 7, if “yes”:
6.
Duration of the breastfeeding:______________________________________
7.
Was there any nutritional problem in infancy with:
a) milk
b) other food
(which food?____________________________________________________)
8.
During the first year of life was the child affected by:
1. cough
2. pneumonia
3. nasal symptoms
4. diarrhea
5. skin changes
6. something else____________________________________________________________
9.
Sibship:
1. no
2. yes
10.
Day-care attendance:
1. no
2. yes
235
11.
Residence and housing conditions?
1. urban
2. rural
1. house
2. flat
12.
High humidity at the home:
13.
Heating conditions:
1. central heating 2. wood heating
14.
Environmental air pollution:
if “no” go to question 17, if “yes”:
16.
Type of air pollution:
1. manure 2. industrial pollutants
17.
Pets ownership:
if “no” go to question 19, if “yes”:
18.
Which pets do you own?
1. dog
2. cat
3. traffic pollutants
3. parrot
Is there a family manufacture at the home?
if “no” go to question 22, if “yes”:
21.
Is the family manufacture associated with exposure to:
a) dust
b) high humidity
c) chemical agents
d) high temperature
e) noise
f) other:____________________
22.
Has the child any nose problem?
if “no” go to question 33, if “yes”:
23.
Type of nose problems:
a) nasal blockage
b) sneezing
c) itching
d) runny nose
24.
2. yes
2. yes
1. no
2. yes
1. no
2. yes
1. no
1. no
1. no
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
4. other_________
At what age did the nose problems occur? ___________________________
236
1. no
1. no
4. other_______
Daily smoking:
a) mother:
b) father:
c) other
20.
2. yes
4. other_______
Green plants:
a) indoors
b) outdoors
15.
19.
3. electric heating
1. no
25.
Is there a seasonal occurrence (spring/summer) of the nasal symptoms?
if “no” go to question 29, if “yes”:
1. no
2. yes
26.
Season of the occurrence of the nose symptoms (month): ______________
Duration: ______________________________________________________
27.
Do the nose symptoms occur year by year?
1. no
2. yes
28.
Is there worsening of the nose symptoms in the environment rich with:
a) trees
b) grasses
1. no
1. no
2. yes
2. yes
29.
Do the nose problems persist year-round
1. no
2. yes
30.
Is there worsening of the nose symptoms by exposure to:
a) dust
1. no
b) smoke
1. no
c) other: ________________________________________________________ 1. no
2. yes
2. yes
2. yes
31.
Is there worsening of the nose symptoms by exposure to cold air?
1. no
2. yes
32.
Are the nose symptoms associated with:
a) respiratory symptoms
b) ocular symptoms
c) skin changes
1. no
1. no
1. no
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
2. yes
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
33.
Has the child any respiratory symptom?
if “no” go to question 40, if “yes”:
34.
Type of the respiratory symptoms:
a) shortness of breath
b) wheezing or whistling
c) cough
d) phlegm
g) chest tightness
35.
At what age did the respiratory symptoms occur?
36.
Has the child had any asthma attack?
if “no” go to question 40, if “yes”:
37.
Are the respiratory symptoms:
1. seasonal
2. persistent
38.
How frequent do the respiratory symptoms occur?
1. daily
2. weekly
3. monthly
39.
Triggers of the respiratory symptoms:
a) exercise
b) cold air
c) wind
d) other_________
237
____________________
4. rarely
40.
Has the child any ocular symptom?
if “no” go to question 44, if “yes”:
41.
Type of the ocular symptoms:
a) tearing
b) redness
c) itching
d) eyelids swelling
1. no
2. yes
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
42.
At what age did the ocular symptoms occur___________________________
43.
Is there seasonal occurrence (spring and/or summer)
of the ocular symptoms?
1. no
2. yes
44.
Has the child any skin change?
if “no” go to question 49, if “yes”:
1. no
2. yes
45.
Type of the skin changes:
a) rash
b) itching
c) angioedema
d) other________________________________________________________
1. no
1. no
1. no
1. no
2. yes
2. yes
2. yes
2. yes
46.
At what age did the skin changes occur? _____________________________
47.
Is there seasonal occurrence (spring and/or summer) of the skin changes?
1. no
2. yes
48.
Are the skin changes associated with
a) food consumption:______________________________________________ 1. no
b) insect swing ___________________________________________________ 1. no
c) other _________________________________________________________ 1. no
2. yes
2. yes
2. yes
49.
Has the child experienced any adverse drug reaction such as:
1. skin rash
2. angioedema
3. shortness of breath
4. diarrhea
5. collapse
6. other _________________
by which drug was the adverse reaction caused _______________________
50.
Do the child actually use any medication?
1. no
which medication if “yes”: _________________________________________
51.
Has the child positive family history of allergic diseases such as:
1. asthma
2. hay fever
3. skin changes
4. insect sting allergy
5. drug allergy
6. other__________________
238
2. yes
Appendix 4.
*Prizes should be corrected due to WAT decrease (11-13%)
Glossary of rhinoconjunctivitis medications
Generic name
Mode of
administration
Commercial name
Cost
[MKD (€))]
Systemic antihistamines
Sedating H1 blockers
Chloropyramine
Synopen* (Pliva)
Injections
Diphenhydramine
Dimidril** (Pliva)
Tablets
Syrup
179.00 (3.0)
161.00 (2.7)
Non-sedating H1 blockers
Cetirizin
Cetirizin* (Replekfarm)
Tablets
Syrup
Tablets
Syrup
183.00 (3.0)
196.00 (3.2)
384.00 (6.3)
183.00 (3.0)
Rinolan** (Pliva)
Tablets
Syrup
Tablets
Syrup
Tablets
Syrup
Tablets
Syrup
242.00 (4.0)
169.00 (2.8)
120.00 (2.0)
68.00 (1.1)
240.00 (4.0)
55.00 (0.9)
205.00 (3.4)
118.00 (2.0)
Aerius***
Xysal***
Tablets
Tablets
Letizen* *
Loratadine
Loratadin** (Alkaloid)
Loratadin** (Lek)
Loratadin*
(Replekfarm)
Desloratadine
Levocetirizine
Local preparations
Cromones
239
Sodium
cromoglycate
Asmatal**
(Replekfarm)
Nasal spray
Nasal spray
Eye-drops
Nasal spray
Eye-drops
Nasal spray
Eye-drops
Lomudal***
Disodium cromoglycate
Cromohexal***
Cromoglicin***
Nedocromil
sodium
385.00 (6.3)
Nasal spray
Eye-drops
Vividrin***
α agonists
Oxymethasoline
Operil** (Lek)
Operil P** (Lek)
Edil** (JAKA 80)
Edil P** (JAKA 80)
Nasal spray
Nose-drops
Nose-drops
Nose-drops
85.00 (1.4)
82.00 (1.4)
38.00 (0.7)
33.00 0.6)
Antihistamines
Levocabastine
Livostin**
Azelastine
Allergodil***
Nasal spray
Eye-drops
Nasal spray
Eye-drops
Antiholinergics
Ipratropium
Nasal spray
Atrovent***
Intranasal corticosteroids
Beclometasone
Budesonide
Fluticasone
Beconase*
(GlaxoSmithKline
Pharmaceuticals)
Gnadion** (Pliva)
Nasal spray
Tafen nazal* (Lek)
Alerzin* (Replekfarm)
Nasal spray
Nasal spray
413.00 (6.9)
427.00 (7.0)
Nasal spray
785.00 (13.0)
Flixonase*
(GlaxoSmithKline
Pharmaeuticals)
Nasal spray
* The drug is included in the Essential Drug List, covered by the Health Insurance Fund of Macedonia
** The drug is not included in the Essential Drug List, covered by the Health Insurance Fund of Macedonia
***The drug is not registered in R. Macedonia
Available 2007, May 31
240
230.00 (3.8)
Appendix 5.
Effect of therapies on rhinitis symptoms
Therapy
Sneezing and
nasal itch
Rhinorrhea
Nasal obstruction
H1 antihistamines
+++
++
+/-
Cromones
+
++
+
Oral
decongestants
-
-
+++
Anticholinergics
-
+++
-
Intranasal
corticosteroids
+++
+++
++
+++
+++
+++
Oral
corticosterois
Adapted from van Cawenberge P, et al. Consensus statement on the treatment of
allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy,
2000; 55(2): 116-134.
241
Appendix 6.
Appendix 6.
Institute of Occupational Health
Skopje
No________________
date_______________
OCCUPATIONAL ALLERGIC RHINITIS QUESTIONNAIRE
Name________________________________ Sex:
1. male
2. female

Age_________________________________
Address ____________________________________
Ethnicity __________________________________________________________________________
Actual employment:___________________
Actual workplace: ___________________________
Duration of the actual employment: ____________________________________________________
1.
Classification of the actual workplace:
1. administrative worker
2. industry worker
3. service worker
4. other ________________________

2.
Is your work:
1) dominantly in a sitting posture when arm muscles are slightly engaged
2) in a sitting posture when arm muscles are increasingly engaged
3) in a standing posture when arm muscles are slightly engaged
4) in a standing posture when arm muscles are increasingly engaged
5) in a standing posture when arm muscles and body are increasingly engaged
6) standing, walking, intensive engagement of whole body muscles
7) other:__________________________________________________________________

3.
Actual workplace hazards:

(1. none 2. high temperature 3. low temperature 4. draught 5. high humidity
6. low ventilation 7. dust 8. vibrations 9. ionizing radiation 10. non-ionizing
radiation 11. physical exercise 12. long-term standing or sitting 13. chemical agents
14. atmospheric pressure changes 15. other)
4.
Is your working engagement
5.
Is your work:
1) night work 2) shift work 3) related to travelling
4) outdoors
5) in water
6) individual 7) team work
8) other specific characteristics of your work____________
1. full time
2. part time


6.
To which chemical agents are you exposed at the actual workplace:
__________________________________________________________________________________
7.
Type of the agent:
242
1. gas 2. fume 3. dust 4. smoke 5. liquid
8.
Have you, at the workplace, contact with:
a) animal and animal products ______________________________________
b) herb and herbal products ______________________________________
v) subjects with contagious diseases or contagious material ______________
1. no 2. yes 
1. no 2. yes 
1. no 2. yes 
9.
Do you use your voice at the workplace (singing, loud speaking)
1. no 2. yes 
10.
Have you any nose symptom?
1. no 2. yes 
11.
Type of symptom:
a) nasal congestion
b) sneezing
v) nasal itching
g) runny nose
d) other _______________________________________________________
1. no
1. no
1. no
1. no
1. no
12.
Have the symptoms occurred after entering the actual workplace?
1. no 2. yes 
13.
Are the symptoms provoked by the actual workplace?
1. no 2. yes 
14.
By which agent __________________________________________________
15.
In what period after beginning the work shift the symptoms occur? ______
16.
Do the symptoms worse during the work shift?
1. no 2. yes 
17.
Do the symptoms improve during
1. weekends
2. vacations
3. other work off periods
1. no 2. yes 
1. no 2. yes 
1. no 2. yes 
2. yes
2. yes
2. yes
2. yes
2. yes





18.
At what age did you first notice the nose symptoms? ___________________
19.
How long had you been employed at the actual workplace before the nose
symptoms have occurred? _________________________________________
20.
How often the symptoms occur:
1. daily 2. weekly 3. monthly 4. a few times per year
5. rarely 6. just in certain circumstances _____________

Are the nose symptoms accompanied by respiratory symptoms (cough,
phlegm, shortness of breath, wheezing or whistling, and/or chest tightness)?
1. no
2. yes
3. from time to time

21.
22.
Have you even be treated for disease of the nose and/or sinuses?
23.
Have you ever had some other chronic disorder?_______________________
24.
Do you feel exhausted during the workshift?
1. no
2. yes
3. sometimes
243
1. no 2. yes 

25.
Smoking status:
1. active smoker 2. ex-smoker 3. non-smoker
26.
Daily mean of cigarettes smoked _________ Smoking experience _________
27.
Do you consume alcohol more than bottle of beer or glass of wine daily?
28.
How long?
29.
Have you any blood relative with:
a) nasal disorder (rhinitis, sinusitis, polyposis)
b) lung disorder (asthma, chronic bronchitis)
c) allergic disorder

1. no 2. yes 
_____________________________________________________
30.
Duration of employment___________________________________________
31.
Previous employments:
1. no 2. yes 
1. no 2. yes 
1. no 2. yes 
1_________________________years: __________ hazards: 
2_________________________years: __________ hazards: 
3_________________________years: __________ hazards: 
4_________________________years: __________ hazards: 
5_________________________years: __________ hazards: 
(1. none 2. high temperature 3. low temperature 4. draught 5. high
humidity 6. low ventilation 7. dust 8. vibrations 9. ionizing radiation 10.
non-ionizing radiation 11. physical exercise 12. long-term standing or sitting
13. chemical agents 14. atmospheric pressure changes 15. other)
32.
Do you use any personal protective during the work shift?
1. no 2. yes 
33.
Do you have regular periodical check-ups?
1. no 2. yes 
34.
When the last periodical check-up was performed? ____________________
244
Appendix 7.
*Prizes should be corrected due to WAT decrease (11-13%)
Glossary for asthma medications
Generic name
Sodium cromoglycate
Nedocromil sodium
Beclomethasone
dipropionate
Fluticasone propionate
Mometasone furoate**
Flunisolide
Budesonide
Cyclosonide**
Commercial name
Mode of
administration
Cost
[MKD ( € )]
inhaled
250.00 (4.0)
inhaled
950.00 (15.0)
inhaled
1800.00 (30.0)
inhaled
1800.00 (30.0)
Controllers
(antiinflammatory) drugs
Cromones
Intal***, Bicromat***
Tilade**
Inhaled corticosteroids
Becotide 50 mcg*
(GlaxoSmithKline Pharmaceuticals)
Becloforte 250 mcg**
(GlaxoSmithKline Pharmaceuticals)
Flixotide 50 mcg*
(GlaxoSmithKline Pharmaceuticals)
Flixotide 125 mcg*
(GlaxoSmithKline Pharmaceuticals)
Asmanex***
Inhacort**
Tafen *(Lek)
Pulmicort**
Alvesco***
245
Sistemic corticosteroids
Prednisone
Prednizon 5 mg**(JAKA 20)
Prednizon 20 mg** (JAKA 20)
Pronizon 5 mg** (Galenika)
Pronizon 20 mg**(Galenika)
Nizon 5 mg** (Bosnalijek)
Solu-decortin H 25 1 mL
Solu-decortin H 25 5 mL
(Merck kGaA)
oral
oral
oral
oral
oral
parenteral
parenteral
Prednisolone
Decortin 5 mg*
Decortin 20 mg*
Decortin 50 mg*
(Merck kGaA)
oral
oral
oral
Methyl
prednisolone
Lemod Solu 20 mg
Lemod Solu 40 mg
Lemod Solu 500 mg
Lemod depo 40 mg
Lemod 4 mg* (Hemofarm)
parenteral
parenteral
parenteral
parenteral
oral
Dexametazon 4 mg/mL
Dexametazon 0,5 mg* (Krka)
Dexsazon 4 mg/mL
Dexazon 0,5 mg (Galenika)
Maxidex 5 ml (Alkon)
parenteral
oral
parenteral
oral
parenteral
Kenalog 40 mg/mL (Krka)
parenteral
Dexamethasone
Triamcinolone
68.00 (1.1)
103.00 (1.6)
107.00 (1.6)
119.00 (2.0)
68.00 (1.1)
195.00 (3.0)
802.00 (13.0)
179.00 (3.0)
40.00 (0.8)
Leukotriene modifiers
Receptor antagonists
Zafirlukast
Montelukast
5-lipoxygenase
inhibitors
Accolate***
Singulair***
oral
oral
Zileuton***
oral
Drugs with possible, but still unproved antiinflammatory effect
Long-acting
β2 agonists (LABA)
Inhaled LABA
Salmeterol
Formoterol
Oral LABA
Bambeterol
Serevent**
Foradyl***
inhaled
inhaled
Bambec***
oral
246
900.00 (15.0)
Methylxanthines
Sustained-release
theophylline
Teotard retard 200 mg** (Krka)
Teotard retard 350 mg** (Krka)
Durofilin retard 125 mg**
(Zdravlje)
Durofilin retard 250 mg** (Zdravlje)
Aminofilin R 350 mg* (JAKA 80)
oral
oral
oral
Aminofilinum retard 350 mg
(Lek)
oral
oral
oral
Relievers
(Bronhodilators)
Short-acting
β2 agonists
Salbutamol
Ventolin 2 mg**
(GlaxoSmithKline GmbH&Co.)
Ventolin 2 mg/5 mL*
(GlaxoSmithKline Production)
Ventolin 100 mcg*
(GlaxoSmithKline Pharmaceuticals)
Salmo 2 mg** (Pliva)
Salmo 2 mg/5 mL** (Pliva)
Salmo 100 mcg** (Pliva)
Salbutamol 2 mg** (Alkaloid)
Salbutamol 2 mg/5 mL** (Alkaloid)
Aloprol 2 mg* (Replekfarm)
Aloprol 2 mg/5 mL* (Replekfarm)
oral
135.00 (2.1)
oral
230.00 (4.0)
inhaled
110.00 (1.8)
oral
oral
inhaled
oral
oral
oral
oral
79.00 (1.2)
Terbutaline
Terbutalin***
Bricanyl***
parenteral
inhaled
Fenoterol
Berotec***
inhaled
Methylxanthines
Theophylline
Aminofilinum 500 mg/2 mL (Pliva)
Aminofilinum 250 mg/10 mL
(Pliva)
Aminofilin 250 mg/10 mL (Alkaloid)
Aminofilin 350 mg* (Alkaloid)
Aminofilin 100 mg* (Alkaloid)
Aminofilin 100mg** (JAKA 80)
Odinal 100 mg** (Replekfarm)
Aminofilinum 100 mg**(Lek)
Tbl. Aminofilin 100 mg** (Famfarm)
parenteral
parenteral
parenteral
oral
oral
oral
oral
oral
oral
* The drug is included in the Essential Drug List, covered by the Health Insurance Fund of Macedonia
** The drug is not included in the Essential Drug List, covered by the Health Insurance Fund of Macedonia
***The drug is not registered in R. Macedonia
Available 2007, May 31
247
110.00 (1.8)
92.00 (1.5)
113.00 (1.8)
122.00 (2.0)
Appendix 8.
Estimated comparative daily dosage for inhaled corticosteroids (ICS)
Drug
Low daily dose
(mcg)
Medium daily dose
(mcg)
High daily dose
(mcg)
Adults
Beclomethasone
dipropionate
200-500
500-1000
> 1000
Budesonide
200-400
400-800
> 800
Flunisolide
500-1000
1000-2000
> 2000
Fluticasone propionate
100-250
250-500
> 500
Children
Beclomethasone dipropionate
100-400
400-800
> 800
Budesonide
100-200
200-400
> 400
Flunisolide
500-750
1000-1250
> 1250
Fluticasone propionate
100-200
200-500
> 500
Adapted from Global Initiative for Asthma. Asthma management program. National
Institutes of Health, National Heart, Lung, and Blood Institute 2004; p. 115-119.
248
Appendix 9.
Actual combined inhaled medications used in asthma treatment
Medication
Content
Form of application
Seretide
Salmeterol
+
Fluticasone
Metered-dosed inhaler
Seretide
Salmeterol
+
Fluticasone
Diskhaler
Symbicort
Formoterol
+
Budesonide
Turbuhaler
249
Appendix 10.
Rush (hospital) immunotherapy
Venomil bee / Venomil wasp
Initial immunotherapy
Initial immunotherapy in extremely sensitive patients*
Day
(1)
(2)
Conc.
(µg insect venom/mL)
0.0001
0.0001
0.0001
0.0001
0.001
0.001
0.001
0.001
Volume
(mL)
0.1
0.2
0.4
0.8
0.1
0.2
0.4
0.8
Conc.
(µg insect venom/mL)
0.00001
0.00002
0.00004
0.00008
0.0001
0.0002
0.0004
0.0008
Initial immunotherapy in commonly sensitive patients
Day
1 (3)
2 (4)
3 (5)
4 (6)
5 (7)
6 (8)
7 (9)
Conc.
(µg insect venom/mL)
0.01
0.01
0.01
0.01
0.1
0.1
0.1
0.1
1
1
1
1
10
10
10
10
100
100
100
100
100
100
100
100
Volume
(mL)
0.1
0.2
0.4
0.8
0.1
0.2
0.4
0.8
0.1
0.2
0.4
0.8
0.1
0.2
0.4
0.8
0.1
0.2
0.4
0.5
0.6
0.8
0.9
1.0
250
Conc.
(µg insect venom/mL)
0.001
0.002
0.004
0.008
0.01
0.02
0.04
0.08
0.1
0.2
0.4
0.8
1
2
4
8
10
20
40
50
60
80
90
100
Maintenance therapy
Concentration of 100 µg insect venom should be injected in:
1.
2.
3.
4.
7 days-interval
14 days-interval
21 days-interval
28 days-interval
The shots should be applied in a 4 week-intervals in a period of 3 years.
* The sensitivity has to be determined prior to immunotherapy initiation by history of
systemic insect sting reaction and positive SPT to concentration of 1µg/mL of the insect
venom extract.
251
Appendix 11.
Conventional (ambulatory) immunotherapy Venomil bee / Venomil wasp
Initial immunotherapy
Initial immunotherapy in extremely sensitive patients*
Day
(1)
(8)
(15)
(22)
Conc.
(µg insect venom/mL)
0.00001
0.0001
0.001
0.01
Volume
(mL)
0.1
0.1
0.1
0.1
Conc.
(µg insect venom/mL)
0.000001
0.00001
0.0001
0.001
Initial immunotherapy in commonly sensitive patients
Day
Conc.
(µg insect venom/mL)
Volume
(mL)
Conc.
(µg insect venom/mL)
1 (29)
0.1
0.1
0.01
8 (36)
15 (43)
22 (50)
29 (57)
36 (64)
43 (71)
50 (78)
57 (85)
64 (92)
71 (99)
78 (106)
85 (113)
92 (120)
99 (127)
106 (134)
0.1
1
1
1
1
10
10
10
10
100
100
100
100
100
100
0.05
0.1
0.2
0.4
0.05
0,1
0.2
0.4
0.05
0.1
0.2
0.4
0.6
0.8
1.0
0.05
0.1
0.2
0.4
0.5
1
2
4
5
10
20
40
60
80
100
Maintenance therapy
Concentration of 100 µg insect venom should be injected in:
5.
6.
7.
8.
7 days-interval
14 days-interval
21 days-interval
28 days-interval
The shots should be applied in a 4 week-intervals in a period of 3 years.
* The sensitivity has to be determined prior to immunotherapy initiation by history
and positive SPT to concentration of 1µg/mL of the insect venom extract.
252
List of abbreviations
AC - allergic conjunctivitis
ACE - angiotensin-converting enzyme
AD - atopic dermatitis
AEDS - atopic eczema/dermatitis syndrome
APC – antigen-presenting cell
APT – atopy patch test
AR – allergic rhinitis
ARIA - Allergic Rhinitis and Its Impact to Asthma
ASIT - allergen-specific immunotherapy
ATS - American Thoracic Society
AV – allergy vaccination
B-ly - B lymphocyte
BTS - British Thoracic Society
C - Celsius grade
Can - canis (dog)
CARAS - Combined Allergic Rhinitis and Asthma Syndrome
CD - cluster of differentiation
CFC – chlorofluorocarbons
CIC – circulating immune complexes
CNS - central nervous system
cm – centimeter
CT – computed tomography
CyA – cyclosporine A
DBPCFC - double-blind placebo-controlled food challenge test
De - Debar
Do - Dojran
DPT – dose-provocative test
EAACI - European Academy for Allergology and Clinical Immunology
EAWP - European Allergy White Paper
ECRHS - European Community Respiratory Health Survey
ECSC - European Community for Steel and Coal
EIA - exercise-induced asthma
ECP – eosinophil cationic protein
ENDA - European Network of Drug Allergy
ENT EPI - European Pollen Information
ERS - European Respiratory Society
Fel - felix (cat)
FEV1 - forced expiratory volume in 1 second
GA2LEN – Global Allergy and Asthma European Network
GI tract – gastrointestinal tract
GINA - Global Initiative for Asthma
GERD – gastroesophageal reflux disease
gr – gram
253
h - hour
ICD-10 – International Statistical Classification of Diseases and Related Health
Problems Tenth Revision
ICS - inhaled corticosteroids
IFN - interferon
IgA - immunoglobulin A
IgG - immunoglobulin G
IgE - immunoglobulin E
IgM - immunoglobulin M
IL - interleukin
ISAAC - International Study of Asthma and Allergies in Childhood
kg. – kilogram
L – litre
LABA – long-acting β2 agonists
LT – leukotriene
m - meter
MBP - major basic protein
mcg - microgram
mcm- micrometer
MEF - maximal expiratory flow
mg - miligram
MHC – major histocompatibility complex
mL - mililitre
mm – milimeter
MRI – magnetic resonance imaging
NAC – nonallergic conjunctivitis
NAR - nonallergic rhinitis
NSAIDs - nonsteroid anti-inflammatory drugs
OA – occupational asthma
OFC – oral food challenge
Oh – Ohrid
PAC – perennial allergic conjunctivitis
PAR – perennial allergic rhinitis
PC20 - provocative concentration 20
Pe – Pehcevo
PEFR – peak expiratory flow rate
PG - prostaglandin
PG - pollen grains
Pr – Prilep
QAU - quality assurance units
QLQ – quality of life questionnaire
RAST – radioallergosorbent test
SAC – seasonal allergic conjunctivitis
SAR - seasonal allergic rhinitis
SCIT - subcutaneous immunotherapy
Sk – Skopje
SLIT - sublingual immunotherapy
254
SOTI – specific oral tolerance induction
SPT – skin prick tests
TCI – topical calcineurin inhibitors
TCS – topical corticosteroids
Th - T helper (lymphocyte)
T-ly - T lymphocyte
T regs - regulatory T cells
UV therapy – ultraviolet therapy
VC - vital capacity
WAO – World Allergy Organization
W/D 12 – wheezing with dyspnea in the last 12 months
WHO – World Health Organization
WRA - work-related asthma
255
Index
A
aeroallergens 48, 80, 116, 139, 150
aeropalinology 48
air pollution 51, 117, 150
air sediment 49
allergen 28
allergic asthma 29, 151
allergic conjunctivitis 28, 100, 139
allergic hypersensitivity 27
allergic rhinitis 28, 99, 116, 139, 162
allergic sensitization 25
allergy vaccination 122
allergen-specic-immunotherapy 122, 215
allergy 27
Alternaria alternata 82, 162
ambrosia 52
anaphylaxis 30, 185, 200, 214
anesthetics 188
antibiotics 188
antigen-presenting cells 25
Aspergilus 80
aspirin 188
asthma 29, 100, 130, 149
atopy 27
atopic eczem/dermatitis syndrome 29, 173
atopic dermatitis 100, 173
B
basophils 25
bee 212
birch 64, 232
bronchial hyperresponsiveness 151
C
carbon monoxide 51
cat 89
Cladosporium 80
cockroach 94
256
D
Dermatophagoides pteronyssinus 86, 117, 150, 162
dog 90
dose-provocative test 187
double-blind placebo-controlled food challenge 201
drug allergy 185
drug hypersensitivity 30, 100, 185
E
environmental factors 117, 149, 165
eozinophils 25, 116, 150
eosinophil cationic protein 25
F
feathers 92
food additives 200
food hypersensitivity 30, 100, 200
G
grass 63, 241
gravimetric aeropalinological method 49
H
hay fever 139
hornet 212
house dust 86
house dust mites 86
hypersensitivity 26
Hymenoptera 212
I
immune response 25
immunoglobulins 25
immunoglobulin A 200
immunoglobulin E 25, 116, 139, 151, 173, 185, 200, 213
immunoglobulin G 27, 185, 200
immunoglobulin M 185, 200
insect 212
insect sting allergy 100, 212
indoor air allergens 80
indor air pollution 150
257
J
juniper 236
L
lung function tests 99, 152
lymphocytes 25
M
maior basic protein 25
mast cells 25, 116, 139, 150
molds 80
mugwort 63
myorelaxants 188
N
nitric oxides 51
nonallergic asthma 29, 151
nonallergic atopic dermatitis 173
nonallergic conjunctivitis 142
nonallergic drug hypersensitivity 185
nonallergic food hypersensitivity 200
nonallergic hypersensitivity 27
nonallergic rhinitis 28, 124
nonsteroidal antinflammatory drugs 188
O
oak 64, 234
occupational asthma 152
occupational allergic rhinitis 116, 251
outdoor air allergens 48, 150
outdoor air pollutants 51, 150
ozone 150
258
P
penicilin 188
Penicillium notatum 84
perennial allergic conjunctivitis 139
perennial allergic rhinitis 100, 116
pin 64, 235
plantain 63
pollen grains 48
pollen calendar 64
pollen cart 64
prostaglandins 25
S
seasonal allergic conjunctivitis 139
seasonal allergic rhinitis 100, 116
skin prick tests 99, 119, 140, 152, 175, 186
smoking 103, 117, 150
sulfonamides 188
sulfur dioxide 51, 117, 150
T
T helper lymphocytes 25
T lymphocytes 25
traffic pollution 165
U
urticaria 29
V
volumetric aeropalinological method 49
W
wasp 212
weed 63, 117, 150, 237
workplace exposure 165
259
Contacts:
Vladimir Cvetanov
Institute of Occupational Health – WHO Collaborating Center
II Makedonska Brigada 43
PO Box 910
1000 Skopje
R. Macedonia
Tel: + 389 2 3110 491
Fax: + 389 2 2621 428
e-mail: [email protected] (office)
[email protected] (private)
Elisaveta Stikova
Medical faculty ; National Public Health Insitute
ul.50 Divizija br. 6
1000 Skopje
R.Macedonia
Tel.: +389 2 3 147 052
GSM: + 389 70 230 183
e-mail: [email protected]
[email protected]
Jovanka Karadzinska-Bislimovska
Institute of Occupational Health – WHO Collaborating Center
II Makedonska Brigada 43
PO Box 910
1000 Skopje
R. Macedonia
Tel: + 389 2 3110 491
Fax: + 389 2 2621 428
e-mail: [email protected](office)
[email protected] (private)
Mirko Spiroski
Macedonian Society of Basic and Clinical Immunology and Allergology
50 Divizija 6
PO Box 60
1000 Skopje
R. Macedonia
Tel: + 389 2 3110 556
Fax: + 389 2 3110 558
web site: www.msbcia.org.mk
e-mail: [email protected] (private)
Jordan Minov
Institute of Occupational Health – WHO Collaborating Center
II Makedonska Brigada 43
PO Box 910
1000 Skopje
R. Macedonia
Tel: + 389 2 3110 491
Fax: + 389 2 2621 428
e-mail: [email protected] (office)
[email protected] (private)
260
261